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Résumé 
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MAGL, ERG 
 
 
Le système endocannabinoïde (eCB) est présent dans le système nerveux central 
(SNC) de mammifères, incluant la rétine, et est responsable de la régulation de nombreux 
processus physiologiques. Bien que la présence du récepteur cannabinoïde de type 1 (CB1R) a 
bien été documenté dans la rétine de rongeurs et primates, il y a encore une controverse quant 
à la présence du récepteur cannabinoïde de type 2 (CB2R) au niveau du SNC. En utilisant la 
microscopie confocale, nous sommes les premiers à signaler les patrons d’expression du 
CB2R dans la rétine de singe. Nos résultats démontrent que le CB2R est exprimé 
exclusivement dans les cellules de Müller de la rétine du singe. En outre, nous avons comparé 
les différents patrons d’expression du système eCB dans la rétine de la souris, du toupaye, 
ainsi que du singe vervet et macaque. Nous rapportons que les distributions de CB1R, FAAH 
(fatty acid amid hydrolase), MAGL (monoacylglycerol lipase) et DAGLα (diacylglycerol 
lipase alpha) sont hautement conservées parmi ces espèces alors que CB2R et NAPE-PLD (N-­‐
acyl	  phosphatidylethanolamine	  phospholipase	  D) présentent différents profils d'expression. 
CB2R n'a pas été détecté dans les cellules neuronales de la rétine des primates. 
L’immunoréactivité de NAPE-PLD est présente dans les couches de la rétine de souris et 
toupayes, mais a été limitée à la couche des photorécepteurs des singes vervet et macaque. 
 
Pour étudier les corrélats neuronaux et le rôle de la signalisation du système eCB dans 
la rétine, nous avons établi un protocole standard pour l'électrorétinographie (ERG), puis 
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enregistré la réponse ERG de la rétine après le blocage des récepteurs avec des antagonistes 
spécifiques pour CB1R (AM251) et CB2R (AM630). Comparé au témoin, dans des conditions 
photopiques, et à certaines intensités faibles du stimulus, le blocage de CB1R diminue 
l'amplitude de l'onde-b, alors qu’à des intensités plus élevées, le blocage de CB2R augmente 
l'amplitude des deux-ondes a et b. De plus, le blocage des récepteurs cannabinoïdes provoque 
une augmentation de la latence des deux ondes a et b. Dans des conditions d’adaptation à 
l'obscurité, le blocage de CB1R et CB2R réduit l’amplitudes de l'onde a seulement à des 
intensités plus élevées et réduit l’onde b à intensités plus faibles. Des augmentations 
significatives de latence ont été observées dans les deux cas. Ces résultats indiquent que les 
récepteurs CB1 et CB2 chez les primates non humains sont impliqués dans la fonction 
rétinienne conditions photopiques. 
En outre, nous avons évalué le profil d'expression du CB1R, de FAAH et de NAPE-
PLD au-delà de la rétine dans le corps géniculé latéral des singes et nous rapportons pour la 
première fois que CB1R et FAAH sont exprimés davantage dans les couches 
magnocellulaires. La NAPE-PLD a été localisée à travers les couches magno- et 
parvocellulaires. Aucune de ces composantes n’est exprimée dans les couches 
koniocellulaires. 
Ces résultats nous aident à mieux comprendre les effets des cannabinoïdes sur le 
système visuel qui pourraient nous mener à trouver éventuellement de nouvelles cibles 
thérapeutiques. 
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Abstract 
Keywords: endocannabinoid, vision, monkey, CB1R, CB2R, FAAH, NAPE-PLD, DAGL, 
MAGL, ERG 
 
The endocannabinoid (eCB) system is present in the mammalian central nervous 
system, including the retina, and is responsible for the regulation of many physiological 
processes. Anatomical and functional data collected in the retina indicate that cannabinoid 
receptors are important mediators of retinal function. Although the presence of the 
cannabinoid receptor type 1 (CB1R) has been documented in the rodent and primate retina, 
there is still some controversy regarding the presence of the CB2 receptor (CB2R) within the 
central nervous system. By using confocal microscopy, we are the first to report the 
distribution patterns of CB2R in the monkey retina. Our results show that CB2R is expressed 
exclusively in the Müller cells of the primate retina. Furthermore, we compared the eCB 
system distribution patterns in the retinas of mice, tree shrews, and vervet and macaque 
monkeys. We report that CB1R, FAAH, MAGL, and DAGLα distributions are highly 
conserved among these 3 species whereas CB2R and NAPE-PLD exhibit different expression 
patterns. CB2R was not detected in the neuroretinal cells of primates. NAPE-PLD 
immunoreactivity was present in the retinal layers of mice and tree shrews but was restricted 
to the photoreceptor layer in both species of primates studied. 
 
To study the neural correlates and the role of eCB signaling in the retina, we first 
established a standard protocol for electroretinography (ERG) and then recorded the ERG 
response of the retina after blocking receptors with specific antagonists for CB1R (AM251) 
and CB2R (AM630). Compare to control, in photopic conditions, at certain low flash 
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intensities, only the blockade of CB1R decreases the amplitude of the a-wave and b-wave, 
while at some high flash intensities, blockade of CB2R increase the amplitude of both a- and 
b-waves. Also the blockade of the cannabinoid receptors causes an increase in the latency of 
both a- and b-waves. In dark-adapted eyes, blockade of the CB1R and CB2R reduces the a-
wave only amplitudes in the higher intensities and decrease the b-wave in lower intensities. 
Some significant increases in latency were observed in both cases. These results indicate that 
CB1 and CB2 receptors in primates are involved in retinal function under photopic and 
scotopic conditions.  
 
In addition, we assessed the expression pattern of eCB components CB1R, FAAH, and 
NAPE-PLD beyond the retina in the dorsal lateral geniculate nucleus (dLGN) of primates and 
report for the first time that while CB1R and FAAH are more abundantly expressed in the 
magnocellular layer, NAPE-PLD is distributed throughout both the magno- and parvocellular 
layers. None of these components are expressed in the koniocellular layer. 
 
These findings augment our understanding of the effects of cannabinoids on the visual 
system and may lead to novel therapeutics targeted to eCB signaling. 
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Historical aspects 
We cannot talk about cannabinoid system research and not citing the cannabis plant 
and marijuana related subjects. Certainly, this is in part due to the ancient history of the 
cannabis plant. Marijuana has been cultivated as hemp for manufacturing and personal reasons 
for thousands of years, while recreational use of marijuana as a euphoric agent can be dated 
back to ancient Zoroastrian rituals (Mechoulam, 1986; Di Marzo, 2006;). It also has an ancient 
history of prescription as a medicinal herb in North Africa, Middle East, India, and far Asia. 
Half a century after Napoleon carried the Egyptian cannabis seeds to France (1799), an Irish 
physician working in Calcutta assessed the therapeutic effects of cannabis scientifically and 
publicized it to the Western World, setting the foundation for cannabinoid research 
(O’Shaughnessy, 1840 ). 
Long after, in the middle of 20th century, Gaoni and Mechoulam elucidated the 
structure of Δ9-tetrahydrocannabinol (THC), the main psychoactive substances of the 
cannabis, marking another significant step in cannabinoid research (Mechoulam and Gaoni, 
1965). The leading studies in the field during that period focused on the adverse effects of 
cannabis. Two decades later, the first THC binding site – a G-protein-coupled receptor – 
Cannabinoid receptor 1 (CB1R), was found (Matsuda et al., 1990). This was followed by a 
second receptor CB2R (Munro et al., 1993). Later on, the isolation of the endogenous ligands 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) revealed their cannabinoid-like 
behavior (Figure 1-1) (Devane et al., 1992; Mechoulam et al., 1995; Di Marzo, 2006).  
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Figure 1-1. Cannabinoid research throughout the history (Di Marzo, 2006) 
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Chemistry and taxonomy of cannabis 
The flowering plant family of Cannabaceae, endogenous to central and south Asia, includes 
three main different species, Cannabis sativa, indica and ruderalis. Besides for its medicinal 
and recreational uses, the cannabis plant has been utilized as fiber (hemp), seeds and seed oils 
for long time (Figure 1-2). Up to more than 525 constituents have been isolated and identified 
from C. sativa among them, 85 cannabinoids, belong to the chemical class of terpenophenolics 
(El-Alfy et al., 2010). The most common natural cannabinoids are THC, cannabidiol (CBD), 
cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN) that are mostly in a 
very low quantity and poorly characterized (Figure 1-3). 
The ratio of cannabinoid content in different species is dissimilar. C. ruderalis has the lowest 
THC content compared to C. sativa or C. indica. The cannabidiol (CBD) content of C. indica 
is higher than C. sativa strains (Hillig and Mahlberg, 2004).  
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Figure 1-2 C. Sativa. Male flower (1), pollen sac (2 and 3), pollen grain (4), female flower with cover petal (5); female 
flower (6); female fruit cluster (7), fruit with cover petal (8); seed without hull (13). (Franz Eugen Köhler's drawing 
1887) 
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Figure 1-3. Chemical structure of cannabinoids: Δ9-tetrahydocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-
THC), cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC). 
 
Δ9-tetrahydocannabinol (Δ9-THC) 
The cannabis principal psychoactive constituent, mainly called THC, is a lipophilic aromatic 
terpenoid that has a very low solubility in water and solubilized thoroughly in organic 
solvents, lipid and alcohol. The role of the THC in the Cannabis plant is supposed to be a self-
defense mechanism of the plant against the herbivores. It might also play a role in protection 
of the plant from harmful effects of the UV due to its high UV-B (280–315 nm) absorption 
properties (Lydon et al., 1987). THC produces and affects several positive and negative 
symptoms such as reducing nausea, fertility, tumor growth, intra ocular pressure (IOP) 
reduction, analgesia, impaired short-term memory and motor coordination and appetite 
stimulation (Mechoulam, 2002; Iversen, 2003; Yazulla, 2008). 
Δ8-tetrahydocannabinol (Δ8-THC) 
It is about 20% less active than Δ9-THC and considered as a THC artifact. 
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Cannabidiol (CBD) 
As the first discovered member of the family is the most abundant cannabinoid in the 
industrial hemp and accounts for up to 40% of the plant extract. Compare to the main role 
player in psychoactive symptoms, CBD is believed to have a broad capacity for therapeutic 
usage (Campos et al., 2012). 
Cannabigerol (CBG) 
Hemp is rich in this non-psychoactive cannabinoid that is supposed to play a role in reducing 
the IOP and beneficial to pressure-associated optic neuropathy, glaucoma (Colasanti et al., 
1984) and play a role in inflammatory conditions of colon of the large intestine, small intestine 
and inflammatory Bowel Disease (IBD) (Borrelli et al., 2013). 
Cannabinol (CBN) 
CBN is poorly characterized. A scant amount of this substance can be found in C. sativa and 
C. indica, as the metabolites of CBD and THC.  
Cannabichromene (CBC) 
CBC is not well characterized although some of the anti-inflammatory, anti-viral and 
analgesic effects of cannabis have been imputed to CBC (Mechoulam and Gaoni, 1967).  
 
Cannabis effects 
 
The body effects of Marijuana included congestion of the conjunctival blood vessels 
(red eye), decrease of intraocular pressure, xerostomia (dry-mouth), sensation of hot and cold 
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in hands and feet, increase in heart rate and muscle relaxation (Ashton, 1999; Green et al., 
2003). The psychoactive effects of cannabis are more subjective and difficult to assess due to 
two main reasons. First, the outcomes are dissimilar in each subject based on the dosages of 
the drug and its mode of administration. Second, the social setting and expectation results in 
completely inverse symptoms (Yazulla, 2008). Additionally, brain-imaging and behavioural 
techniques have been widely used to study the effects of marijuana consumption on brain 
(Chang and Chronicle, 2007). Cannabis consumption alters the level of consciousness, impairs 
the short- term memory (Kanayama et al., 2004; Jager et al., 2006; Han et al., 2012), 
coordination and psychomotor behaviour (Pillay et al., 2004; Rodríguez de Fonseca et al., 
2005). It can increase the appetite and craving food (Mattes et al., 1994), relieve nausea 
(Tramer et al., 2001) and reduce pain (Pini et al., 2012). In some cases, it can block the anxiety 
feeling and in other cases cause anxiety (Coscas et al., 2013) (Figure 1-4). 
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Figure 1-4. Effects of cannabis on the brain with their corresponding area. (Adapted from Maryanne Murray info-
graphic and Experimental and Clinical Psychopharmacology, 1994)  
 
The Endocannabinoid System (eCB)  
The experience of discovering endogenous ligand for opiate receptors and morphine-
like compounds raises this question that the cannabinoids might follow the same track. Devane 
et al, isolated a brain constituent that binds to the receptors of cannabinoid, 
arachidonylethanolamide, known as anandamide1 as the first endogenous cannabinoid with 
THC-like performance (Devane et al., 1992), later on designated as eCB (Di Marzo and 
Fontana, 1995).  
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Ananda in Sanskrit means joy, bliss, delight	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Function 
 
A number of specific roles have been ascribed to the eCB system in physiological and 
functions of the synapsis, such as neuroprotection, nociception, motor activity, neurogenesis, 
synaptic plasticity, in memory (Xu and Chen, 2014), and vision (Yazulla, 2008). The 
alteration of the normal level of eCBs is considered as a disorder called Clinical eCB 
deficiency (CECD). CECD is one of the explanation for therapeutic benefits of cannabis in 
migraine, fibromyalgia, irritable bowel syndrome, and other treatment-resistant conditions 
(Russo, 2008). More and more, studies suggest that the modulation of eCB activity holds 
therapeutic promise for a broad range of diseases, including neurodegenerative, cardiovascular 
and inflammatory disorders (Robson, 2001). Using genetics and pharmacological tools 
suggests that eCB system plays the role of neuromodulator in various physiological processes 
(Yazulla, 2008). Among the vast research projects on revealing the roles of endocannabinoid 
system, particularly in attention, memory, appetite, stress response, inflammation, immune 
functions, analgesia, sleep and etc., here in this thesis we mainly focus on their visual 
functions. 
 
Evolution  
The cannabinoid receptors are found in many mammals, as well as in various classes 
of vertebrates and invertebrates, in all major subdivision of bilaterians, in urochordate and 
cephalochordates, but not in the nonchordate invertebrate phyla like insects (McPartland et al., 
2006a; McPartland et al., 2007; Cottone et al., 2013). Thus, it has been suggested that the 
cannabinoid receptors may have evolved in the last common ancestor of bilaterians with a 
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secondary loss in insects and other clades (McPartland et al., 2006a). The enzymes responsible 
for the biosynthesis and degradation of eCBs are present throughout the vertebrates and most 
of the animals (McPartland et al., 2006b; Elphick, 2012). Beyond doubt, the eCB system is 
widely distributed phylogenetically and points to a fundamental modulatory role of eCBs in 
the control of many central and peripheral biological functions, and is a promising tool for its 
pharmacological manipulation and potential therapeutic exploitation (Di Marzo, 2009).  
 
Main Role Players 
The eCB system is composed of the ensemble of cannabinoid receptors (CB1R, 
CB2R), their endogenous ligands (AEA, 2-AG, N-arachidonoyl-dopamine (NADA), 
virodhamine (OAE), lysophosphatidylinositol (LPI)), enzymes of synthesis (N-acyl 
phosphatidylethanolamine-specific phospholipase D (NAPE-PLD), diacylglycerol lipase 
(DAGL), phospholipase C (PLC)), degradation (fatty acid amide hydrolase (FAAH), 
monoacylglycerol lipase (MAGL), cyclooxygenase-2 (COX-2)), and other proteins that 
regulate ligand concentrations (cannabinoid receptor interacting protein (CRIP1a)).  
Endocannabinoids 
Full endogenous agonists 
2-Arachidonoylglycerol (2-AG) 
 
 
Highly present in CNS, 2-AG is an agonist of CB1R and CB2R. 2-AG is synthesized 
from arachidonic acid-containing diacylglycerol (DAG) mediated by Phospholipase C (PLC) 
and diacylglycerol lipase (DAGL). Monoacylglycerol lipase (MAGL), fatty acid amide 
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hydrolase (FAAH) degrade the 2-AG, immediately after release (Sugiura et al., 1995; Di 
Marzo, 2011). 
Synthesis and degradation 
 
Phospholipase C (PLC) facilitates the synthesis of DAG from the arachidonic acid 
present in the membrane phospholipids. DAG is then hydrolyzed by DAGL (Bisogno et al., 
2003), localized in plasma membrane and stimulated by Ca2+, to form 2-AG. The degradation 
procedure of the 2-AG is mediated by MAGL. MAGL is hydrolyzing the binding of 
arachidonic acid to glycerol (Pertwee, 2005). In more than 85% of the brain and CNS, 2-AG is 
inactivated by MAGL. The remained 15% is shared between two less characterized enzymes: 
β-hydrolase 6 (Abhd6) and α, β-hydrolase 12 (Abhd12) (Blankman et al., 2007).  
DAGL 
 
DAGL has two isoforms, α and β, with around 33% similarity in sequence level. It has 
been shown that the α isoform of DAGL is more abundant in the adult brain and β is more 
prevalent during development. There is a 80% decrease in 2-AG levels in the brain’s of 
DAGLα knockout mice. This number is about 50% in DAGLβ knockouts. Thus, DAGLα is 
necessary and essential in the synthesis of the 2-AG and endocannabinod signaling in the rat 
brain (Gao et al., 2010).  
MAGL 
 
Monoacylglycerol lipase (MAGL) is a 33-kDa, membrane-associated serine hydrolase. 
MAGL is localized presynaptically with a nearly complementary expression pattern with 
FAAH (postsynaptic) in rat hippocampus, cerebellum and amygdala (Dinh et al., 2002). 
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Mechanism of action 
 
Highly lipophilic eCB agonists, unlike the other water-soluble neurotransmitters, 
cannot be stored in the vesicles and are produced “on demand“ (Piomelli, 2003). Cannabinoid 
receptors (CBRs) are subtypes of the cell membrane G-protein coupled receptors. As G-
protein receptors, CBRs include seven transmembrane domains that activate a signal 
transduction pathway inside the cell by detecting a signal from the outside.  
The presynaptic CBRs can reduce neurotransmitter release retrogradedly and 
mediating transient synaptic plasticity (short-term depression (STD) whether as 
depolarization-induced suppression of excitation (DSE)(Kreitzer and Regehr, 2001) or 
inhibition (DSI) (Ohno-Shosaku and Kano, 2014; Wilson and Nicoll, 2001). Additionally, 
eCB can mediate long-term depression (LTD) at both excitatory (Chevaleyre and Castillo, 
2003; Marsicano et al., 2002) and inhibitory synapses (Gerdeman et al., 2002). Throughout the 
CNS, both LTD and STD regulate various types of GABAergic and glutamatergic synapses 
(Figure 1-5A). High levels of this system are found in cerebral regions that correspond to the 
pharmacological effects of THC. The disturbance of normal eCB activity may be associated 
with some diseases (Bluett et al., 2014; McPartland et al., 2014; Russo, 2008; Smith and 
Wagner, 2014). Some studies suggest that the modulation of eCB activity holds therapeutic 
promise for a broad range of diseases, including neurodegenerative, cardiovascular and 
inflammatory disorders (Robson, 2001). 
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2-AG in eCB-STD 
  
The augmentation of the intracellular Ca2+ and/or activation of Gq/11 coupled receptors 
induce the release of 2-AG from postsynaptic neurons. 2-AG binds to presynaptic CB1R and 
inhibits the release of neurotransmitter. The retrograde signaling terminates when MAGL 
degrades 2-AG (Tanimura et al., 2012; Ohno-Shosaku and Kano, 2014) (Figure 1-5A).  
2-AG in eCB-LTD 
 
Utilizing a similar mechanism to eCB-STD (Ca2+ driven eCB release), eCB-LTD is 
induced mostly by repetitive stimulations that trigger the release of glutamate from excitatory 
presynaptic terminals. Glutamate activates the post-synaptic mGluRs and induces activation of 
CB1R via 2-AG release (Figure 1-5B). Generally 2-AG induces a fast, transient and point-to-
point retrograde signal. 
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Figure 1-5 eCB and (A) STD: Influx of the Ca2+ from voltage gated Ca2+ channels (VGCCs) triggered by a 
postsynaptic activity. Ca2+ stimulates the production of eCB via DAGLα. The activation of the postsynaptic group I 
metabotropic glutamate receptors (mGluRs I) can also prompt the eCB mobilization via PLCβ . (B) Inhibitory and 
excitatory LTD via eCBs. eCB (2-AG) inhibits the postsynaptic mGluRs that has activated by glutamate released via 
reduction in adenylyl cyclase (AC) and protein kinase A (PKA) activity. On the other hand, in the inhibitory synapses, 
eCB reduces the GABA release via decreased PKA activity, in conjunction with activation of the Ca2+-sensitive 
phosphatase calcineurin (CaN)(Castillo et al., 2012) 
 
 
Anandamide 
 
 
N-arachidonoylethanolamine (AEA) also known as anandamide is a CB1R and CB2R 
endogenous agonist. It is found in very low concentrations and has a short half-life. It can be 
found throughout the CNS and periphery. It may a play role in human behavior, such as eating 
and sleeping patterns, and pain relief (Di Marzo and Fontana, 1995; Wilson and Nicoll, 2001; 
Mouslech and Valla, 2009). 
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Synthesis and degradation 
 
Di Marzo et al suggested a hypothesis for the synthesis of the AEA, for the first time. 
The neurons, which are stimulated with a membrane-depolarizing agent, produce anandamide 
in response to intracellular Ca2+ elevation (Di Marzo et al., 1994). The calcium dependent N-
acyltransferase (NAT) synthesizes the immediate precursor of AEA, N-acyl-
phosphatidylethanolamine (NAPE) from phospholipids. The phospholipase D enzyme, NAPE-
PLD, produces the AEA from NAPE (Pertwee, 2005). The enzyme FAAH hydrolyzes the 
anandamide from its binding site and degrades it to arachidonic acid and ethanolamine rapidly 
(Figure 1-6A)(Pertwee, 2005; Wang and Ueda, 2009).  
 
 
 
 
NAPE-PLD 
 
This cell-membrane-associated enzyme composed of 396 (in mouse) and 393 (in 
human) highly homologous residues (90% similarity between rat and human) produce a 46 
kDa protein. In rodents, NAPE-PLD is widely distributed with higher expression in the brain 
(specially thalamus) and testis (Okamoto et al., 2004; Morishita et al., 2005).  Besides its role 
in eCB biosynthesis, many other physiological roles have been proposed for NAPE-PLD, such 
as anti-inflammatory (Lambert et al., 2002), anorexic (Rodriguez de Fonseca et al., 2001), and 
pro-apoptotic effects (Maccarrone et al., 2002). 
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FAAH 
 
The catabolic enzyme, FAAH, is the principal integral membrane hydrolase for all 
fatty acid amides including; anandamide (eCB), oleamide (sleep inducing lipid), N-
acyltaurines transient receptor potential (TRP) channels, etc. (Cravatt et al., 1996). FAAH is 
highly expressed in the cerebellum, hippocampus, neocortex, olfactory bulb, thalamus, mid 
brain, hind brain, entorhinal cortex, and amygdala. Comparing the pattern of expression of 
FAAH and CB1R, they show complementary, overlapping and unrelated distribution 
(Egertová et al., 2003). 
 
 
Figure 1-6 Endocannabinoid biosynthesis and degradation pathways for (A) anandamide and (B) 2-AG. NAAA, N-
acylethanolamine-hydrolyzing acid amidase; PA, phosphatidic acid (Wang and Ueda, 2009). 
 
Anandamide and eCB signaling 
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Anandamide mediates eCB-LTD with high-frequency stimulations. Anandamide’s 
contribution to LTD is not limited to eCB receptors. Part of the LTD effect is induced via 
transient receptor potential vanilloid type 1 (TRPV1) and intracellular calcium (Lerner and 
Kreitzer, 2012).  TRPV1, capsaicin receptor or the vanilloid receptor 1, is mainly responsible 
for regulation of body temperature and nociperception. The effect of the anandamide on 
TRPV1 depends on the species and tissue. Moreover, cannabinoid receptor activation via 
AEA, modulate TRPV1 responsiveness. In some cases, the coactivation of both receptors 
makes it difficult to distinguish the exact signaling pathway (Toth et al., 2009) 
Anandamide, unlike 2-AG, contributes to homeostatic plasticity in the hippocampus by 
making an eCB tone (Figure 1-7) (Kim and Alger, 2010).  
 
 
Figure 1-7 Function of anandamide in eCB and TRPV1 signal transmission 
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Receptors 
Two leading receptors and a potential receptor have been introduced for the eCB system so 
far. 
 
CB1R 
 
Known as the primary receptor for the eCB system, CB1R is responsible for the main 
physiological and psychological actions of the cannabinoids; CB1R, a 472 amino acid protein, 
is the most abundant G-protein-coupled receptor in the brain. It is the first CB receptor that 
was cloned from the rat (Matsuda et al., 1990) and shows up to 98% similarity across species 
(Elphick and Egertová, 2001). Like all other G-protein-coupled receptors, CB1R contains 
seven transmembrane domains connected by three extracellular and three intracellular loops, 
an extracellular N-terminal tail, and an intracellular C-terminal tail (Figure 1-8). It couples to 
inhibitory G-proteins (Gi/o) implying that cannabinoid agonists inhibit adenylate cyclase (AC) 
and decrease the activity of PKA, decreasing the release of neurotransmitters. Activation of 
CB1R, coupling to Gi/o proteins, decreases the intracellular cAMP concentration and augments 
the activity of MAP kinase. It can also activate the adenylate cyclase via Gs proteins (Pertwee, 
2006). The modulation of cAMP will indirectly influence several ion channels and enzymes 
such as inwardly rectifying potassium channels, calcium channels, PKA, protein kinase C 
(PKC), Raf-1, ERK, JNK, p38, c-fos, c-jun, and others (Demuth and Molleman, 2006; Pagotto 
et al., 2006). 
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Expression 
 
CB1R is the most abundant G-protein-coupled receptor in the brain, it is copious in the 
CNS as a pre-synaptic receptor at both glutamatergic and GABAergic interneurons (Elphick 
and Egertová, 2001). CB1R is primarily found in the hippocampus, the association cortices, 
cerebellum and basal ganglia (Herkenham et al., 1991; Tsou et al., 1998), peripheral nervous 
system (Egertová and Elphick, 2000), central and peripheral parts of the retina (Straiker et al., 
1999; Yazulla et al., 1999; Bouskila et al., 2012) of rodent and primate. Its presence is also 
reported in certain populations of interneurons in somatosensory area, primary motor, 
thalamus, retinal and visual cortex of the rodent (Marsicano and Lutz, 1999; Zabouri et al., 
2011a) and primates (Eggan and Lewis, 2007; Bouskila et al., 2012). It is also expressed in 
peripheral tissues such as lungs, testes, the uterus, the immune system, intestine, bladder, and 
retinal cells endothelial however at a lower concentration than in the CNS (Sugiura and Waku, 
2002).  Also, CB1R is expressed in human sperm and ovaries, oviducts myometrium, decidua, 
and placenta (Pagotto et al., 2006).  
 
Known functions of CB1R 
 
Activation of CB1R inhibits the release of excitatory or inhibitory neurotransmitters, 
such as acetylcholine, noradrenaline, dopamine, 5-HT, GABA, glutamate, D-aspartate, and 
cholecystokinin and acts as retrograde synaptic mediators (Pertwee, 2008). In some diseases 
such as in hepatocellular carcinoma and prostate cancer cells, the expression of CB1R is 
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amplified. It is proposed that this modulation of neurotransmitter release prevents pain and 
inflammation response (Pisanti et al., 2013).  
The removal of the CB1R of GABAergic and glutamatergic neurons in cnr1 knockout 
mouse results in opposite behavior changes. Exploration of objects, socialization, and open 
field movement increased in GABAergic cnr1 knockout mice and decreased in glutamatergic 
cnr1 knockouts (Haring et al., 2011).  
As the main role player in psycho-effective symptoms of cannabis, CB1R principal 
behavioral effects include but are not limited to the disruption of psychomotor behavior (Pillay 
et al., 2004; Rodríguez de Fonseca et al., 2005), short-term memory impairment (Kanayama et 
al., 2004; Jager et al., 2006; Han et al., 2012) stimulation of appetite (Mattes et al., 1994), anti-
nociceptive actions (Pini et al., 2012) and anti-emetic effects (Tramer et al., 2001). The eCB 
system has been shown to be prevalent in the development of the retina (Zabouri et al., 2011a; 
Zabouri et al., 2011b), development of CNS (Fernández-Ruiz et al., 2000), axon guidance 
(Argaw et al., 2011), and proper development of the rodent embryo (Pagotto et al., 2006).  
 
Exogenous synthetic agonists 
 
WIN 55,212-2 
 
This synthetic agonist is an aminoalkylindole derivative that has a similar effect to 
THC with much higher affinity to CB1R with a completely different structure that is not 
similar to any classical and nonclassical eicosanoid cannabinoids.  
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CP 55,940 
 
This is a synthetic full agonist for both CB1R and CB2R made by Pfizer. It is 45 times 
more potent than THC and acts as the antagonist of GPR55. 
 
Antagonists:  
Rimonabant  
 
 
SR141716 or rimonabant was the first CB1R blocker that has been developed by 
Sanofi as an anorectic anti-obesity drug branded under the name of Acomplia. It has also been 
approved for smoking cessation in Europe. Mainly in vitro and at the molecular level, 
rimonabant is acting as an agonist, a neutral antagonist or an inverse agonist (Fong and 
Heymsfield, 2009). At physiological levels, rimonabant reduces food intake, liver lipid 
production, and fat mass but increases the energy expenditure (Addy et al., 2008). 
In 2008, the European Medicines Agency's Committee for Medicinal Products for 
Human Use announced that due to the risk of serious psychiatric problems and suicidal 
thoughts, the risk of rimonabant outweighed its benefits. 
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AM251 
 
AM251 is another cannabinoid inverse agonist of CB1R. It has a very similar structure 
to rimonabant and a better binding affinity for the receptor (Lan et al., 1999). 
 
Figure 1-8 Structures of the CB1R (blue) and CB2R (green). 
 
 
 
CB2R 
 
Comprised of approximately 360 amino acids in human, with about 44% of similarity 
in sequence level and high likeliness in structure to CB1R, CB2R is another G-protein-coupled 
receptor of the eCB system. Rats and humans share up to 81% homology in their CB2R genes 
(Griffin et al., 2000). Due to its abundant expression in the immune system, it was first 
informally considered as the “peripheral” cannabinoid receptors (Munro et al., 1993). The 
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variations (mainly increase) in the expression level of CB2R in different diseases such as 
nerve injury, multiple sclerosis, amyotrophic lateral sclerosis, make it attractive as a 
therapeutic target (Wotherspoon et al., 2005; Yiangou et al., 2006).  Later on, some other 
groups reported the expression of CB2R in brain and CNS (Cabral et al., 2008). 2-AG is 
considered as the principal agonist due to its higher efficacy to activate CB2R (Lynn and 
Herkenham, 1994). Anandamide, on the other hand, has a lower affinity for the receptor and is 
considered as a partial agonist for CB2R (Showalter et al., 1996). The exogenous agonist 
cannabinol has higher affinity towards CB2R (Felder et al., 1995).  
Similar to CB1R, CB2R inhibits the adenylyl cyclase through the Gi/o coupled G 
protein receptor (Shoemaker et al., 2005). Moreover, it has been proposed that CB2R can 
regulate a series of complex signal transduction via the MAPK-ERK pathway (Demuth and 
Molleman, 2006). Unlike CB1R, CB2R is not a proper modulator for calcium and inwardly 
rectifying potassium channels (Felder et al., 1995).  Interestingly, the pharmacological 
responses of the CB2R vary from one species to another (Mukherjee et al., 2004).   
 	  
Expression 
 
As a “peripheral” eCB receptor, CB2R mRNA was found in immune cells such as 
monocytes, macrophages, B-cells, and T-cells, and immune/peripheral tissues such as the 
spleen, tonsils, and thymus gland 10-100 times more than CB1R (Galiègue et al., 1995). In the 
CNS, the expression of CB2R is reported in rodent cerebellum purkinje, granule cells and 
white matter (Skaper et al., 1996; Ashton et al., 2006). This expression in the cerebellum was 
not colocalized with astrocyte marker glial fibrillary acidic protein (GFAP) and were probably 
	   42	  
microglial or neuronal (Ashton et al., 2006). The expression of CB2R has been reported in 
rodent brainstem’s cochlear and vestibular nuclei (Baek et al., 2008), many areas of 
hippocampal formation (Onaivi, 2006; Onaivi et al., 2006), striatum and hypothalamus (Gong 
et al., 2006). The immunoreactivity of CB2R has been reported in many thalamic nuclei, 
olfactory bulbs, cortex and midbrain despite the nonappearance of the mRNA or protein 
expression (Gong et al., 2006; Onaivi, 2006).  CB2R is present throughout the rodent retina 
and along the retino-thalamic pathway (Cecyre et al., 2013; Duff et al., 2013).  	  
 
Known functions of CB2R 
 
Due to the expression pattern of the CB2R, its role in immune system has been widely 
studied, particularly its effects on the immunological activity of leukocytes, immune 
suppression, induction of apoptosis, and induction of cell migration (Kaminski, 1998; Basu et 
al., 2011). Since the CB2R agonist inhibits T-cell receptor signaling by changing cAMP level, 
the possibility of applying the CB2R agonist as a treatment of inflammation and pain is under 
investigation (Cheng and Hitchcock, 2007). CB2R can play a noteworthy role in neurogenesis. 
For instance, JWH-015, a CB2R agonist, eliminates the beta-amyloid protein that impairs 
neural activity in Alzheimer patients (Tolon et al., 2009). The CB2R may play a modulatory 
role in axon guidance and participate in the retinothalamic pathway formation (Duff et al., 
2013). It has been shown that in the rat brain and human neurons, the CB1R and CB2R form 
functional heteromers in which the activation of one resulted in a negative modulation of the 
other receptor (Callen et al., 2012).  This heterodimerization may explain the co-expression of 
these receptors in some parts of the brain (Koch et al., 2008) as well as the negative cross talk 
between the CB1R antagonist and the CB2R agonist and inverse agonists.  
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Agonist 
 
JWH-015 
 
A synthetic agonist from naphthoylindole family that binds 28 times stronger to CB2R than 
CB1R. Despite of the selectivity of this agonist on CB2R, in some models it activates CB1R 
efficaciously. Due to some modulatory effects of this agonist, it is considered as a possible 
therapeutic candidate to treat pain and inflammation (Balter et al., 1993). 	  
 
Antagonists  
AM630 
 
 
AM630 is a selective inverse agonist for CB2R and a partial agonist for CB1R. It is a 
derivative of indole and commonly used to investigate the CB2R signalization (Shoemaker et 
al., 2005; Pertwee, 2006).   
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SR144528 
 
SR144528 is a highly selective inverse agonist of CB2R with a very low affinity for CB1R 
that binds 660 times stronger to CB2R than CB1R and used in research as a candidate to 
isolate the activity of CB2R (Rinaldi-Carmona et al., 1998). 
Table 1-1 Comparison of the CB1R and CB2R agonists’ efficacy 
 CB1Ra affinity 
(Ki) 
Efficacy 
towards 
CB1R 
CB2R affinity 
(Ki) 
Efficacy 
towards 
CB2R 
Type 
THC1 10 nM Partial agonist 24 nM Partial agonist Phytogenic 
2-AG2 58.3 nM Full agonist 145 nM Full agonist Endogenous 
AEA3 78 nM Full agonist 370 nM Partial agonist Endogenous 
JWH-0154 383 nM Partial agonist 13.8 nM Full agonist Synthetic 
JWH-1331 680 nM Weak agonist 3.4nM Full agonist  Synthetic 
WIN 55,212-25 62.3 nM Agonist  3.3 nM Agonist Synthetic 
 
ACEA6 1.4 nm Agonist 3100nm Weak agonist Synthetic 
1. PDSP Database – UNC. NIMH Psychoactive Drug Screening Program. 2013; 2. Sugiura et al., 1994;  
3. Devane et al., 1992; 4. Aung et al 2000; 5-Felder et al., 1995; 6. Hillard et al., 1999.  
 
GPR55 
 
Human GPR55 is composed of 319 amino acids and shares only 13.5% similarity to 
CB1R and 14.4 % identity to CB2R, while it is very similar to rhodopsin family (Sharir and 
Abood, 2010). GPR55 is potentially activated by endogenous L-α-lysophosphatidylinositol 
(LPI) but also responds to AM251, rimonabant, THC, 2-AG, and anandamide. Despite all the 
controversies and disagreements, GPR55, as an orphan G-protein-coupled receptor, is 
considered as the third potential cannabinoid receptor (Ryberg et al., 2007).  Interestingly, the 
strong CB1R and CB2R agonist, WIN 55,212-2, cannot activate the GPR55 despite its unique 
	   45	  
structure (Johns et al., 2007). GPR55 activates the PLC and RhoA signal transduction 
pathways via Gq  and G 12/13 and promotes the ERK1/2 signaling pathway (Oka et al., 2007).  
Expression 
 
The expression of the GPR55 mRNA reported, from the highest to lowest, in the 
adrenals, caudate, putamen, frontal cortex, striatum, jejunum, hypothalamus, brain stem, 
hippocampus, cerebellum, spleen, spinal cord, long, liver, uterus, bladder, stomach and kidney 
(Ryberg et al., 2007).   GPR55 was also found in various cell types including, endothelial and 
Schwann cells (Daly et al., 2010), human and mouse oseteoclasts and osteoblasts (Whyte et 
al., 2009), murine insulin secreting β-cells (Romero-Zerbo et al., 2011), rat prostate and 
ovarian cells (Pineiro et al., 2011).    
 
Known functions of GPR55 
 
The physiological functions of GPR55 are poorly characterized. The gpr55 knockout 
mice showed no specific phenotypes (Johns et al., 2007). Referring to the role of GPR55 in 
increasing the intracellular Ca2+ in large-diameter dorsal root ganglion neurons, a modulation 
of nociception was suggested after tissue damage and inflammation in nervous system (Gold 
and Gebhart, 2010). An increase in GPR55 mRNA and protein in patients with type-2 
diabetes, visceral adiposity and higher level of circulating LPI in obese patients suggests its 
role in energetic metabolism (Maccarrone et al., 2010; Moreno-Navarrete et al., 2012). The 
abundance of the GPR55 and LPI in the brain also insinuates a modulatory role of the GPR55 
in the CNS (Oka et al., 2009). Other studies suggest potential roles for GPR55 in bone 
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physiology and activity of osteoclasts (Whyte et al., 2009), cancer (Sutphen et al., 2004), and 
cell proliferation (Andradas et al., 2011).   
 
Agonists 
L-α-Lysophosphatidylinositol (LPI) 
 
Found in sodium salt of soybeans and also made in human body, it induces phosphorylation of 
ERK and augmentation of intracellular Ca2+ via GPR55. 
O-1602 
	  
A synthetic agonist with a very low affinity towards the classical CB1R and CB2R but with a 
high affinity for GPR55 and some other orphan G-protein coupled receptors. O-1602 creates 
some of the well-known cannabinoid symptoms such as appetite stimulation, anti-
inflammatory role and analgesic effect. Interestingly it doesn’t trigger any psychoactive and 
pain relief symptoms of the common cannabinoid agonists. 
Antagonists 
CID-16020046 
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A synthetic selective antagonist that inhibits many effects of GPR55 activations such as 
restraint of the Ca2+ signaling prompted by LPI, phosphorylation of ERK1/2 and activation of 
the transcription factor mediated by GPR55. 
O-1918 
 
O-1918 is a synthetic cannabidiol related antagonist of GPR55 and GPR18 and used to study 
the non-CB1R  non-CB2R related effect of cannabinoids. 
 
PSB-SB-487 
 
Selective antagonist of GPR55, that plays the role of a weak antagonist for CB1R and partial 
agonist for CB2R. As a derivative of coumarin, it is a weak antagonist of CB1R and a partial 
agonist of CB2R. 
Cannabidiol 
	  
As one of the natural components found in cannabis that has no significant effect on CB1R 
and CB2R, cannabidiol is an antagonist of GPR55 
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The Visual System  
The visual system of all vertebrates comprises three main constituents: the eye, as a 
capturing machine detects the light that converts optical data to electro-chemical neuronal 
messages; visual pathways, which transfer the neuronal message from the eye to the brain; and 
visual brain, that translates the neuronal messages to practical images.  
 
Eye 
The light reflected from surrounding objects is refracted through the clear cornea, 
passes through the pupillary opening in the middle of the beautiful iris to reach the lens. The 
lens focuses the light entering the eye on the retina. The retina transduces the optical stimuli 
into electrical impulses, which are transmitted to the brain. (Figure 9). The axons of the 
ganglion cells in the retina transfer the retinal electrical impulse via optic nerve to optic 
chiasm and via optic tract to the dorsal lateral geniculate nucleus (dLGN) and superior 
colliculus (SC). The dLGN relays the signal for a basic analysis to the occipital lobe of the 
brain where the visual cortex resides (Purves et al., 2012).        
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Figure 1-9 Anatomy of the primate eye (taken from Principles of Neural Science, Eric Kandel et al.) 
 
The bulbus oculi (globe of the eye) that creates a cavity for the vitreous is composed of three 
layers. The outermost layer, sclera, is a series of opaque collagen and elastic fibers that 
support the wall of the eyeball. The choroid layer, in the middle, provides nutrition and 
oxygen to the eyes and reduces the light reflection inside the globe via its melanin-pigmented 
layers. The most inner layer is the retina  (Figure 1-9).    
Structure of the Retina 
 
The light sensitive thin and fragile meshwork of the retina is considered as an 
extension of the brain that initiates the visual perception encountering the light. It is composed 
of three layers of nerve cells (inner nuclear layer (INL), outer nuclear layer (ONL), and 
ganglion cell layer (GCL)) and two layers of synapses (inner plexiform layer (IPL), outer 
plexiform layer (OPL)). INL contains the nuclei of horizontal cells, bipolar cells and amacrine 
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cells. ONL is composed the cell bodies of rods and cones. The ganglionic cell layer contains 
the ganglion cells and some displaced amacrine cells. In the plexiform layers, the IPL is the 
designation of the location where synapses between bipolar cells’ axons and ganglion and 
amacrine cell dendrites connect to each other. The OPL is the crossroad of the rods and cones’ 
synapses with the bipolar, amacrine and horizontal cells (Figure 1-10). 
 
Figure 1-10 Structure of the primate retina (from ELSEVIER Netterimages.com) 
 
The photoreceptors 
 
Photoreceptor cells, found in the back of the eye adjacent to the pigment epithelium 
and behind all other retinal cells, trigger the potential change in the cell membrane by 
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absorbing light photons and initiating the visual processing. Light absorption isomerizes the 
visual pigment that hyperpolarizes the photoreceptor. Rods and cones are the two chief 
photoreceptors in the retina. They are in the depolarized state and release glutamate 
continuously before being stimulated.	  Cones are the main role player for the photopic vision, 
and rods mediate scotopic vision.   
Cones 
 
Cones are less responsive to light and highly sensitive to small changes, capable of 
detecting contrast, faster response and responsible for the color vision. In the retina of human 
and non-human primates, three types of cones are present. S cones that are absorbing the short 
wavelength light (blue, 420–440 nm), M cones for medium wavelength (green, 534–545 nm) 
and L cones that are reacting to the long wavelength (red, 564–580 nm) (Bowmaker and 
Dartnall, 1980) (Figure 1-11). 
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Figure 1-11 Rods and cones sensitivity spectra. A) Color visions and light absorption spectra for rods and cones. B) 
The luminance thresholds of the vision and each correspondent role player (taken from Purves et al., third edition).  
 
 Around five million cones can be found in human retinal with the highest density in the rod-
free central fovea and macula. The quantity of cones is declined as one moves towards the 
peripheral retina (Curcio et al., 1990). Each cone is associated with two bipolar cells: ON and 
an OFF. Cones release glutamate neurotransmitter that inhibit (hyperpolarizes) ON bipolar and 
excites (depolarizes) the OFF cells. Lack of light and darkness depolarizes the cones so that 
they open the synaptic voltage-gated Ca2+ channels, increase the Ca2+ in terminals and release 
the glutamate. The release of glutamate inhibits the ON bipolar cells (Schiller, 1992).  
Inversely, the light closes the voltage-gated Ca2+ channels and reduces the influx of Ca2+ and 
consequently, decreases the release of glutamate that hyperpolarizes the OFF bipolar cells 
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(Figure12). Moreover, glutamate opens a form of cation channel in OFF cells that carries an 
inward Na+ current into cells. Light exposure after a full dark adaptation causes a temporary 
saturation of the cones (Schiller, 1992).  
 
 
Figure 1-12 Conte retinal circuitry. Retinal connection to ON and OFF bipolar cells in light and dark. Red arrows 
indicate sign-preserving connections through electrical or glutamatergic synapses. Gray arrows represent sign-
inverting connections through GABAergic, glycinergic, or glutamatergic synapses (Principles of Neural Science- 
Kandel 2013). 
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Rods 
 
With higher concentration in the outer segments of the retina, rods play an important 
role in dim light and peripheral vision. Human retina possess approximately 125 million rods. 
Rods are more sensitive to light than cones due to their abundant photosensitive visual 
pigments. While about ten photons are required to evoke an electrical response in cones, one 
photon will be enough to evoke a similar response in a rod. Rods create a very convergent 
system with their bipolar neurons. Many rods can have synapses on the same bipolar cell as 
their target thus signals from rods are pooled and reinforce each other in the bipolar cells.  
Rods are connected to ON bipolar cells. In the dark, the depolarized rods release glutamate 
and hyperpolarize the bipolar cells.  The rhodopsin in rods captures a photon and triggers a 
cascade of events that close the cyclic guanosine monophosphate (cGMP)-gated channels that 
are normally opened in darkness (Yee and Liebman, 1978; Burns and Baylor, 2001).  
 
Table 1-2 Comparison of the photoreceptors: rods and cones (adapted from Principles of Neural Science, Eric Kandel 
et al.) 
 
Rods Cones 
Sensitivity to light High: night vision Low: day vision 
Photopigments More Less 
Light amplification High: single photon detection Low 
Temporal resolution Low: slow response, long 
integration time 
High: fast response, short 
integration time 
Sensitivity to  More scattered light More direct axial rays 
Acuity Low; not in fovea, highly 
convergent retinal pathway 
High; concentrated in fovea, 
dispersed retinal pathway 
Chromaticity Achromatic Chromatic 
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Rod and Cone structure 
 
Both rods and cones have a similar basic structure. Rods are more abundant and a little 
longer and leaner than the cones.  
Photoreceptors have three major functional regions (Figure 1-13): 
1- Outer segment; filled with photo-absorbing pigments, specialized for signal transduction. 
The outer segment of both photoreceptors contains a stack of membrane discs that resides in 
the photopigments.  
2- Inner segment; include the nucleus and biosynthetic machinery. 
3- Synaptic terminal; make contacts with the targets. 
 
 
 
  
Figure 1-13 Similar structure of the photoreceptors, rods and cones. A) morphology B) outer segment of the 
photoreceptors (taken from Principles of Neural Science, Eric Kandel et al.) 	  
Horizontal cells 
In the INL of the vertebrate’s retina, horizontal cells laterally connect the neural 
population of the retina. Most mammals have two types of horizontal cells (Figure 1-14) that 
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assist the regulation and modulation of the feedback onto both rods and cones and possibly to 
bipolar cells’ dendrites and adjust the eye to see in dim light and bright light conditions 
(Muller and Peichl, 1993; Masland, 2012). The photoreceptors release of glutamate in scotopic 
conditions depolarizes horizontal cells and triggers the release of GABA. As an inhibitory 
neurotransmitter, GABA hyperpolarizes the adjacent photoreceptors. Inversely, illumination 
results in hyperpolarization of the horizontal cells and depolarization of the surrounding 
photoreceptors (Masland, 2012). 
 
Bipolar cells 
 
Found in the middle layer of the retina, bipolar cells transmit signals from either cones 
or rod to ganglion cells.  Generally divided into two main categories of ON and OFF cells, 
bipolar cells have a diverse morphology (Figure 1-14). Based on the extent of the dendritic 
arbor, there are two types of bipolar cells in the primate retina; midget cells that contact a 
single cone and diffuse cells that contact multiple cones. Both rods and cones release 
glutamate in scotopic conditions that inhibit the ON (hyperpolarize) and excite the OFF 
(depolarize) bipolar cells. The glutamate hyperpolarizes ON bipolar cells through 
metabotropic receptors mGluR6 or glutamate transporter (Koyasu et al., 2008) while they 
depolarize OFF bipolar cells through ionotropic glutamate receptors (iGluR) (DeVries, 2000). 
Mainly the ON bipolar cells synapses in the inner layer of IPL and OFF bipolar cells terminate 
in the outer IPL. Rod bipolar cells do not directly contact the ganglion cells but synapse with 
all amacrine cells and consequently inhibit the cone OFF bipolar cells and excite cone ON 
bipolar cells (Stell et al., 1977; Schiller, 1992). 
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Amacrine cells 
 
Amacrine cells, with more than 29 types (Figure 1-14), are the most variable neuronal 
cells in the retina. Main inputs of retinal ganglion cells from bipolar cells are transduced via 
amacrine cells. Residing adjacent to axon terminals of bipolar cells makes amacrine cells an 
apt regulator of the output signal of bipolar cells to ganglion cells (Masland, 2001). Amacrines 
make a heterogenous population that play an important role in analysis of the spatial and 
temporal parameters of visual information in the inner retina (MacNeil and Masland, 1998). In 
addition, they may orchestrate the ganglion cell firing. Inputs from an amacrine cell correlate 
several ganglion cells to fire simultaneously. This characteristic expands the capacity of the 
optic nerve to pass the visual information (Masland, 2001).  
 
Ganglion cells 
 
In vicinity of the INL, ganglion cells receive the visual information of the 
photoreceptors via the bipolar, horizontal and amacrine cells. They are the only neural cells 
that transfer action potentials from the eye to rest of the brain. Approximately 1.5 million 
ganglion cells receive visual input from about 125 million photoreceptors; every 100 
photoreceptors give input to a ganglion cell (this ratio varies from the fovea to the periphery).  
Morphologically, about ten to fifteen types of retinal ganglion cells have been identified that 
are different in terms of size, connections, and responses to visual stimulation (Masland, 2001) 
but all of them have a long axon which originates in GCL passing through optic nerve, optic 
chiasm, and optic tract, and terminating in the brain.  
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Similar to bipolar cells, most ganglion cells have concentric (ON and OFF) receptive 
field organization, which receive input from ON and OFF bipolar cells respectively. Hence, in 
the middle of their receptive fields, ON ganglion cells are depolarized in light spot and OFF 
ganglion cells will respond to a dark spot.   
Based on the projection and function, there are at least five main classes of retinal 
ganglion cells: parasol cell (magnocellular, M cells), midget cell (parvocellular, P cells) and 
non-M non-P cells including; bistratified cell (koniocellular, K cells), photosensitive ganglion 
cells, other ganglion cells projecting to the superior colliculus for eye movements (saccades). 
Parasol cell 
 
The ganglion M cells, with larger dendritic trees and cell body size and make up 5% of 
the retinal ganglion cells. They have larger receptive fields and receive the signal from many 
photoreceptors. M ganglion cells are faster in conducting the action potentials in the optic 
nerve and are more sensitive to low contrast. They transfer the retinal action potential to 
magnocellular layer of the dorsal lateral geniculate nucleus (dLGN). 
 
 
Midget cell 
 
The ganglion P cells, with small dendritic trees and cell body size, make up about 90% 
of the retinal ganglion cells. They have smaller receptive fields and receive the input from few 
photoreceptors. P ganglion cells are slower in conducting the action potentials to the optic 
nerve. They are more sensitive to colors and less responsive to feeble changes in contrast. 
They transfer the retinal action potential to parvocellular layer of the dLGN. 
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Bistratified cell 
 
Despite their very large receptive fields, the small ganglion K cells make up only 5% 
of the ganglion cells and project to the koniocellular layer of the dLGN. They receive inputs 
from some rods and cones and have a moderate spatial resolution and contrast sensitivity.  
Their receptive fields contain only the center field and are constantly ON for blue and OFF for 
red and green cones (Bears et al 2007). Other non-M non-P cells like photosensitive retinal 
ganglion cells are less assessed. Some of their proposed roles include circadian rhythms, and 
pupillary control (Wong et al., 2005).  
 
Figure 1-14 Major cells in the mammalian retina. Adapted from (Masland, 2001) 
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Retinal glial cells 
 
In addition to several microglia in retina, Müller cells, found as main retinal macroglia 
in vertebrates, are responsible for homeostatic and metabolic support of retinal neurons across 
the retinal thickness, important elements for immune responses and disposal of the metabolic 
wastes (Newman and Reichenbach, 1996). Müller cells are produced from progenitor cells of 
retina and are in contact with all retinal neurons (Distler and Dreher, 1996). They are roughly 
150 µm in length with a cylindrical, fiber-like shape. Glutamine synthetase (GS), which is 
uniquely present in Müller cells and glia, rapidly convert glutamate into glutamine. Müller 
cells release this glutamine that is mainly utilized by bipolar and ganglion cells as a precursor 
for glutamate and/or GABA (Bringmann et al., 2009).  On other hand, Müller cells collect the 
neuronal GABA and glutamate and release metabolic substrate to prevent oxidative stress 
(Bringmann et al., 2009). They are so crucial for support of photoreceptor function, especially 
cones, that in transgenic mice that lack Müller cells the photoreceptors face apoptosis (Shen et 
al., 2012).  Müller cells control the osmotic and ionic homeostasis of extracellular potassium 
level via passive current through Kir4.1 channels (Bringmann et al., 2009). Additionally, 
resembling a living optic fiber, Müller cells minimize the light scattering and direct the light 
towards the photoreceptors in inner layers of the retina (Franze et al., 2007). Astrocytes are 
produced in brain and migrate through the optic nerve fibers to the of ganglion cell layer 
(Huxlin et al., 1992). 
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Beyond The Retina 
All the axons of the ganglion cells are packed together in optic disk and exit the retina 
towards the brain through a neuronal cable called the optic nerve.  Lack of photoreceptors in 
the optic disk region makes it insensitive to light and cause the blind spot phenomena. Optic 
nerves cross at the base of the diencephalon at the optic chiasm. In primate, about 60% of the 
nerves cross over the opposite side of the brain while the remaining cells continue into the 
brain onto the ipsilateral side. The set of axons passing the optic chiasm to the ipsilateral 
dLGN is called optic tract (Figure 1-15).   
 
Figure 1-15 The primary visual pathway from the retina to the visual cortex. The resulted visual image in each eye 
after damages in different point along the pathway (taken from Purves et al., third edition). 
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Dorsal Lateral geniculate nucleus 
Located in the dorsal thalamus, dLGN receives and analyzes the majority of the retinal 
visual information coming via the optic tract and relays them to the efferent visual cortex. A 
coronal section of the primate dLGN is similar to a laminar «Bicorne hat» consisting of 6 
layers with 5 interlayers. This laminar structure shows that the specific elements of visual 
information should be treated differently at this level. The first two ventral laminae of the 
dLGN are magnocellular layers (an ipsilateral and a contralateral) that obtain their inputs from 
M ganglion cells. Each layer receives the visual information from one eye only.  The four 
dorsal layers called parvocellular layers (two ipsilateral and two contralateral) receive inputs 
of P ganglion cells. The interlaminar layers, called the koniocellular layers, are the destination 
of the non-M and non-P ganglion cells (Figure 1-16). Similar to M ganglion cells, 
magnocellular layers have larger cells with a large receptive field and rapid axon conduction.  
The magnocellular pathway plays a role in coarse-grain information transmission and 
perception of movement. The magnocellular layers contribute to the ventral stream that is 
associated with object recognition and form representation. The dorsal stream, also known as 
the “where or how” pathway, is involved in the spatial awareness, guidance of action and 
analyzing the movements. On the other hand, the four parvocellular layers with small cell 
volume and receptive field, play a role in object recognition, form representation and highly 
selective for color vision. Including the majority of the dLGN cells, parvocellular layers 
contribute to ventral stream or “what” pathway.  The koniocellular layers have the smallest 
relay cells that are stimulated by blue short-wavelength cones (Martin et al., 1997).   
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Figure 1-16 The dLGN Organization. Ganglion cells’ projection to dLGN layers (adopted from Principles of Neural 
Science, Eric Kandel et al and studydroid.com).  
 
 
Table 1-3 Comparison of the M, P and K pathways.    
 Cell size Source Response Functions 
Magnocellular Large Rods Fast Motion perception, Depth, 
sensitive to brightness, nystagmus 
Parvocellular Small Cones Slow Color and form 
Koniocellular Very 
small 
Blue 
cones 
In 
between 
Yellow and blue color perception 
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Visual cortex 
Via dLGN, the visual information is transferred to the visual cortex that consists of a 
multitude of areas in the occipital, parietal, and temporal lobes.  The visual cortex is divided 
into striate cortex (includes primary visual cortex (V1)) and the extrastriate areas that contain 
the visual areas two (V2), three (V3), four (V4), and five (V5) (Figure 1-17).  
 
Figure 1-17 The visual cortex subdivisions in the macaque monkey (taken from Principles of Neural Science, Eric 
Kandel et al.) 
 
 
 
V1 is the most studied part of the visual cortex. Located in the occipital lobe, V1 
neurons are tuned for spatial frequency processing, pattern recognition, visual orientations, 
and color perception. Both dorsal and ventral streams initiate in V1 and pass to V2 project to 
V5 (MT), and posterior parietal cortex or to V4, and to the inferior temporal cortex, 
respectively.    
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The 2 mm thick visual cortex in primates is divided into six layers. The layer 4, which 
receives the majority of the dLGN projections, is subdivided into four sub-layers: 4A, 4B, 
4Cα, and 4Cβ. Magnocellular layer cells are first projected into 4Cα, and then 4B (Figure 1-
18). 4B cells are projected into middle temporal (MT) and a large stripe towards V2, from 
which cells project to MT. Parvocellular layers mainly target the 4Cβ with a thin strip towards 
V2 that may turn the project into V4. Collaterals of both project and receive robust 
corticogeniculate feedback to and from layer 6 (Van Horn et al., 2000).  
 
 
           
Figure 1-18 The geniculocortical and corticogeniculate pathway in the primate brain. 	  	  
Prestriate cortex (V2) sends and receives robust connections from and to V1. It also 
sends connections to V3, V4, and V5. As V1, it plays a crucial role in perception of 
orientation of the objects, their color and horizontal disparity. V2 continues the analysis of the 
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contour (specially illusory contours) began in V1 and affects both dorsal and ventral stream. 
V4, placed anteriorly to V2, plays a role exclusively in color vision. Moreover, V4 also 
responds to a combination of color, form and orientation of the stimuli (Goddard et al., 2011).  
Area MT or V5 is the motion perception site of the visual cortex. MT receives inputs mainly 
from V1, V2 (Felleman and Van Essen, 1991), Magnocellular and Koniocellular layers of 
dLGN (Sincich et al., 2004). A lesion in MT and medial superior temporal area (MST) impairs 
motion perception and smooth-pursuit eye movement in primates (Dursteler et al., 1987; 
Newsome and Pare, 1988). The dorsomedial area or V6 is part of the dorsal stream and 
associated with self-motion perception (Cardin and Smith, 2010).   
 
Cannabinoids and The visual system 
 Cannabinoid and The Ocular Tissues 
The presence of the eCBs in ocular tissues has been demonstrated in the ciliary body, 
iris, choroid, trabecular meshwork and retina in rodent, porcine, bovine, monkey and human 
(Matsuda, 1997; Porcella et al., 1998; Porcella et al., 2000; Chen et al., 2005; Chang et al., 
2007). In bovine retina, activation of the CB1R stimulates monoamine oxidase (Gawienowski 
et al., 1982). In guinea pig retina, same activation results in inhibition of the dopamine release 
(Schlicker et al., 1996). Cannabinoid agonists increase the cone response to light offset (Struik 
et al., 2006). The CB1R mRNA level is ten time more prevalent in the ciliary body compared 
to retina of rodent and human (Porcella et al., 1998; Porcella et al., 2000). Except for the lens, 
the eCBs AEA and 2-AG has been found in all ocular tissues of human (Chen et al., 2005).  
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The expression of CB1R, FAAH and CB2R was demonstrated during postnatal 
development of the rodent retina. FAAH is widely distributed in the retina of zebra fish and 
gold fish (Yazulla and Studholme, 2001; Glaser et al., 2005). In the adult rodents, the CB1R, 
FAAH and CB2R are expressed throughout the retina (Zabouri et al., 2011a; Zabouri et al., 
2011b). The presence of eCBs in ocular tissues, including the ciliary body, iris, choroid and 
trabecular meshwork has been clearly showed by physiological and biochemical studies 
(Matsuda et al., 1990; Porcella et al., 1998; Porcella et al., 2000; Chen et al., 2005; Stumpff et 
al., 2005). Our lab reported that in non-human primate, the CB1R is expressed throughout the 
retina, from the foveal pit to the far periphery. CB1R is present in the photoreceptor, outer 
plexiform, inner nuclear, inner plexiform, and retinal ganglion cell layers (PRL, OPL, INL, 
IPL, and RGCL, respectively) (Bouskila et al., 2012). CB1R is also expressed in the visual 
cortex with higher expression in layer 6 and the lowest abundance in layer 4. Higher-order 
visual areas such as MT and MST show greater expression of CB1R in non-human primates 
(Eggan and Lewis, 2007). During development, CB1R mRNA was detected in the rat’s 
embryo, in the ganglion cells from the embryonic day 15 and what appears to be the inner 
nuclear layer (INL) from day 20 (Buckley et al., 1998). In the developing rat retina, CB1R was 
found in all cell types except rod photoreceptors and Müller cells (Bouskila et al., 2012; 
Bouskila et al., 2013a; Zabouri et al., 2011a). Recently, the expression of the MAGL and 
DAGLα were studied in developing mice and show that DAGLα is highly expressed in mouse 
photoreceptor, horizontal, amacrine, and ganglion cells from the early stage of development 
but MAGL appears later during the development in amacrine and Müller cells (Cécyre et al., 
2014b). 
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The variation of the content of eCBs in certain diseases suggests that they may play a 
crucial role in ocular homeostasis. In patients with glaucoma, a decrease in 2-AG level of 
ciliary bodies was reported (Chen et al., 2005).  Unlike patients with diabetic retinopathy, in 
age-related macular degeneration (AMD) patients, 2-AG levels amplified in the iris and AEA 
increased in the retina (Matias et al., 2006). The same pattern of augmentation of AEA was 
observed in retina, choroid, ciliary body and cornea of the AMD patients (Matias et al., 2006).  
 
Besides the well-known “red eye” effect (vasodilation) of marijuana and reduction of 
intraocular pressure (IOP) (Green, 1979; Porcella et al., 1998), the functional effect of 
cannabinoids on vision is still not well identified. Case studies interviewed high-potency 
heavy cannabis smokers and reported several categories of visual disturbances, including: 
visual distortions, distorted perception of distance, illusions of movement of stationary and 
moving objects, color intensification of objects, dimmed color, dimensional distortion and 
blending of patterns and objects (Levi and Miller, 1990; Lerner et al., 2011). The popular 
urban myth about dilated pupil and marijuana has not been supported by experimental data 
(Brown et al., 1977).  
 
Cannabis causes impaired performance in tests that require fine psychomotor control 
such as tracking a moving point of light on a screen (Adams et al., 1975; Adams et al., 1978). 
THC increases the time course of glare recovery by several seconds (5-10%) only at low 
contrast (Adams et al., 1978).  Higher doses of THC can produces side effects, including 
blurred vision (Noyes et al., 1975), double vision and vision dimness (Consroe et al., 1997). 
Numerous reports claim that smoking marijuana improves dim light vision (Dawson et al., 
1977; Merzouki and Mesa, 2002; Russo et al., 2004). Acute consumption of marijuana reduces 
	   69	  
the Vernier and Snellen acuity, alters color discrimination, increases photosensitivity and 
decreases dark adaptation (Kiplinger et al., 1971; Dawson et al., 1977; Russo et al., 2004). No 
significant effect has been observed on static visual acuity (Adams et al., 1975) after 
consumption of THC with alcohol. Although there was a marked reduction in acuity of 
moving targets when coordinated eye movements were required (Leweke et al., 1999). 
Binocular depth inversion is reduced in regular cannabis users while it does not affect the 
normal depth perception (Leweke et al., 1999; Semple et al., 2003). Dronabinol, a synthetic 
THC, impaired binocular depth inversion and the top-down processing of visual sensory data 
(Leweke et al., 1999).  
Testing the visual functions by use of steady state visual evoked potential (SSVEP) 
and Electroencephalography (EEG) on occipital lobe suggests a disruption of later-stage visual 
processing in regular users (Skosnik et al., 2006). In rats, CB1R at the visual thalamic level 
plays a dynamic modulatory role in sending visual information into the visual cortex (Dasilva 
et al., 2012). Recently, Cécyre et al reported that the amplitude of the electroretinogram (ERG) 
a-wave is increased in cnr2 knockout mice only and not cnr1 (Cecyre et al., 2013). Yoneda 
and colleagues reported that the expression and localization of CB1R in the visual cortex of 
the mouse is regulated during the development and through visual experiences. In mouse, 
expression of CB1R in deep layers of V1 decreased after dark rearing from birth to P30. 
However, two days of monocular deprivation up-regulated the localization of CB1R in 
inhibitory nerve terminal in deep layers (Yoneda et al., 2013). 
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The Animal model; Vervet Monkeys (chlorocebus sabaeus) 
The extensive resemblance of the non-human primates to homo sapiens in various 
aspects, from genome sequence and molecular pathways to physiology and cognition, makes 
them the closest laboratory model to human that cannot be approximated by any other animal 
model. Among the monkeys, old world monkeys are the closest to the human physiology and 
behavior, after the apes. Old world monkeys show more inter-species brain anatomy similarity 
compared with human and apes (Jasinska et al., 2013).  The animal model that was used in 
these studies, vervet monkey or green African monkey, is an old world monkey from the 
cercopithecidae family native to Africa that 23 million years ago diverged from the hominoid 
family (Figure 1-19) (Goodman et al., 1998). Like all the other old-world monkeys, vervets 
are medium to large size, have a tail with prehensile nerve ending and are omnivorous with 
preference to plant matters. The St-Kitts vervet monkeys were imported from Senegambia in 
the seventeenth century (Palmour et al., 1997). Vervet monkeys are progressively employed in 
biomedical research with a second citation record among the non-human primates after rhesus 
macaque (Jasinska et al., 2013).  Vervets are very similar in physiology and behavior to 
macaque, but they are more accessible, disease-free with less health and safety risks. 
From the visual point of view, old world monkeys have a foveal binocular vision with 
laminated retina with a high cone density that decreases with eccentricity, trichromatic color 
vision and a six-layered dLGN. In monkeys the organization of the retinal mosaic has an 
impact on visual functions; the center being largely involved in visual acuity, color-coding and 
photopic sensitivity (cone vision), whereas the periphery is more concerned with scotopic 
functions (rod vision) (Wässle et al., 1995; Jacobs, 2008).  
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Figure 1-19 a) Venn diagram of comparison of monkeys with human, tree shrew and mouse gene families. Adopted 
from(Fan et al., 2013)  b) Primate phylogenetic tree. Adapted from (Petkov and Jarvis, 2012)  
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Objectives & Hypothesis 
The main objective of this doctoral thesis was to investigate the expression pattern and 
role of the eCB system in the monkey retinogeniculate pathway. The majority of the 
cannabinoid studies on vision have previously been done in rodents. Despite the high quality 
of those interesting researches, it was difficult to translate them to human models due to 
physiological differences in rodent visual systems. For this study, we used vervet monkeys as 
our model rather than rodents; their visual system is much closer to that of humans. This study 
was divided into three specific aims:  
 
Firstly, we sought to investigate the hypothesis that the eCB system components would 
express in different patterns in the monkey retina. Based on our previous findings that CB2R 
expresses differently in monkeys than rodents, we predicted that the expression pattern of 
other eCB components would also vary among different species. By using classic 
immunohistochemistry, we visualized the eCB system throughout the retina of vervet 
monkeys and compared the expression patterns to three other species: mouse, tree shrew, and 
macaque.  (We presume that the tree shrew, as a phylogenetic intermediary, expresses a 
pattern in between mouse and monkey.)  
 
Secondly, due to the differential expression of CB1R and CB2R in retinal layers, we 
hypothesized that their blockade would affect the amplitude of the ERG waves. To test this, 
we blocked the CB1 or CB2 receptors in the normal monkey retina with specific antagonists 
(AM251 and AM630, respectively) and measured the alteration in electrical responses by 
electroretinography (ERG).   
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Thirdly, we expect that the eCB system should be present beyond the retina in the 
dLGN of vervets with a distinctive laminar pattern of expression. To examine this, we 
assessed the expression pattern of the main cannabinoid receptors in the dLGN of the vervet 
monkey by confocal microscopy.  
 
	   74	  
CHAPTER 2: Müller cells express the cannabinoid CB2 receptor 
in the vervet monkey retina 
 
Published in J Comp Neurol. 2013 Aug 1; 521(11): 2399-415. doi: 10.1002/cne.23333. 
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Abstract 
The presence of the cannabinoid receptor type 1 (CB1R) has been largely documented in the 
rodent and primate retinas in recent years. There is however some controversy concerning the 
presence of the CB2 receptor (CB2R) within the central nervous system. Only recently, CB2R 
has been found in the rodent retina, but its presence in the primate retina has not yet been 
demonstrated. The aim of this study was twofold: 1) to characterize the distribution patterns of 
CB2R in the monkey retina and compare this distribution to that previously reported for CB1R 
and 2) to resolve the controversy on the presence of CB2R in the neural component of the 
retina. We therefore thoroughly examined the cellular localization of CB2R in the vervet 
monkey (Chlorocebus sabeus) retina, using confocal microscopy. Our results demonstrate that 
CB2R, like CB1R, is present throughout the retinal layers with however striking 
dissimilarities. Double labeling of CB2R and glutamine synthetase shows that CB2R is 
restricted to Müller cell processes, extending from the internal limiting membrane with very 
low staining, to the external limiting membrane with heavy labeling. We conclude that CB2R 
is indeed present in the retina but exclusively in the retinal glia whereas CB1R is only 
expressed in the neuro-retina. These results extend our knowledge on the expression and 
distribution of cannabinoid receptors in the monkey retina, although further experiments are 
still needed in order to clarify their role in retinal functions. 
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Introduction 
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are endocannabinoids (eCBs) 
that bind to cannabinoid receptors (CB1R and CB2R) to exert their physiological effects 
(Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995; Piomelli, 2003). The eCBs 
are endogenous lipid messengers that are involved in the regulation of many physiological 
processes in mammals (Di Marzo et al., 2007). They are synthetized on demand and rapidly 
degraded by enzymes, particularly fatty acid amide hydrolase (FAAH), monoglycerol lipase 
(MAGL) and cyclooxygenase-2 (COX-2) (Cravatt et al., 1996; Dinh et al., 2002; Kozak et al., 
2000). The activation of cannabinoid receptors by eCBs leads to cannabis-like effects and 
CB1R is considered to be the main element responsible of those properties. The eCB system 
present in the retina likely plays a role in the visual effects of cannabis (Yazulla, 2008 for 
review). The distribution of CB1R has been well characterized in the retina of rodents and 
primates (Yazulla et al., 1999; Straiker et al., 1999; Bouskila et al., 2012). It is present in cone 
pedicles and rod spherules, bipolar cells, amacrine cells, horizontal cells, and ganglion cells. 
This pattern is also observed in the central and peripheral parts of the monkey retina (Bouskila 
et al., 2012). 
 
Concerning CB2R, its mRNA was first detected by reverse transcription polymerase 
chain reaction (RT-PCR) in the adult mouse retina and by in situ hybridization in the adult rat 
retina (Lu et al., 2000) but not in rat embryos (Buckley et al., 1998). Interestingly, using 
different transcripts, CB2 mRNA was not detected in rat and human retinas (Porcella et al., 
1998, 2000). In agreement with (Lu et al., 2000), using immunohistochemistry, CB2R protein 
was localized in rat retinal pigment epithelium, inner photoreceptor segments, horizontal and 
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amacrine cells, cells localized in the ganglion cell layer, and in fibres of inner plexiform layer 
(López et al., 2011). However, this study did not proceed by double labeling with specific 
retinal cell markers. Instead, cell types were identified based on the position in the retinal layer 
and on the morphology of the cells. CB2R expression was found in the trabecular meshwork 
of the porcine eye, in which an injection of a CB2R agonist increased aqueous humour 
outflow (Zhong et al., 2005). The presence of both CB1R and CB2R has been reported in 
human retinal pigment epithelial cells in primary cultures and ARPE-19 cells (Wei et al., 
2009). Recently, CB2R expression was found at mRNA levels by RT-PCR and protein by 
Western blot analysis in in vitro retinal explants and primary cultures of human Müller glia 
(Krishnan and Chatterjee, 2012). 
 
The human CB2R was cloned first (Munro et al., 1993). Subsequent studies on CB2R 
expression patterns focused on the presence of CB2R in peripheral tissues of the immune 
system (Galiègue et al., 1995). Later on, CB2R was cloned in the mouse (Shire et al., 1996) 
and rat (Griffin et al., 2000). Unlike CB1R, which is highly conserved across mammalian 
species, sequences of the murine and human CB2R are divergent, raising the possibility of 
species-specific amino acid sequences. Indeed, CB2R has evolved far more rapidly 
(McPartland et al., 2007), such that there is only an 81% sequence homology at the amino acid 
level between the rat and human CB2R, increasing to 87% identity in the critical trans-
membrane regions (Griffin et al., 2000). As a result, rodent models may not reliably predict 
the performance of a CB2R agonist for human CB2 receptors (Mackie, 2008). Consequently, 
accurate comparisons between human and rodent receptors are crucial considering that 
cannabinoids vary in their affinity to CB2R depending upon the species (Mukherjee et al., 
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2004). Our study will fill an important gap in the knowledge of the expression patterns of 
CB2R in the retina. 
 
The presence of CB2R in neurons has raised an important debate in the scientific 
community (Atwood and Mackie, 2010). While some are convinced that CB2R is not present 
in neurons, or at least at very low levels (Atwood and Mackie, 2010), others suggest otherwise 
(Onaivi et al., 2012). Nevertheless, all agree that CB2R is present in the CNS and could be 
expressed in its glial elements. Despite the extensive knowledge of the distribution of CB2R in 
the rodent brain, there are no published reports regarding its expression and localization in the 
human and monkey retinas. Given that eCBs are present in human ocular tissues especially the 
retina (Chen et al., 2005), it is reasonable to assume the presence of cannabinoid receptors 
therein. Therefore, the main objective of this study is to characterize the expression and 
localization patterns of CB2R throughout the in vivo monkey retina. 
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Materials and Methods 
Choice of species. Monkey tissue, the experimental model for the current study, was chosen 
for several reasons. First monkey tissue allows us to generalize more easily to humans. The 
anatomical similarity between the monkey and human retina is remarkable. Primates are 
mammals that have a macular/foveal region and multiple cone types, which offers them high 
visual acuity and color vision. Finally, the high cross-reactivity between human and monkey 
antigens increases chances of success for targeting CB2R in monkeys using an anti-human 
CB2R antibody. 
 
Animal Preparation. Three adult vervet monkeys (Chlorocebus sabaeus) were used for this 
study. Monkey tissues were kindly provided by Professor Roberta Palmour from McGill 
University, Montreal, Canada. The monkeys were part of Dr. Palmour’s and Dr. Ptito’s 
research project that was approved by the McGill University Animal Care and Use 
Committee. The animals were born and raised in enriched environments in the laboratories of 
the Behavioural Sciences Foundation (St-Kitts, West Indies) that is recognized by the 
Canadian Council on Animal Care (CCAC). The animals were fed with primate chow (Harlan 
Teklad High Protein Monkey Diet; Harlan Teklad, Madison, WI) and fresh local fruits, with 
water available ad libitum. The experimental protocol was reviewed and approved by the local 
Animal Care and Use Committee and the Institutional Review Board of the Behavioural 
Science Foundation. Each animal was sedated with ketamine (10 mg/kg, i.m.), deeply 
anaesthetized with sodium pentobarbital (25 mg/kg, i.v.) and perfused transcardially with 
phosphate buffer saline (PBS pH 7.4), followed by 4% paraformaldehyde. 
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Antibody characterization. All the primary antibodies used in this work, their sources and 
working dilutions, are summarized in Table 2-1. These antibodies were successfully used in 
previous studies and are well characterized in regards to the specific primate retinal cell type 
immunostaining, as described below for each antibody. 
Table 2-1 Primary antibodies used in this study 
 
 
GS. The mouse monoclonal (IgG2a) to glutamine synthetase (GS) was obtained from 
Chemicon International (Temecula, CA) and directed against GS purified from sheep brain. 
This antibody generates a single 45 kDa band in immunoblots of adult mammalian brain tissue 
(manufacturer’s data sheet). This antibody labels Müller cells in rat (Riepe and Norenburg, 
1977) and monkey retinas (Nishikawa and Tamai, 2001; Bouskila et al., 2012). 
 
	   83	  
Calbindin. The mouse monoclonal (IgG1) to calbindin (CB) was obtained from Sigma (St. 
Louis, MO) and directed against purified bovine kidney Calbindin-D-28K. This antibody 
recognizes a 28 kDa band on Western Blots (manufacturer’s data sheet). The calbindin 
antibody labels cones outside the foveal region, cone bipolar cells and a subset of horizontal 
cells in human and monkey retinas (Chiquet et al., 2002; Fischer et al., 2001; Kolb et al., 
2002; Martínez-Navarrete et al., 2007; Martínez-Navarrete et al., 2008; Bouskila et al., 2012). 
 
PKC. The mouse monoclonal (IgG2a) to protein kinase C (PKC) was developed by Santa 
Cruz Biotechnology (Santa Cruz, CA) by using as immunogen purified bovine PKC and its 
epitope is mapped to its hinge region (amino acids 296–317). It detects the PKCa isoform, a 
well-known specific marker for rod bipolar cells (Mills and Massey, 1999). As stated by the 
manufacturer, this antibody gives a single band of 80 kDa on Western blots of human cell 
lines, and has been previously used for immunohistochemistry on rodent (Zabouri et al., 
2011a; Zabouri et al., 2011b) and monkey (Cuenca et al., 2005; Martínez-Navarrete et al., 
2008; Bouskila et al., 2012) retinas. 
 
PV. The mouse monoclonal (IgG1) to parvalbumin (PV) was obtained from Sigma (St. Louis, 
MO) by using as immunogen purified frog muscle PV. It recognizes a 12 kDa band from 
human, bovine, pig, canine, feline, rabbit, rat, and fish tissues (manufacturer’s technical 
information). The pattern of labeling with this antibody was the same as reported previously 
(Kolb et al., 2002; Bordt et al., 2006). This small calcium-binding protein is expressed in the 
primate retina by horizontal cells (Wässle et al., 2000) and the antiserum has been used to 
visualize monkey thalamic nuclei (Qi et al., 2011). 
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Syntaxin. The mouse monoclonal (IgG1) to syntaxin (clone HPC-1) was developed by 
Barnstable et al. (1985) and is distributed by Sigma (St. Louis, MO). This antibody recognizes 
syntaxin-1, a 35 kDa protein, from hippocampal, retinal and cortical neurons (Inoue et al., 
1992). This antibody labels horizontal cells and amacrine cells, in the developing and adult 
human retina (Nag and Wadhwa, 2001). The staining pattern obtained in the current study was 
similar to that found in human retina (Nag and Wadhwa, 2001). We have used this antibody to 
label monkey retinal amacrine and horizontal cells (Bouskila et al., 2012).  
 
Brn3a. The mouse monoclonal (IgG1) to Brn3a was obtained from Chemicon International 
(Temecula, CA) and made against amino acids 186-224 of Brn3a fused to the T7 gene 10 
protein. The Brn3a antibody shows no reactivity to Brn3b or Brn3c by western blot and no 
reactivity to Brn3a knockout mice (manufacturer’s technical information). Its specificity for 
rodent (Nadal-Nicolás et al., 2009) and monkey (Xiang et al., 1995) retinal ganglion cells has 
been documented. We used the POU-domain transcription factor Brn3a to label the nuclei of 
retinal ganglion cells (Bouskila et al., 2012). 
 
CB1R. The rabbit anti-CB1R was obtained from Sigma (St. Louis, MO). It was developed by 
using a highly purified fusion protein containing the first 77 amino acid residues of the rat 
CB1R as the immunogen. It recognizes a major band of 60 kDa and less intense bands of 23, 
72, and 180 kDa (manufacturer's data sheet, C1233). This antibody targets the rat CB1R 
(Zabouri et al., 2011a) but specifically recognizes the CB1R (60 kDa) from many species 
(manufacturer’s data sheet), including vervet monkey retinal tissue (Bouskila et al., 2012). 
	   85	  
 
CB2R. The rabbit anti-CB2R was obtained from Cayman Chemical (Ann Arbor, MI). It was 
developed by using a synthetic peptide corresponding to the amino acids 20-33 
(NPMKDYMILSGPQK) of the human CB2R sequence conjugated to KLH as immunogen. 
This antibody recognizes a band at 45 kDa and a band at 39-40 kDa (manufacturer’s data 
sheet, 101550). This antibody was used in human nervous tissues (Ellert-Miklaszewska et al., 
2007; Zurolo et al., 2010). Its specificity to CB2R was recently validated in CB2R knockout 
mice retinal tissue. CB2R immunohistochemistry signal present in CB2R wild-type mice was 
completely absent in their knockout littermates (Argaw et al., 2011). 
 
GAPDH. The mouse monoclonal (IgM) to GAPDH (GlycerAldehyde-3-Phosphate 
DeHydrogenase, clone GAPDH-71.1) was obtained from Sigma (St. Louis, MO) by using as 
immunogen purified rabbit muscle GAPDH (whole molecule). As stated by the manufacturer, 
this antibody recognizes monkey GAPDH and gives a single band at about 37 kDa. 
 
Kir4.1. The goat polyclonal anti-Kir4.1 antibody was purchased from Osenses (Keswick, 
South Australia). This antibody was raised against a synthetic peptide corresponding to amino 
acids 352-368 (PEKLKLEESLREQAEKE) of human KCNJ10 (Kir4.1) conjugated to an 
immunogenic carrier protein and gives a single band at about 37 kDa in Western Blot. The 
peptide is homologous in mouse and rat and was predicted to react in rat, mouse and human 
tissues (manufacturer’s technical information, cat. #OSP00134W). It has been characterized 
by immunoblot and immunostaining of HEK cells transfected with Kir4.1 and used to target 
the Kir4.1 in mouse cortical astrocytes (Li et al., 2001). 
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CB2R blocking peptide. The CB2R blocking peptide containing the human CB2R amino 
acid sequence 20-33 (NPMKDYMILSGPQK; Cayman Chemical; catalog number 301550) 
was used in the present study for immunohistochemistry and western blot analysis. The 
specificity of the CB2R antibody was also tested by preincubation with the corresponding 
blocking peptide. For preadsorption, the primary antibody was diluted in PBS and incubated 
with a ratio 1:1 for 2 hours at room temperature with occasional inversion. Thereafter, the 
antibody-blocking peptide solution was added to the slices and subsequent 
immunohistochemistry followed the protocol as described further. 
 
Tissue preparation. The eyes were extracted and the retina was dissected free from the 
eyecup in a PBS bath. The retina was laid flat so that the vitreous body could be removed by 
blotting with filter paper and gentle brushing (Burke et al., 2009). Samples of retina (4 mm2) 
were taken from the center (radius of 4 mm around the fovea), middle (radius of 10 mm 
around the fovea) and periphery (radius of 20 mm around the fovea), along with the fovea. 
Each sample was cryoprotected in 30% sucrose overnight and embedded in Shandon 
embedding media at -650C. Retinal samples were sectioned in a cryostat (18 µm) and mounted 
onto gelatinized glass microscope slides, air-dried and stored at -200C. 
 
Western blotting. In order to test the specificity of the CB2R antisera, Western blots were 
performed on monkey tissue. A fresh dissected sample of retina, visual cortex or cerebellum 
was homogenized by hand by using a sterile pestle in RIPA buffer (150 mM NaCl, 20 mM 
Tris, pH 8.0, 1%, NP-40 (USB Corp., Cleveland, OH, USA), 0.1% SDS, 1 mM EDTA), 
supplemented with a protease-inhibitor mixture (aprotinin (1:1,000), leupeptin (1:1,000), 
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pepstatin (1:1,000) and phenylmethylsulfonyl fluoride (0.2 mg/ml); Roche Applied Science, 
Laval, QC, Canada). Samples were centrifuged at 4°C for 10 minutes, and the supernatant was 
extracted and stored at -20°C until further processing. Protein content was equalized by using 
a Thermo Scientific Pierce BCA Protein Assay Kit (Fisher Scientific, Ottawa, ON, Canada). 
Thirty micrograms of protein/sample of the homogenate was resolved with 10% sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, transferred onto a nitrocellulose 
membrane filter (BioTrace NT, Life Sciences, Pall, Pensacola, FL), blocked for 1 hour in 5% 
skim milk (Carnation, Markham, ON, Canada) in TBST (0.15 M NaCl, 25 mM Tris-HCl, 25 
mM Tris, 0.5% Tween- 20), and incubated overnight with the primary antibody, namely, 
rabbit anti-CB2R (1:500) in blocking solution. The following day, the blot was exposed to a 
secondary antibody conjugated to horseradish peroxidase (1:5,000; Jackson ImmunoResearch, 
West Grove, PA) in blocking solution for 2 hours. Detection was carried out by using 
homemade ECL Western blotting detection reagents (final concentrations: 2.50 mM luminol, 
0.4 mM p-coumaric acid, 0.1 M Tris-HCl pH 8.5, 0.018% H2O2). The membrane was then air-
stripped, reblocked, and exposed to a second primary antibody, namely mouse anti-GAPDH 
(1:20,000), until all proteins of interest were tested. Densitometric analysis was performed by 
using ImageJ software (Version 1.45; http://rsb.info.nih.gov/ij/) on scanned films. 
 
Immunohistochemistry. Single, double and triple labeling of the retina were performed 
according to previously published methods (Bouskila et al., 2012). Briefly, sections were 
postfixed for 5 minutes in 70% ethanol, rinsed 3 x 5 minutes in 0.1 M Tris buffer, pH 
7.4/0.03% Triton and blocked for 90 minutes in 10% normal goat serum (NDS) in 0.1 M Tris 
buffer/0.5% Triton. Sections were incubated overnight at room temperature with primary 
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antibody in blocking solution. The CB2R antibody was used conjointly with a known retinal 
cell type marker: calbindin, PKCa, syntaxin, Brn3a, or glutamine synthetase (Table 2-1). The 
next day, sections were washed for 10 minutes and 2 x 5 minutes in 0.1 M Tris /0.03% Triton, 
blocked in 10% NDS, 0.1 M Tris /0.5% Triton for 30 minutes and incubated with secondary 
antibody for 1 hour: Alexa 488 donkey anti-mouse, Alexa 488 donkey anti-goat, Alexa 555 
donkey anti-mouse or biotinylated donkey anti-rabbit followed by the addition of streptavidin-
Alexa 647 (1:200), all in a blocking solution as described above. Sections were washed again 
in Tris buffer, counterstained with bisbenzimide (Hoechst 33258, Sigma, 2.5 µg/mL), a 
fluorescent nuclear marker, and coverslipped with Fluoromount-GTM Mounting Medium 
(SouthernBiotech, Birmingham, AL). 
 
Sequential labeling of CB1R and CB2R. The CB1R and CB2R antibodies that we selected 
came from the same host, making the use of simultaneous double-labeling protocol not 
adequate. To circumvent this problem, we used a sequential protocol previously described by 
our research group (Zabouri et al., 2011a; Zabouri et al., 2011b; Bouskila et al., 2012). Briefly, 
the sections were labeled in a serial manner. The exposition to the first primary antibody was 
conducted as described above, followed by incubation of a goat anti-Fab fragment solution 
(Jackson ImmunoResearch Laboratories, West Grove, PA); Brandon, 1985). This allowed for 
the tagging of the first primary antibody as goat rather than rabbit. The sections were revealed 
with a secondary Alexa donkey anti-goat 488. Thereafter, they were exposed to a second 
primary antibody overnight and revealed the following day with an Alexa donkey anti-rabbit 
647. The validity of the sequential staining was then verified for CB1R/CB2R co-labeling with 
the following two controls: (1) omission of the second primary antibody resulted in a strong 
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staining with the goat secondary 488 but no staining with rabbit secondary 647; (2) omission 
of the first secondary and second primary antibodies revealed faint signal for the goat 
secondary 488 and no signal for the rabbit secondary 647. 
 
Confocal microscopy. Fluorescence was detected with a Leica TCS SP2 confocal laser-
scanning microscope (Leica Microsystems, Exton, PA), using a 40X (n.a.: 1.25 – 0.75) or a 
100X (n.a.: 1.40 – 0.7) objective. Images were obtained sequentially from the green and far-
red channels on optical slices of less than 0.9 µm of thickness. Throughout the Results section, 
images taken from the green channel correspond to the retinal cell markers and from the far-
red channel to CB2R. When co-expression of CB2R and retinal cell markers was ambiguous 
in some retinal layers, co-labeling or its absence was demonstrated by taking z-stacks with 
optimized steps. This allowed for visualization of the cells in the X-Y, X-Z and Y-Z axes, 
thereby confirming the presence or absence of CB2R in the cells. All photomicrograph 
adjustments, including size, color, brightness, and contrast were done with Adobe Photoshop 
(CS5, Adobe Systems, San Jose, CA) and then exported to Adobe InDesign (CS5, Adobe 
Systems, San Jose, CA), where the final figure layout was completed. The schematic panels of 
Figure 9 were created using Adobe Illustrator (CS5, Adobe Systems, San Jose, CA). 
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Results 
CB2R antibody specificity. Immunoblots of CB2R antisera in homogenates of fresh vervet 
monkey retina, visual cortex, and cerebellum (Figure 2-1A) showed one intense band at 
45 kDa for each homogenate. Pre-incubation with CB2R blocking peptide completely 
abolished antibody signal (Figure 2-1B). The same blot was reprobed using the GAPDH 
antibody (37 kDa) to ensure the proper equalization and loading of all samples (Figure 2-1A 
and 2-1B, lower panels). As an added control, the CB2R antibody was preadsorbed with its 
blocking peptide prior to incubation with retinal sections, resulting in an absence of staining 
signal in the section (Figure 2-1D, see CB2R blocking peptide paragraph in the Materials and 
Methods section). Furthermore, the CB2R knock out mice validated the specificity of anti-
CB2R by elimination of the immunolabeling (Argaw et al., 2011). CB2R-immunoreactivity 
(IR) was present throughout the monkey retina, extending from the fovea centralis to the 
periphery and from the external limiting membrane to some cell bodies of the inner nuclear 
layer (Figure 2-1C). CB2R was densely expressed in the Henle Fiber layer (Figure 2-1C), 
comprising the cone photoreceptor oblique axons with accompanying Müller glial cell 
processes and forming a pale-staining fibrous-looking area not seen in the peripheral retina 
(Figure 2-3H). 
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Figure 2-1 Characterization of CB2R antibody in the vervet monkey. Western blot analysis of total protein samples 
from retina (A – lane 1), visual cortex (A – lane 2) and cerebellum (A – lane 3) showing detection of one heavy protein 
band at 45 kDa. The band was not detected when the antibody was pre-incubated with the corresponding CB2R 
blocking peptide (BP) (B – lanes 1-3). All lanes contained 10 µg of total protein. The lower blots for CB2R and CB2R-
BP show the expression of the protein GAPDH and demonstrates loading in all lanes. Immunohistochemistry on vervet 
retinal tissue with the anti-CB2R antibody revealed a unique staining profile (C). When the CB2R antibody was pre-
incubated with its BP, it revealed an absence of staining (D). HFL, Henle fiber layer; INL, inner nuclear layer; IPL, 
inner plexiform layer; GCL, ganglion cell layer. Scale bar = 75 µm. 
 
CB2R immunoreactivity throughout the monkey retina. The expression pattern of CB2R 
near the fovea and in the peripheral retina seems different on visual examination, but this is 
misleading, because Müller cells have different morphological characteristics in the central 
and peripheral retina (Distler and Dreher, 1996). If one looks at the pattern of Müller cell 
processes, CB2R distributions are rather similar. The strongest CB2R signal is localized in the 
Henle fiber layer with generally weaker signals in the inner retina (Figure 2-2). 
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Figure 2-2 Labeling pattern of CB2R-IR throughout the monkey retina. Confocal micrographs taken from the fovea 
(A), and from 1 mm (B), 2 mm (C), 5 mm (D), 10 mm (E), 20 mm (F) of the fovea. Note that the most prominent 
staining of CB2R is located in the Henle fiber layer present in samples of central retina. ONL, outer nuclear layer; 
HFL, Henle fiber layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, 
ganglion cell layer; GCFL, ganglion cell fiber layer. Scale bar = 75 µm. 
 
Double-label immunohistochemistry. In order to verify the retinal cell type expression, 
double immunostaining was carried out for CB2R and a specific molecular marker for primate 
retinal cells. A consistent staining pattern across all three monkey retinas was found for each 
double staining. Although labeling was located in all distal layers of the retina, from the 
photoreceptor to the inner nuclear layers, CB2R-IR was most prominent in the Henle Fiber 
layer within the central retina (Figures 2-3, 5, 6, 9). 
 
Cellular distribution of CB2R 
CB2R is present in Müller cells. The extensive CB2R-immunoreactive fibers along the 
external limiting membrane were suggestive of Müller cells (Figure 2-3A-C). This hypothesis 
was tested by double-labeling CB2R-IR with GS-IR, which labels Müller cells in the 
mammalian retina, including vervet monkey retina (Riepe and Norenburg, 1977; Bouskila et 
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al., 2012). All fibers that were GS-immunoreactive were also double labeled for CB2R-IR in 
the central retina (Figure 2-3D-F) and in the middle retina (Figure 2-3G-I). This included all 
the Müller cell fibers but not Müller cell bodies (Figure 2-3A-C). Most prominent staining was 
found in the distal retina with only faint staining in the proximal retina. On occasion, some 
GS-immunoreactive proximal fibers were not CB2R-immunoreactive. Villous processes 
extending beyond the external limiting membrane (arrows) did not co-localize with CB2R-IR. 
 
Figure 2-3 CB2R co-localizes extensively with glutamine synthetase-labeled Müller cells in the monkey retina. A-I: 
Vertical sections taken near the fovea (A-F) and in the middle retina (G-I). Confocal micrographs of retinas co-
immunolabeled for CB2R and glutamine synthetase (GS), a cell type specific marker for Müller cells. Each protein is 
presented alone in gray scale in the first columns. The merge image is presented in the last column (GS in green and 
CB2R in magenta). Arrows indicate the projections of the Müller cell membrane in the apical margin known as apical 
villi that lack CB2R. Arrowheads point at Müller cell bodies that do not express CB2R. D-F: Higher magnification 
views of the outer limiting membrane (OLM) demonstrate the absence CB2R/GS double labeling in the Müller cell 
villi. OLM, outer limiting membrane; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
GCL, ganglion cell layer. Scale bar = 75 µm for A-C, and 30 µm for D-I. 
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No expression of CB2R in cones. Because the Henle fiber layer comprises densely packed 
oblique cone photoreceptor axons with accompanying Müller cell processes, CB2R and 
calbindin co-localization was needed to rule out the possibility that CB2R was present in 
cones. Given that CB labels cones outside the foveola, a central (Figure 2-4A-C) and middle 
(Figure 2-4D-F) retinal samples were taken to perform co-localization with CB2R and CB. 
Although the patterns of CB2R-IR throughout the ONL and OPL appeared very similar to 
those of GS-IR, it was not clear from an overlay projection presented in Figure 4 that CB2R-
IR is truly adjacent to cone axons. A flattened Z-series indicated that CB2R-IR in the ONL 
was due exclusively to fibers of the Müller cells and do not include cone axons (Figure 2-4G). 
In order to further corroborate the localization of CB2R in GS-positive fibers, but not in CB-
positive axons, confocal optical sections, were investigated in the X-Z and Y-Z projections. 
The X-Z and Y-Z images were drawn through the point of double-labeling between CB-IR 
and CB2R-IR, and the two orthogonal views clearly show no overlap (Figure 2-4H). 
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Figure 2-4 Double-label immunofluorescence illustrating localization of calbindin (CB) and CB2R. A-C: Calbindin-IR 
labeled cone photoreceptors in the monkey central retina, and these were not CB2R immunoreactive. Note that CB2R-
IR appears co-localized in the ONL, but a flattened Z-series (G) and a 3D reconstruction in the X-Z and Y-Z axes 
showed no co-localization (H). CB2R-IR was not present throughout cones outside of the central region, as illustrated 
in the overlay of the two micrographs (D-F). This overlay clearly shows that the CB2R-immunoreactive outer 
processes were neighboring to the CB-immunoreactive cone photoreceptors. ONL, outer nuclear layer; OPL, outer 
plexiform layer; INL, inner nuclear layer. Scale bar = 75 µm. 
 
CB2R is not present in rod bipolar cells. Occasionally, there were CB2R-immunoreactive 
cell fibers in the proximal INL that looked like PKC-immunoreactive rod bipolar cell axons in 
the central retina (Figure 2-5A-C) and peripheral retina (Figure 2-5D-F). No PKC-
immunoreactive rod bipolar cell, including its cell body, axon and axon terminal, was co-
localized with CB2R-IR, confirming that CB2R-IR was not present in rod bipolar cells. 
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Figure 2-5 Double-label immunofluorescence illustrating the localization of PKC and CB2R. A-F: Vertical sections 
showing PKC-positive fibers representing rod bipolar cell axons that appear co-localized near the fovea (A-B) and in 
the middle retina (D-F). CB2R-IR followed the Müller cell processes insinuating themselves between cell bodies of the 
neurons in the inner nuclear layer. No PKC-immunoreactive cell was CB2R-immunoreactive. OLM, outer limiting 
membrane; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. 
Scale bar = 75 µm. 
 
 
Horizontal cells do not express CB2R. CB2R-IR did not co-localize with PV-IR in the 
central retina (Figure 2-6A-C) and peripheral retina (Figure 2-6D-F) indicating that horizontal 
cells were not CB2R-immunoreactive. The PV-IR is classically associated with equal staining 
of 2 morphological types of horizontal cells in the primate retina (arrows), H1 and H2 
horizontal cells (Röhrenbeck et al., 1987), and no clear co-localization was found in any 
horizontal cells of the vervet monkey retina (Figure 2-6A-F). 
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Figure 2-6 Localization of parvalbumin (PV) and CB2R within the central and peripheral retina. Note that the CB2R 
labeling (magenta) is not located within PV-immunoreactive horizontal cell somata and processes (green). High-
magnification images of PV, CB2R, and merged views, respectively in the central retina (A-C) and in the middle retina 
(D-F). Occasional CB2R-immunoreactive fibers in the OPL surround the horizontal cell somata (arrows). HFL, Henle 
fiber layer; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer. Scale bar = 37.5 µm for 
A-C and 75 µm for D-F. 
 
CB2R is not present in amacrine cells. The monoclonal antibody HPC-1 that recognizes 
syntaxin in horizontal and amacrine cells was used to evaluate CB2R-IR expression in 
amacrine cells (Figure 2-7A-C). Despite variations in intensity of immunolabeling, virtually 
no amacrine cells showed expression of CB2R-IR in the central retina (Figure 2-7D-F) or the 
middle retina (Figure 2-7G-I). Although there was no visible expression of CB2R in horizontal 
cells (arrows) and amacrine cells (arrowheads), the staining found in the layers of horizontal 
and amacrine cells was limited to the Müller cell processes (Figure 2-7B and 2-7E). 
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Figure 2-7 Double-label immunofluorescence illustrating the localization of syntaxin (green) and CB2R (magenta) in 
the monkey retina. A-C: Syntaxin-immunoreactive horizontal (arrows) and amacrine cells (arrowheads) were clearly 
not labeled with CB2R in the central retina. D-F: Higher magnification of syntaxin-IR and CB2R-IR in the central 
retina. G-I: Syntaxin-IR and CB2R-IR in the middle retina. Syntaxin-IR labeled heavily the membrane of horizontal 
cells in the OPL but lightly their cytosol, and also labeled heavily the membrane of amacrine cells and IPL but lightly 
their cytosol. OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell 
layer; NFL, nerve fiber layer. Scale bar = 75 µm for A-C and G-I, and 37.5 µm for D-F. 
 
CB2R is absent in ganglion cells. Brn3a immunoreactivity specifically labels retinal ganglion 
cell nuclei. CB2R-IR was not detected in ganglion cell bodies (arrowheads) either in the 
central (Figure 2-8A-C) or middle retina (Figure 2-8D-F). Displaced Brn3a-positive cells 
located in the IPL were not CB2R-immunoreactive (arrows). Double-labeling Brn3a/CB2R 
showed that CB2R was not expressed in ganglion cells. 
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Figure 2-8 Double-label immunofluorescence illustrating localization of CB2R (magenta) and Brn3a (green) in the 
central retina (A-C) and in the middle retina (D-F). The antibody against Brn3a labels the nucleus of ganglion cells in 
the monkey retina and these cells were not CB2R immunoreactive. The occasional labeling of CB2R in the ganglion 
cell layer was localized in the Müller cells inner processes. Arrows point at Brn3a positive cell that is not localized in 
the GCL and arrowheads indicate Brn3a positive ganglion cells that are not CB2R-immunoreactive. ONL, outer 
nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar = 75 µm. 
 
 
Differential CB1R and CB2R labeling. Double-labeling of CB1R-IR and CB2R-IR was 
performed in a retinal sample of 2 mm eccentricity from the fovea (Figure 2-9A-C) and of 
6 mm eccentricity from the fovea (Figure 2-9J-L) to differentiate the localization of these 
cannabinoid receptors. There was no large overlap in the expression of these two receptors in 
the ONL, INL, IPL, and GCL, but apparent overlap in the HFL. Detailed analysis of the 
expression of CB1R for each cell type has been previously characterized (Bouskila et al., 
2012) and precise expression of CB2R is presented in Figures 3-8. Note that for the most part, 
CB1R expression is found throughout the retinal neurons of the monkey retina and CB2R in 
the retinal Müller cells. In order to distinguish CB1R-IR from CB2R-IR in the HFL, a 6 mm 
eccentricity sample of the monkey retina was taken, as the HFL is only present in the central 
retina close to the fovea. Figure 2-9A-C shows immunostaining for the complete protocol 
where strong signals for both CB1R (Figure 2-9A) and CB2R (Figure 2-9B) can be seen. 
Figure 2-9D-F illustrates the first control in which the second primary antibody was omitted: a 
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clear signal for CB1R (Figure 2-9D) whereas no staining for CB2R (Figure 2-9E). Figure 9G-I 
presents the results for the second control where the first secondary and second primary 
antibodies were omitted: no staining for CB1R (Figure 2-9G) and CB2R (Figure 2-9H). Figure 
2-9J-L clearly shows no co-localization of CB1R (Figure 2-9J) and CB2R (Figure 2-9K) in the 
outer retina. Arrowheads follow a CB1R-positive cone cell body and axon; note that CB2R-
positive Müller cell processes envelop this cone. These data are summarized in Figure 2-10A 
for all retinal cell types. 
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Figure 2-9 Comparison of CB1R and CB2R retinal expressions. Confocal micrographs of retinas co-immunolabeled 
for CB1R (green) and CB2R (magenta). CB1R (A, D, G, J), CB2R (B, E, H, K) signals, and their overlay (C, F, I, L). A-
C: Complete sequential protocol in the central retina. D–F: The second primary antibody was omitted. G–I: The first 
secondary and second primary antibodies were lacking. J-L: Localization of CB1R and CB2R in the outer retina. 
Arrowheads follow a CB1R-positive cone cell body and axon, and CB2R-positive Müller cells processes that enroll this 
cone. ONL, outer nuclear layer; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, 
ganglion cell layer. Scale bar = 75 µm. 
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Figure 2-10 Schematic illustration representing the localization of the principal cannabinoid receptors (A) and a 
hypothetical function for CB2R (B) in the monkey retina. CB1R is localized in neural components and CB2R in glial 
components (Müller cells). Color bars in the legend indicate the intensity of CB1R (green) and CB2R (magenta) 
expressions. OS/IS, outer and inner segments of rods and cones; ONL, outer nuclear layer; OPL, outer plexiform 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; C, cones; R, rods; H, horizontal 
cells; B, bipolar cells; A, amacrine cells; G, retinal ganglion cells; M, Müller cells. 
 
Triple labeling of CB2R, GS, and Kir4.1. Triple immunofluorescent labeling was performed 
in order to verify if potassium channels co-localize with CB2R in Müller cells. Expression of 
Kir4.1 was found in CB2R positive and GS positive Müller cells of the central retina. Co-
expression of CB2R and Kir4.1 was found in the HFL but scarcely in the proximal parts of 
Müller cells (Figure 2-11A-D). There was a large overlap in the expression of GS and Kir4.1 
in the INL, IPL, and GCL (Figure 2-11E-L). 
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Figure 2-11 Triple immunofluorescent labeling of CB2R, glutamine synthetase (GS), and the potassium ion channel 
Kir4.1 in the monkey central retina. Each protein is presented alone in gray scale in the first columns. The merge 
image is presented in the last column (CB2R in blue, GS in red, and Kir4.1 in green). A-D: Low magnification images 
showing Kir4.1 and CB2R expression in GS positive Müller cells. E-H: High magnification images of Kir4.1, CB2R, 
and GS immunoreactivity in the distal retina showing co-localization of CB2R and Kir4.1 in Müller cell fibers of the 
Henle fiber layer. I-L: High magnification images of Kir4.1 expression in the proximal retina. HFL, Henle fiber layer; 
INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar = 75 µm for A-D and 30 µm 
for E-L. 
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Discussion 
This study reports the presence of cannabinoid CB2 receptor (CB2R) in Müller cells of 
the vervet monkey retina. These findings are important because, although the presence of 
CB1R in the monkey retina is well established (Straiker et al., 1999; Bouskila et al., 2012), we 
are still far from identifying the exact role of eCB signaling in the monkey retina. 
Furthermore, CB2R has been previously ascribed a critical role in CNS glial function (Cabral 
et al., 2008) and its visual function remains elusive. Our aim was to characterize further the 
retinal localization of cannabinoid receptors, especially by comparing CB2R expression 
profile with CB1R localization. We demonstrate here that CB2R is present in the retina of the 
vervet monkey and specifically in retinal Müller cells. These data, in agreement with CB2R 
glial expression in the CNS, suggest that the CB2 receptor plays a role in retinal functions. 
 
There are 3 types of glial cells in the primate retina: Müller cells, astrocytes and 
microglia. Müller cells are the principal glial cells of the retina and are radially oriented across 
the thickness of the retina, analogous to CB2R expression profile in the distal retina. Their 
processes extend from the outer limiting membrane to the inner limiting membrane. Given that 
the expression of the CB2R followed the same pattern, with a higher polarization towards the 
outer retina, we suggest that CB2R is localized in these glial cells, verified by the co-
localization of CB2R-IR with GS-IR. Müller cell processes surround neuronal cell bodies in 
the nuclear layers and envelop groups of neural processes in the plexiform layers. A 3D 
visualization was therefore needed in order to determine whether or not CB2R-IR was present 
in neurons. The outer limiting membrane, which represents the outer border of CB2R 
expression, is composed of junctions among Müller cells, and photoreceptor cells. However, 
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CB2R-IR was not detected in the apical villi of Müller cells that extend distally from the 
OLM. The inner limiting membrane, formed by the conical endfeet of Müller cells, appeared 
devoid of CB2R-IR. Müller cells also form endfeet on the large retinal blood vessels at the 
inner surface of the retina. Given the apparent absence of CB2R-IR in the most proximal 
retina, CB2R may not have a role in the regulation of inner retinal blood vessels. 
 
The presence of CB2R in Müller cells and CB1R in the retinal neuronal cells, points 
towards a complementary relationship between neurons and glia regarding eCB function. 
CB2R in Müller cells could protect neurons from exposure to excess neurotransmitters such as 
L-glutamate (Placzek et al., 2008). Generally, CB2R activation leads to sequences of activities 
of a protective nature (Pacher and Mechoulam, 2011 for review). Stimulation of CB2R 
increases microglial cell proliferation (Carrier et al., 2004) and reduces the release of harmful 
factors, including tumor necrosis factor (TNF) and free radicals (Eljaschewitsch et al., 2006; 
Ramírez et al., 2005; See Stella, 2009 for review). In fact, exposure to eCBs in activated 
primary human Müller glia inhibited the production of several proinflammatory cytokines 
(Krishnan and Chatterjee, 2012). CB2R in Müller cells might therefore be an important player 
in inflammation, neurotoxicity and neuroprotection. The localization of CB1R in the 
photoreceptor layer already suggested that the transduction of light (Yazulla, 2008) occurring 
at this stage could also be modulated by the CB2R expressed in distal Müller cells fibers. 
Perhaps, the whole eCB system participates in the modulation of light transduction, where 
CB1R is neuronal and CB2R glial. The expression of CB1R in bipolar cells, shown by double-
labeling with CHX10 and PKC retinal cell type markers, suggested that the eCB system acts 
as an autoregulation system that modulates the signal received by the photoreceptors in order 
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to transmit it to ganglion cells (Yazulla et al., 1999; Yazulla, 2008; Bouskila et al., 2012). 
Similarly, this could also occur in horizontal and amacrine cells that show little expression of 
CB1R (Bouskila et al., 2012). Finally, it is possible that the results of Lu et al. (2000) who 
demonstrated the expression of CB2R in the ganglion cell layer of the adult rat retina using in 
situ hybridization and RT-PCR did include CB2R-immunoreactive Müller cell processes. In 
agreement with the latter study, using immunohistochemistry and cell morphology, López et 
al. (2011) suggested that CB2R was localized in photoreceptors, horizontal cells, amacrine 
cells and cells localized in the GCL of the adult rat retina. These studies differ with ours not 
only regarding the animal model (rat versus monkey) but the choice of the antibody used. 
While we used an antibody targeted against the 20-33 amino acids of the human CB2R, López 
et al., (2011) used an antibody against residues 326–342 of the rat CB2R. Moreover, double-
labeling of CB2R with a retinal cell marker was not performed and given that Müller cells 
envelop the cell bodies in the GCL it could be CB2R positive cells. In addition, CB1R-IR in 
the Henle fiber layer and ganglion cell layer of the monkey retina has the most prominent 
staining found throughout the retinal layers (Bouskila et al., 2012), as opposed to only the 
Henle fiber layer that has the highest CB2R signal. Recently, Krishnan and Chatterjee (2012) 
showed that CB2R protein was expressed in homogenates of 12-18 days ex vivo retinal 
explants and 18 days in vitro primary Müller glia from human retina by Western blotting. We 
provide here direct evidence for the in vivo expression pattern of CB2R in monkey Müller 
cells by immunohistochemistry. 
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Hypothetical functional consequences 
Activation of photoreceptors by light evokes an increase of K+ ions in the retinal 
extracellular space (Newman and Reichenbach, 1996). In order to maintain an electrolytic 
balance, Müller cell inwardly rectifying K+ channels (KIR) release the excess K+ ions into the 
vitreous. This spatial buffering mechanism is termed K+ siphoning (Newman et al., 1984). 
Immunoreactivity to the KIR4.1 channel in rat retina was densely distributed around 
photoreceptor cells in ONL, where the distal ends of Müller cells surround PR cells, and in a 
scattered manner around ganglion cells in GCL in rat retina (Ishii et al., 1997). Interestingly, 
KIR4.1-IR as reported by Ishii et al., (1997) for the rodent retina is similar to CB2R expression 
found in Müller cells in the present study in the monkey central retina (Figure 2-11). The 
cellular origin of the b-wave component of the ERG is attributed to an interaction between 
ON-bipolar cells and Müller cells (Stockton and Slaughter, 1989; Wen and Oakley, 1990). The 
b-wave of the ERG reflects the K+ mediated spatial buffering currents of Müller cells (Miller 
and Dowling, 1970; Kline et al., 1985). Moreover, blocking K+ channels in Müller cells 
reduces the ERG b-wave (Wen and Oakley, 1990). Given that activation of CB2R leads to a 
reduction of cAMP and PKA levels due to coupling via Gi/o (Howlett et al., 2002 for review 
Bolognini et al., 2010) and that PKA increases the activity of KIR4.1 channels in Müller cells 
(MacGregor et al., 1998), it is reasonable to propose that CB2R plays a role in the generation 
of the b-wave. CB2R could act therefore as a negative modulator of K+ channels. Conversely, 
blocking CB2R activates K+ channels (because of the constitutive activity of CB2R) that in 
turn produce a constant influx of K+ ions into the Müller cell and an enlarged b-wave (Figure 
2-10B). Further experiments are however still needed in order to verify this retinal CB2R 
putative function. 
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Abstract 
The endocannabinoid (eCB) system comprises the cannabinoid receptors, the 
endogenous cannabinoid ligands (eCBs), and the enzymes regulating the levels of eCBs. This 
system is widely expressed in various parts of the central nervous system, including the retina. 
The localization of the key eCB receptors, particularly CB1R and CB2R, has been recently 
reported in rodent and primate retinas with striking interspecies differences. However, little is 
known about the enzymes involved in the synthesis and degradation of these eCBs. We 
therefore examined the expression and localization of the main components of the eCB system 
in the retina of three vertebrates: mice, tree shrews and monkeys. We found that the CB1R and 
FAAH distributions are well preserved among these species. The NAPE-PLD expression in 
monkeys is however circumscribed to the photoreceptor layer, unlike mice and tree shrews. In 
contrast, the CB2R expression is variable across these species; in mice, CB2R is found in the 
retinal neurons; in tree shrews, it is expressed in the Müller cell processes of the outer retina 
and in the retinal neurons of the inner retina. In monkeys, CB2R is restricted to the Müller 
cells that span the entire retinal thickness. The expression patterns of MAGL and DAGLα are 
juxtaposed in the inner retinal layers. Overall, these results provide the evidence that the eCB 
system is differently expressed in the retina of these mammals and suggest a distinctive role of 
endocannabinoids in visual processing. 
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Introduction 
Marijuana contains over 70 cannabinoids that mimic the endogenous ligands called 
endocannabinoids (eCBs) and cause global psychoactive and physiological effects. The eCB 
system is mainly made up of the G-protein-coupled receptors CB1 and CB2 (CB1R and 
CB2R) and the eCBs anandamide (AEA) and 2-arachidonoyl glycerol (2-AG). It also contains 
the enzymes of synthesis: N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-
PLD) and diacylglycerol lipase a (DAGLα); the degradation enzymes: fatty acid amide 
hydrolase (FAAH) and monoacylglycerol lipase (MAGL) that regulate the levels of the eCBs. 
The cannabinoid receptors are found in many mammals, as well as in various classes of 
vertebrates and invertebrates, in all major subdivisions of bilaterians, urochordates and 
cephalochordates, but not in the nonchordate invertebrate phyla like insects (McPartland et al., 
2006a; McPartland et al., 2007; Cottone et al., 2013). The cannabinoid receptors may have 
evolved in the last common ancestor of the bilaterians with a secondary loss in the insects and 
other clades (McPartland et al., 2006a). The enzymes responsible for the biosynthesis and the 
degradation of the eCBs are present throughout the animal kingdom (McPartland et al., 2006b; 
Elphick, 2012). For example, in the rat hippocampus, cerebellum and amygdala, the 
distribution of the cytosolic enzyme MAGL is nearly complementary to the FAAH, with a 
presynaptic localization similar to DAGLα rather than postsynaptic (Dinh et al., 2002). The 
eCB system appears widely distributed in the central nervous system and points to a 
fundamental modulatory role of the eCBs in the control of many central and peripheral 
biological functions (Di Marzo, 2009). A number of specific roles have been ascribed to the 
eCB system in biological functions, such as neuroprotection, neurogenesis, axon guidance, 
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synaptic plasticity, nociception, motor activity, and memory (Harkany et al., 2007; Harkany et 
al., 2008; Argaw et al., 2011; Duff et al., 2013; Xu and Chen, 2014). Disturbances of normal 
eCB activity may therefore be associated with various brain disorders (Russo, 2008; Bluett et 
al., 2014; McPartland et al., 2014; Smith and Wagner, 2014). 
The eCB system is also found in the retina of various mammalian species (Yazulla, 
2008) albeit noticeable differences in its anatomical organization. Compared to rodents, the 
retina of tree shrews is more similar to primates (Fan et al., 2013). Mice have a rod-dominated 
retina that is specialized for scotopic conditions (Jeon et al., 1998) with a low visual resolution 
(Prusky and Douglas, 2004). Mouse and tree shrew retinas have no fovea compared to 
primates. However, tree shrews have a well-developed binocular visual system, with a cone-
dominated retina (Muller and Peichl, 1993). Interestingly, the highest density of both cones 
and rods are in the inferior retina, not in the central area (Muller and Peichl, 1989). Monkeys, 
on the other hand, have a fovea with a high cone density that decreases with eccentricity 
(Herbin et al., 1997). Comparative studies on the organization of the retina of different animal 
species led to the conclusion that ancestral mammals may have already developed cone 
photopigments (Jacobs, 2008). These cone pigments are still present in many contemporary 
representatives from four of the major vertebrate groups (fishes, birds, amphibians, and 
reptiles); thus, many vertebrates maintained the capacity for elaborate color vision over their 
histories (Imamoto and Shichida, 2014). 
 
Concerning the retina, the expression of the cannabinoid receptors is well preserved in 
many species including mice, rats, chicks, larval tiger salamanders, goldfish, and rhesus 
monkeys (Straiker et al., 1999). CB1R and CB2R are present in various retinal cell types 
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(cones, bipolar, ganglion, horizontal, and amacrine cells) with however some differences 
(Yazulla, 2008; Zabouri et al., 2011a; Zabouri et al., 2011b; Bouskila et al., 2012; Bouskila et 
al., 2013; Cécyre et al., 2014a). For example, CB2R is expressed throughout the mouse retina 
(Cécyre et al., 2014a) but it is present exclusively in the Müller cells of the vervet monkey 
(Bouskila et al., 2013). While DAGLα is widely distributed throughout the IPL in the mouse 
retina, MAGL is only present in rod spherules, cone pedicles in OPL, but also the IPL (Hu et 
al., 2010). Both MAGL and DAGLα have been found in an overlapping pattern with CB1R 
and CB2R in the rat retina. In rats, DAGLα is expressed from the early stages of development 
in photoreceptors, horizontal, amacrine, and ganglion cells and MAGL later during 
development mainly in amacrine and Müller cells. (Cécyre et al., 2014b). The expression and 
distribution of the major components of the eCB system, notably the metabolizing enzymes 
(NAPE-PLD, DAGLα, FAAH, MAGL), in the retina of different mammals have not been 
studied in depth. It is therefore our aim to analyze the expression of several components of the 
endocannabinoid system and to characterize their distribution pattern in the distinct retinal 
layers and cell types of three different mammalian species: mice, tree shrews and monkeys 
(vervets and macaques). 
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Materials and Methods 
Biological material. Eyes from three adult mice (C57BL/6), two tree shrews (Tupaia 
belangeri), three vervet monkeys (Chlorocebus sabeus), and two rhesus monkeys (Macaca 
mulatta) were used in this study. The animals were part of ongoing research projects that were 
approved by the University of Montreal and McGill University Animal Care and Use 
Committees. For all species, anterior segment of the eye and vitreous were cut away. The 
eyecups were bathed in 4% paraformaldehyde made in 0.1 M sodium phosphate buffer at 
pH 7.4. After the fixation, the eyecups were kept in a 30% sucrose solution in the phosphate 
buffer for at least two days before being frozen in an OCT embedding medium. 
 
Immunohistochemistry. Single-, double-, and triple-labelings of the retina were performed 
according to previously published methods (Bouskila et al., 2012; Bouskila et al., 2013a, b). 
Briefly, the sections were post-fixed for 5 minutes in 70% ethanol, rinsed 3 x 5 minutes in 
0.1 M Tris buffer, pH 7.4/0.03% Triton and blocked for 90 minutes in 10% normal goat serum 
(NDS) in 0.1 M Tris buffer/0.5% Triton. Sections were incubated overnight at room 
temperature with primary antibodies prepared in blocking solution. The cannabinoid-related 
antibodies (CB1R, FAAH, NAPE-PLD, CB2R, DAGLα, MAGL) were also used conjointly 
with a known specific retinal cell type marker such as rhodopsin, calbindin, glutamine 
synthetase, and Brn3a (Table 1). The next day, sections were washed for 10 minutes and 2 x 5 
minutes in 0.1 M Tris /0.03% Triton, blocked in 10% NDS, 0.1 M Tris /0.5% Triton for 60 
minutes and incubated with secondary antibody for one hour: Alexa 488 donkey anti-mouse, 
and biotinylated donkey anti-rabbit followed by the addition of streptavidin-Alexa 647 
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(1:200), all in a blocking solution as described above. Sections were washed again in Tris 
buffer, counterstained with bisbenzimide (Hoechst 33258, Sigma, 2.5 µg/mL), a fluorescent 
nuclear marker, and coverslipped with Fluoromount-GTM Mounting Medium 
(SouthernBiotech, Birmingham, AL). 
Antibody characterization. The source and the working dilution of all primary antibodies 
used in this study are summarized in Table 3-1. 
 
Brn3a. The mouse monoclonal (IgG1) to Brn3a was acquired from Chemicon and directed 
against amino acids 186–224 of Brn3a fused to the T7 gene 10 protein. The antibody has no 
reactivity with Brn3b or Brn3c in Western blots. Its specificity for rodent (Nadal-Nicolás et 
al., 2009) and monkey (Bouskila et al., 2013) retinal ganglion cells has been already 
documented. This antibody has been used to label the nuclei of retinal ganglion cells (Bouskila 
et al., 2012). 
 
Calbindin. The mouse monoclonal (IgG1) to calbindin (CB) was purchased from Sigma (St. 
Louis, MO) and directed against purified bovine kidney calbindin-D-28K. This antibody 
produces a 28 kDa band on Western blots (manufacturer’s data sheet). The CB antibody labels 
cones outside the foveal region, cone bipolar cells, and a subset of horizontal cells in human 
and monkey retinae (Bouskila et al., 2012). 
 
CB1R. The rabbit anti-CB1R was purchased from Calbiochem (Gibbstown, NJ, USA) and 
was developed by using a highly purified fusion protein with the first 77 amino acid residues 
of the rat CB1R. According to the manufacturer's data sheet, it recognizes a major band of 
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60 kDa with also less intense bands of 23, 72, and 180 kDa. This antibody was shown to be 
specific using cnr1 knockout mouse retinal tissue (Zabouri et al., 2011). It recognizes the 
CB1R (60 kDa) from many species, including the vervet monkey tissues (Bouskila et al., 
2012). 
 
CB2R. The rabbit anti-CB2R was purchased from Cayman Chemical (Ann Arbor, MI) and 
was developed by using a synthetic peptide corresponding to the amino acids 20-33 
(NPMKDYMILSGPQK) of the human CB2R sequence conjugated to keyhole limpet 
hemocyanin (KLH) as immunogen. This antibody recognizes a band at 45 kDa and a band at 
39-40 kDa (manufacturer’s data sheet; 101550). Its specificity to CB2R was validated in cnr2 
knockout mouse (Cécyre et al., 2014) and monkey (Bouskila et al., 2013) retinal tissue. 
 
DAGLα. The goat anti-DAGLα (Diacylglycerol lipase α) antibody was purchased from Novus 
Biologicals (Littleton, CO, USA) and was developed by using the synthetic peptide 
corresponding to PAKQDELVISAR of the C-terminus of human DAGLα. This sequence has 
a 100% identity homology with old world monkeys, 92% with marmoset, and 83% identity 
with mouse, rat, hamster, and tree shrews. 
 
FAAH. The rabbit anti-FAAH (Fatty acid amide hydrolase) was purchased from Cayman 
Chemical (Ann Arbor, MI, USA) and developed by using a synthetic peptide corresponding to 
amino acids 561-579 (ELCLRFMREVEQLMTPQKQPS) of the rat FAAH conjugated to 
KLH. As expected, it recognizes a dense band at about 66 kDa and a very light one below 
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37 kDa. The specificity of this antibody has been demonstrated in rat (Suárez et al., 2008; 
Zabouri et al., 2011) and vervet monkey (Bouskila et al., 2012) tissues. 
 
GS. The mouse monoclonal (IgG2a) to glutamine synthetase (GS) was obtained from 
Chemicon (Temecula, CA, USA) and directed against the GS purified from sheep brain 
(manufacturer’s data sheet). This antibody generates a single 45 kDa band in immunoblots. 
This antibody labels Müller cells in the rodent (Elphick and Egertova, 2005; Riepe and 
Norenburg, 1977) and monkey retinae (Bouskila et al., 2012). 
 
MAGL. The rabbit anti-MAGL (Monoacylglycerol lipase) was obtained from Cayman 
Chemical (Ann Arbour, MI) and was developed by using a synthetic peptide from amino acids 
1-14 (MPEESSPRRTPQSI) of the human MAGL. It has a high identity protein sequence 
between human, mouse and tree shrews and has a molecular weight of approximately 33 kDa 
on western blot. 
 
NAPE-PLD. The rabbit anti-NAPE-PLD (N-acyl phosphatidylethanolamine-specific 
phospholipase D) was obtained from Cayman Chemical (Ann Arbor, MI, USA) and developed 
by using a synthetic peptide from human NAPE-PLD amino acids 159-172 
(YMGPKRFRRSPCTI). Its cross reactivity has been tested in many species, and it recognizes 
an intense band at 46 kD on a western blot of the human cerebellum (manufacturer's data 
sheet). 
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Rhodopsin. The mouse monoclonal (IGg1) anti-rhodopsin (clone Rho 4D2) was purchased 
from Abcam (Toronto, ON, Canada) and developed by using as immunogen the bovine 
rhodopsin. This antibody recognizes a 39 kDa band on Western Blots and is predicted to react 
with human retinal tissues (manufacturer's data sheet). It has been proven effective to 
specifically label rods in the rodent (Ozawa et al., 2008) and the monkey (Bouskila et al., 
2013b) retina. 
 
Protein kinase C. The mouse monoclonal (IgG2a) to protein kinase C (PKC) was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA) and developed by using as immunogen 
purified bovine PKC, and its epitope is mapped to its hinge region (amino acids 296–317). In 
western blot this antibody gives a single band of 80-kDa on human cell lines and has been 
previously used in vervet monkeys and rodent (Zabouri et al., 2011; Bouskila et al., 2012).  
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Table 3- 2 List of antibodies used in this study 
Antibody Immunogen Source† Working 
dilution 
Brn3a 
Fusion protein containing aa 186–224 of 
Brn3a protein 
Chemicon, Temecula, CA; 
MAB1585, mouse monoclonal, clone 
5A3.2 
1:100 
CB Purified bovine kidney calbindin-D28K 
Sigma, St. Louis, MO; C9848, mouse 
monoclonal, clone CB0955 
1:250 
CB1R 
Fusion protein containing aa 1–77 of rat 
CB1R 
Sigma, St. Louis, MO; C1233, rabbit 
polyclonal 
1:150 
CB2R 
Synthetic peptide corresponding to aa 
20–33 of human CB2R 
Cayman Chemical, Ann Arbour, MI; 
101550, rabbit polyclonal 
1:150 
DAGLα 
Peptide with sequence 
CPAKQDELVISAR, from the C Terminus 
of the protein sequence 
Novus, Littleton, CO; 
NBP2-31856, rabbit polyclonal 
1:100 
FAAH Synthetic peptide aa 561–579 of rat FAAH 
Cayman Chemical, Ann Arbour, MI; 
101600, rabbit polyclonal 
1:150 
GS Full protein purified from sheep brain 
Chemicon, Temecula, CA; MAB302, 
mouse monoclonal, clone GS-6 
1:500 
MAGL Human MAGL aa 1-14 
Cayman Chemical, Ann Arbour, MI; 
100035, rabbit polyclonal 
1:150 
NAPE-
PLD 
Purified protein corresponding to aa 159-
172 NAPE-PLD human 
Cayman Chemical, Ann Arbour, MI; 
10305, rabbit polyclonal 
1:200 
Rhodopsin Bovine rhodopsin 
Abcam, Toronto, ON; ab98887, 
mouse monoclonal, clone Rho 4D2 
1:500 
PKCα 
Peptide mapping the aa 296–317 of 
human PKCα 
Santa Cruz Biotechnology, Santa 
Cruz, 
CA; sc-8393, mouse monoclonal, 
clone H-7 
1:500 
 
Confocal microscopy. Fluorescence was detected with a Leica TCS SP2 confocal laser-
scanning microscope (Leica Microsystems, Exton, PA), using a 40X (n.a.: 1.25 – 0.75) or a 
100X (n.a: 1.40 – 0.7) objective. Images were obtained sequentially from the green, blue and 
far-red channels on optical slices of less than 0.9 µm of thickness. All photomicrograph 
adjustments, including size, color, brightness, and contrast were done with Adobe Photoshop 
(CS5, Adobe Systems, San Jose, CA) and then exported to Adobe InDesign (CS5, Adobe 
Systems, San Jose, CA), where the final figure layout was completed. 
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Results 
Single-label immunocytochemistry 
CB1R is present throughout the retina of all three species. A fairly consistent retinal 
distribution pattern of CB1R across all six retinal layers was observed in mice, tree shrews, 
vervet and rhesus monkeys, as illustrated in immunolabeled retinal sections (Figure 3-1A-D).  
 
FAAH expression is found throughout the retina of all three species. FAAH, like CB1R, is 
expressed in all five retinal layers and in the photoreceptor layer of the three species (Figure 3-
1E-H). In mice and tree shrews, there is an increased protein expression in the IPL (see arrow 
in Figure 3-1E,F) compared to primates (Figure 3-1G,H). There is a high expression of FAAH 
in NFL of all species (arrowhead in Figure 3-1E-H). 
 
NAPE-PLD distribution is dissimilar between the species. NAPE-PLD is abundantly 
expressed in the GCL and NFL (arrowheads Figure 3-1I,J) of mice and tree shrews, and in 
lower concentration in the ONL for all three species (Figure 3-1I-L). In mice, NAPE-PLD is 
distributed in all layers, especially the GCL and NFL, except the ONL. In tree shrews, NAPE-
PLD is found in all five retinal layers, but mostly in the OPL (arrow in Figure 3-1J) and NFL 
(arrow Figure 3-1J). Inversely, in both vervet and macaque monkeys, NAPE-PLD is located in 
the outer retina, mainly in photoreceptors, ONL and OPL (arrows in Figure 3-1K-L). 
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Figure 3- 1 CB1R system immunoreactivity pattern in the retina. Shown are the retinal sections immunolabeled for the 
CB1R (A-D), FAAH (E-H), and NAPE-PLD (I-L) in mouse, tree shrew, vervet and macaque monkeys. Arrows and 
arrowheads point out areas of different levels of expression between retinal segments. ONL, outer nuclear layer; OPL, 
outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar = 
75 µm 
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CB2R expression is restricted to Müller cells in monkeys. Unlike CB1R, the 
immunolabeling pattern of CB2R is not consistent in the 3 species. In mice, CB2R is not 
detectable in ONL and very little in INL but strongly expressed in OPL (arrow Figure 3-2A), 
IPL, GCL, and NFL (arrowhead Figure 3-2A). In tree shrews, CB2R is expressed throughout 
all five retinal cell layers with more emphasis (contrary to the mouse) in the external layers 
(ONL and OPL) (arrow Figure 3-2B) and INL (arrow Figure 3-2B). In both vervets and 
macaques, CB2R expression is more abundant in ONL (arrows Figure 3-2C-D). 
Localization of MAGL. In mice, the MAGL is expressed in the OPL, INL, IPL, GCL and 
NFL with the most prominent staining towards the bottom two layers (Figure 3-2E). The two 
bands that are strongly seen in the IPL of the mouse retina probably represent an accumulation 
of MAGL in the dendrites and synaptic layers (arrows in Figure 3-2E). In tree shrews, MAGL 
is expressed in all five layers and most strongly in the GCL (arrow) and IPL (arrowhead 
Figure 3-2F). In vervets and macaques, the MAGL is expressed mainly in the OPL (arrows 
Figure 3-2G,H). It is also found in the GCL (arrowheads Figure 3-2G, H). 
Expression of the DAGLα . In mice, DAGLα  is expressed weakly in ONL and OPL (Figure 
3-2I) but more strongly in IPL (arrowhead in Figure 3-2I), GCL and NFL (arrows in Figure 3-
2I). In tree shrews, the DAGLα  is strongly expressed in a band of the upper GCL (arrow in 
Figure 3-2J). In vervets and macaques, DAGLα  is weakly expressed in the ONL, INL and 
IPL. There is a high expression in the OPL (arrows) and GCL (arrowheads Figure 3-2K,L). 
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Figure 3- 2 CB2R system immunoreactivity pattern in the retina. The retinal sections immunolabeled for CB2R (A-D), 
MAGL (E-H), and DAGLα  (I-L) in mouse, tree shrew, vervet and macaque monkeys. Arrows and arrowheads point 
out areas of different levels of expression between retinal segments. ONL, outer nuclear layer; OPL, outer plexiform 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar = 75 µm. 
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Double-label immunocytochemistry 
CB1R in INL. The PKC labels the rod bipolar cells and a subset of amacrine cells, were 
colocalized with the CB1R at INL (arrows) and IPL in all the species (arrowheads Figure 3 A-
D). The cone-dominant retina of the tree shrew has much less rod bipolar cells. 
CB2R and Müller cells. To label Müller cells, glutamine synthetase (GS) was used. This 
antibody has proved to be efficient to label Müller cells in the rat (Riepe and Norenburg, 
1977), mouse (Cécyre et al 2013), and monkey retinas (Nishikawa and Tamai, 2001; Bouskila 
et al., 2012; Bouskila et al., 2013). In mice, the CB2R is weakly expressed in the ONL (arrow 
Figure 3-3E) although intense expression was found in the inner layers. In tree shrews, CB2R 
and GS were both expressed in the photoreceptor layer and ONL (arrow Figure 3F). CB2R is 
co-localized with GS and on other cases was differentially expressed. In both vervet and 
macaque monkeys, the CB2R was expressed throughout the photoreceptor layer (arrow Figure 
3-3G-H) and also is well co-localized with GS in OPL (arrowhead Figure 3-3G-H). These 
results indicate that the expression of CB2R in Müller cells is an exclusive feature of primates. 
 
MAGL and DAGLα . The expression of MAGL and DAGLα  were assessed (Figure 3-3 I-L). 
MAGL and DAGLα  are complementarily expressed in the inner retinal layers of mice, tree 
shrews, vervets, and macaques especially in the GCL (arrows in Figure 3-3I-L). To label the 
nuclei of retinal ganglion cells, Brn3a was utilized. MAGL. The colocalization of MAGL with 
ganglion cells is more apparent in macaque and vervet monkeys (arrows Figure 3-3 M-P)  
 
NAPE-PLD, cones and rods. Calbindin (CB) is a marker of cones outside the foveal region, 
cone bipolar cells, and a subset of horizontal cells (Bouskila et al., 2012; Fischer et al., 2001). 
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CB is strongly expressed in the mouse OPL alongside with NAPE-PLD, but none of them 
were present in ONL (Figure 3-3Q). In tree shrews, CB is highly co-expressed with NAPE-
PLD in the OPL (arrowhead in Figure 3-3R) and ONL (arrow in Figure 3-3R). CB is 
expressed in the ONL of the monkey retina where NAPE-PLD is not very abundant (arrows in 
Figure 3-3S-T) and highly co-expressed in OPL (arrowhead Figure 3-3S). The rhodopsin 
antibody was used to label rods in the retina. In the mouse, NAPE-PLD was not co-expressed 
with rods (arrow in Figure 3-3U). However, in the cone-dominant retina of the tree shrew with 
only very few rods, NAPE-PLD is slightly co-localized with rods (arrow Figure 3-3V). In 
monkeys, NAPE-PLD is abundantly expressed in rods (arrow in Figure 3-3W-X). 
Interestingly, comparing the two synthesis enzymes, NAPE-PLD and DAGLα in different 
species, revealed that in mice, the expression pattern of both enzymes is similar throughout the 
retina.  
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Figure 3- 3 Double-labeling of components of the eCB system with retinal cell specific markers. High magnification 
double-labeling of the retinal sections in the mouse, tree shrew, macaque and vervet monkey. A-D are stained for 
CB1R (magenta) and rod bipolar cells (green) labeled by PKC E-H are stained for GS-positive Müller cells (green) and 
CB2R (magenta) in ONL and OPL. I-L double labeling of MAGL (magenta) and DAGLα  (green) M-P are labeled for 
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Brn3a-positive ganglion cells (green) and MAGL (magenta) in IPL and GCL. Q-T are marked for calbindin-positive 
cones (green) and NAPE-PLD (magenta) in ONL, OPL and INL. U-X are stained for rhodopsin-positive rods (green) 
and NAPE-PLD (magenta) in ONL and OPL. Arrows and arrowheads point out areas of different levels of expression 
between segments. ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; GCL, ganglion cell layer. Scale bar = 75 µm. 
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Discussion 
In this study, we compared the localization of two cannabinoid receptors (CB1R, 
CB2R), two endocannabinoid synthesizing enzymes (NAPE-PLD and DAGLα), and two 
endocannabinoid degrading enzymes (FAAH and MAGL) in the retina of mice, tree shrews, 
and monkeys. This is the first study that shows the expression pattern of all the above-
mentioned eCB components in the tree shrew retina as well as the localization of the NAPE-
PLD, MAGL and DAGLα in the monkey retina. These phylogenetically related species were 
chosen due to the specialization of their visual systems; from the primitive monocular, rod-
dominated visual system in mice with a low visual resolution to the well-developed visual 
system (Sirotin and Das, 2010) in monkeys that is similar to humans (Jacobs, 2008). Tree 
shrews are a species with binocular cone-dominated vision that is phylogenetically between 
mice and monkeys (Muller and Peichl, 1989; Muller and Peichl, 1993). We also compared two 
phylogenetically close primate models: the vervet and the macaque, to demonstrate that their 
visual systems are similar enough to use either in vision research.  
 
	  
Figure 3- 4 Comparison of the expression patterns of CB1R (magenta), NAPE-PLD (light-blue), FAAH (dark-blue), 
CB2R (black), DAGLα  (red) and MAGL (green) in the retina of mice, tree shrews, vervets and macaques. 
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The cannabinoid receptors: localization vs function 
We recently reported that the distribution of the CB2R in the primate retina (Bouskila 
et al., 2013) is different than the rodent retina (Cécyre et al., 2014). While the CB2R is 
expressed in the rodent retinal neuronal cells (Cécyre et al., 2014), it is only expressed in the 
primate retinal glia, the Müller cells (Bouskila et al., 2013a). This finding prompted us to look 
into the retinal eCB system expression profiles across species. Interestingly, we show that only 
some components of the eCB system are preserved across the three animal species studied 
here while others are strikingly different. Notably, as reported by Elphick in his thought-
provoking review (Elphick, 2012), CB1R and CB2R are unique to chordates, but the enzymes 
involved in the biosynthesis and the inactivation of the eCBs like NAPE-PLD and FAAH are 
found throughout the animal kingdom (McPartland 2006b). These proteins may have therefore 
evolved as presynaptic or postsynaptic receptors for eCBs. This is fascinating because 
although the expression and the localization of the evolutionary preserved receptor CB1R, and 
the enzyme FAAH, seem to be similar in mice, tree shrews, and primates, it is not comparable 
for CB2R, NAPE-PLD, MAGL and DAGLα. 
 
There are many controversies on the neuronal and/or peripheral expression of CB2R. 
Our results show that the expression pattern of the CB2R differs from the mouse to the 
monkey. Similar to CB1R, CB2R shows a general expression in the neuro-retina: 
photoreceptors, horizontal cells, amacrine cells, and cells localized in the GCL of rodents 
(Cécyre et al., 2013; Lopez et al., 2011). In the mouse, CB2R expressed in the photoreceptor 
layer, was mostly found in cones and some rods (Cécyre et al., 2013). Similar to its position in 
the phylogeny tree, the tree shrew has an in-between position showing expressions in all 
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layers, as in rodents, and in Müller cells, as in primates (Figure 3-2B). In agreement with the 
CB2R glial expression in the CNS, the primate retina expresses CB2R mainly in Müller cells, 
with a higher polarization towards the outer retina (Bouskila et al., 2013a). The Müller cells, 
with their unique anatomy, span the entire thickness of the retina and contact with the majority 
of the retinal neurons (Reichenbach et al., 1995). It is known that the activation of CB2R leads 
to a series of neuro-protective properties such as cell proliferation (Carrier et al., 2004), 
reduction of tumor necrosis factors and free radicals (Stella, 2009). The emergence of the 
CB2R in the Müller cells in well developed visual systems may be related to the specialization 
of the vision protective system in higher animals and can therefore play a role in 
neuroprotection. This complementary expression pattern of CB1R and CB2R in the primate 
retina reveals thus a reciprocal relationship between retinal neurons and glia regarding their 
function via the eCB system. The ubiquitous CB1R system may play a more general role in 
the light transduction in all three species, as previously suggested (Yazulla, 2008). 
 
The function of the cannabinoid receptors in the retina has been highlighted in recent 
ERG studies in adult mice (Cécyre et al., 2013) and vervet monkeys (Bouskila et al., 2014; 
Ptito et al. 2014). Cécyre et al., (2013) demonstrated a significant change in the a-wave 
amplitude of scotopic ERG in CB2R knockout mouse. However they did not find the same 
meaningful difference in cnr1 knockout. They concluded that CB2R is likely to play a greater 
role in mouse retinal processing than CB1R. In monkeys we have recently reported a 
significant increase in the b-wave component of the photopic ERG after blockade of both 
CB1R and CB2R with their specific antagonists (Ptito et al. 2014). This variation can be due 
to the different pattern of expression and specialization of the eCB system in the monkey. 
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Numerous anecdotal reports claim that smoking marijuana improves dim light vision in 
humans (Merzouki and Mesa, 2002; Russo et al., 2004). Acute consumption of marijuana 
reduces the Vernier and Snellen acuities, alters color discrimination, increases 
photosensitivity, glare recovery and decreases dark adaptation (Kiplinger et al., 1971; Dawson 
et al., 1977). These data indicate that the eCBs are more likely to be involved in shaping 
retinal responses to light and suggest a more crucial role for this system in visual processing. 
 
Significance of the distribution pattern of enzymes and cannabinoid receptors 
The expression pattern of CB1R and FAAH has been reported in the CNS as 
complementary, overlapping or unrelated distributions (Egertová et al., 2003; Yazulla, 2008). 
Here, we report an overlapping distribution; CB1R expressing neurons also express FAAH. In 
this case, the degrading enzyme may remotely influence the CB1R (Egertová et al., 2003). 
During development of the mouse retina, CB1R and FAAH expression patterns are present in 
the deepest neuroblast layers at birth, and spread-out throughout the retina in adulthood 
(Zabouri et al., 2011a; Zabouri et al., 2011b). In our three species, the FAAH expression 
overlaps the CB1R distribution pattern not only in the photoreceptor layers but also in the 
ganglion cells (Figure 3-1A-D and I-L). This suggests that cannabinoids act not only on 
photoreceptors (Yazulla, 2008) but also directly on ganglion cell. This expression pattern has 
been reported not only in the retina of the vervet monkey (Bouskila et al., 2012), but also in 
the optic nerve, the dorsal lateral geniculate nucleus (Javadi et al., 2015) and the visual cortex 
of Rhesus monkeys (Eggan and Lewis, 2007). 
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Anandamide (an endogenous agonist of the CB1R) and other N-acylethanolamines 
(NAEs) are biosynthesized from phospholipids of the cell membrane assisted by NAPE-PLD 
hydrolysis. In this study, we report a variation in the expression of this membrane associated 
synthesis enzyme, NAPE-PLD, despite its well-preserved sequence from rodents to humans 
(Okamoto et al., 2004). In the mouse, NAPE-PLD follows the same pattern of expression as 
CB1R and FAAH. Moreover, unlike the mouse but like the primate, the tree shrew has a high 
expression of NAPE-PLD in ONL and OPL. We show here for the first time that NAPE-PLD 
expression in monkeys is exclusively restricted to the photoreceptor layer. Unlike CB1R, 
NAPE-PLD is ubiquitously expressed in the rat brain with the highest level in the thalamus 
(Morishita et al., 2005). Besides its role in the eCB biosynthesis, many other physiological 
roles have been linked to NAPE-PLD such as, anti-inflammatory effect (Lambert et al., 2002), 
anorexic effect (Rodriguez de Fonseca et al., 2001), and pro-apoptotic effect (Maccarrone et 
al., 2002). Moreover, the NAE products in axons suggest a role in the regulation of 
postsynaptic neuron activity as anterograde synaptic signaling molecules (Egertová et al., 
2008). This pattern of expression also suggests another direct role of NAEs in primate photo-
transduction. 
 
Given that the lipophilic eCBs are released and degraded close to their action site, it 
would be reasonable to assume that the DAGLα and MAGL expressions are in the vicinity of 
CB2R. In the mouse retina, the DAGLα and MAGL expressions are often near or in the same 
cell types as CB1R and CB2R. CB1R is present in cones, horizontal, bipolar, amacrine and 
ganglion cells in the rat retina (Zabouri et al., 2011a; Zabouri et al., 2011b). CB2R is present 
in cone and rod photoreceptors, horizontal, bipolar, amacrine and ganglion cells in the adult 
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mouse retina (Cécyre et al., 2013). This distribution pattern may suggest that, in the mouse 
retina, eCBs such as 2-AG are faithfully expressed adjacent to the cannabinoid receptors and 
could be involved in their retinal function (Cécyre et al 2014). But the primates and the tree 
shrews have followed a complementary distribution pattern, and may have adopted a more 
complex and specific strategy to regulate their visual activity via the eCB system. The eCB 
expression pattern in the mouse rod-dominated retina with monocular vision, the tree shrew 
cone-dominated retina with binocular vision, and the monkey duplex retina with binocular 
vision proposed that the retinal eCB system plays a fundamental role in the mammal visual 
processing.  
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CHAPTER 4: Standardized full-field electroretinography in the 
Green Monkey (Chlorocebus sabaeus) 
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Abstract 
Full-field electroretinography is an objective measure of retinal function, serving as an 
important diagnostic clinical tool in ophthalmology for evaluating the integrity of the retina. 
Given the similarity between the anatomy and physiology of the human and Green Monkey 
eyes, this species has increasingly become a favorable non-human primate model for assessing 
ocular defects in humans. To test this model, we obtained full-field electroretinographic 
recordings (ERG) and normal values for standard responses required by the International 
Society for Clinical Electrophysiology of Vision (ISCEV). Photopic and scotopic ERG 
recordings were obtained by full-field stimulation over a range of 6 log units of intensity in 
dark-adapted or light-adapted eyes of adult Green Monkeys (Chlorocebus sabaeus). Intensity, 
duration, and interval of light stimuli were varied separately. Reproducible values of 
amplitude and latency were obtained for the a- and b-waves, under well-controlled adaptation 
and stimulus conditions; the i-wave was also easily identifiable and separated from the a-b-
wave complex in the photopic ERG. The recordings obtained in the healthy Green Monkey 
matched very well with those in humans and other non-human primate species (Macaca 
mulatta and Macaca fascicularis). These results validate the Green Monkey as an excellent 
non-human primate model, with potential to serve for testing retinal function following 
various manipulations such as visual deprivation or drug evaluation. 
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Introduction 
The retina is a complex and well-organized neuronal structure that is vulnerable to 
internal influences such as retinopathies and ocular pathologies, and is furthermore sensitive to 
external factors such as drugs and alcohol toxicity. Full-field electroretinography represents a 
useful diagnostic clinical tool in ophthalmology and is widely used as a measure of retinal 
function. Electroretinogram (ERG) recordings are generated through different summation of 
currents evoked in distinct populations of retinal cells, including photoreceptors (cones and 
rods), neurons (horizontal cells, bipolar cells, amacrine cells, and ganglion cells), glial cells 
(Müller cells), and epithelial cells [1]. Accordingly, the influence of environmental 
manipulations on the function of retinal cells can be assessed objectively in the ERG. Whereas 
the full-field ERG reflects the response of the entire retina to stimulus, it is possible to 
differentiate between responses of various retinal structures to light [2]; in fact, the positive 
and negative waves of the ERG emerge from different levels of retinal processing, and the 
response of particular retinal cell populations and circuits is targeted by the choice of stimulus 
and recording environment. Research on the origins of pathophysiological conditions 
displayed in human electroretinography is mostly carried out in animal models, with non-
human primates remaining particularly important in visual neuroscience research, due to their 
superior emulation of human retinal function [3]. Indeed, the non-human primate ERG plays 
an important role in studies of visual abnormalities and potentially therapeutic 
pharmacological effects in the retina. The International Society for Clinical Electrophysiology 
of Vision (ISCEV) proposes a minimum of five types of measurements in order to obtain 
standardization for investigations in humans [4], all of which can be obtained in non-human 
primates. 
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Green Monkeys have become important non-human primate species for visual 
neuroscience research. The genome of Green Monkeys has 90% parity with the human 
genome, which lends support to its use to model a range of behavioral and non-behavioral 
pathologic disorders in human [5], [6]. In fact, Green Monkeys are used as a model organism 
for the study of diabetes, cardiovascular disease, HIV/AIDS, Parkinson’s disease, substance 
abuse, attention deficit disorder, alcoholism, reproduction, tissue regeneration and other 
conditions [5], [7], [8], [9]. The Green Monkey has been utilized in visual neuroscience for 
many years [7], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], leading to a thorough 
anatomical description of the visual pathways and the publication of anatomical brain atlases 
[20], [21], [22]. Their large brain and ocular size relative to the 3.5 kg bodyweight of adult 
Green Monkeys is particularly advantageous in the electrophysiological study of visual 
abnormalities arising in the retina and optic nerve. The organization of the retina of the green 
monkey is similar to that of other Old World species such as Macaques, for example. The 
retina contains several layers and different cell populations: photoreceptors, bipolar cells, 
ganglion cells, amacrines and horizontal cells. There is a monotonic decrease in the number of 
cones from the fovea centralis (containing mainly cones) to the periphery made out of rods 
[17], [23]. This developed fovea is well suited for high visual acuity, color vision and photopic 
sensitivity whereas the peripheral retina is responsible for scotopic vision (nocturnal) [24]. 
From the study of Herbin et al. (1997), the only one available on the green monkey retina, the 
retinal ganglion cells (RGCs) number derived from retinal wholemounts was estimated at 
1 228 646. The topographical distribution of RGCs shows a strong centro-peripheral gradient, 
with the majority of small cells (P cells) in the fovea, the larger ones being encountered in the 
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periphery (M cells). The axons of the ganglion cells form the optic nerve and their counts 
derived from semi-thin sections (1 220 000) are close to the estimated number of RGCs for the 
vervet monkey and are in the range with those reported for Macaca Mulatta (1 468 000 RGCs) 
[25]. 
However, little is known about the electrophysiology of the Green Monkey retina, 
since most of such studies have been conducted in the rhesus monkey, for which a 
standardized procedure for electroretinographic examination has been published [26]. Due to 
the lack of corresponding data in Green Monkeys despite their growing importance in visual 
neuroscience, a standardized electroretinography protocol is needed. We therefore present here 
full-field ERG data for Green Monkeys, including the five standard responses recommended 
by the ISCEV. 
Table 4-1 Subject profile of animals used in this study 
 Animal ID Sex Weight (Kg) 
IOP (mm Hg) Pupil dilatation 
(mm) 
1 05011-5 Male 3.950 OD 10 / OS 9 OD 9 / OS 9 
2 05010-6 Male 3.725 OD 7 / OS 7 OD 8 / OS 8 
3 09093-1-3-1 Female 3.050 OD 9 / OS 9 OD 9 / OS 9 
4 08274 Female 2.800 OD 10 / OS 11 OD 9 / OS 9 
5 08275 Female 2.925 OD 8 / OS 6 OD 8.5 / OS 8.5 
6 07862 Female 2.875 OD 15 / OS15 OD 8.5 / OS 8.5 
7 08297 Female 2.750 OD 6 / OS 6 OD 9 / OS 9 
8 07866 Female 2.950 OD 12 / OS 12 OD 9 / OS 9 
9 01336-7-1-3 Female 2.950 OD 12 / OS 13 OD 9 / OS 9 
10 08315 Female 2.775 OD 10 / OS 11 OD 9 / OS 9 
11 07868 Female 2.825 OD 8 / OS8 OD 8.5 / OS 8.5 
12 08375 Female 2.900 OD 11 / OS 12 OD 9 / OS 9 
13 08376 Female 2.850 OD 6/ OS 6 OD 9 / OS 9 
14 08336 Female 2.925 OD 14 / OS 15 OD 9 / OS 9 
15 08377 Female 2.852 OD 9 / OS 10 OD 9 / OS 9 
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Materials and Methods 
Animals 
A total of 15 adult male and female Green Monkeys (Chlorocebus sabaeus), aged 3 to 4 years 
and weighing 3.01 ± 0.35 Kg, were used for this study (Table 4-1). The animals were born and 
raised in enriched environments in the laboratories of the Behavioral Science Foundation (St-
Kitts, West Indies). As adults, the animals were fed with primate chow (Harlan Teklad High 
Protein Monkey Diet; Harlan Teklad, Madison, WI) and fresh local fruits, with water available 
ad libitum. Infant Green Monkeys are born into an outdoor social group comprising several 
females, one male and other offspring of the same general age. Infants live with their parents 
until about 8 months of age, at which time they move to a playpen with 5 other age-mates. The 
natal cage is equipped with swings, perches, hiding places and jungle gyms. We do put in toys, 
but the animals are so busy playing with one another that they ignore the toys. In the smaller 
playpens, there are also swings, perches and climbing spots, as well as puzzle feeders and 
foraging boards. At about 18 months of age, youngsters graduate to a large, outdoor peer 
group of about 16 animals (like-ages, both sexes) where there are tunnels, swings, ladders, 
jungle-gyms and a variety of manipulanda (more complex puzzle feeders; natural forage 
opportunities, such as brush and vines; foraging boards). Plastic chain and baited balls are 
popular toys, but vervets of this age are uninterested in most other commercially available 
toys. All experiments were performed according to the guidelines of the Canadian Council on 
Animal Care (CCAC) and the Association for Research in Vision and Ophthalmology 
(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. The 
experimental protocol was also reviewed and approved by the local Animal Care and Use 
Committee (University of Montreal, protocol # 14-007) and the Institutional Review Board of 
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the Behavioral Science Foundation that is recognized by the CCAC. None of the animals were 
sacrificed for this study. 
 
Animal preparation for ERG recording 
The following procedure describes a typical recording session in Green Monkeys, including 
successively a 30 minutes of animal preparation, 30 minutes of dark adaptation, 15 minutes of 
scotopic recordings, 2 minutes of light adaptation, 15 minutes of photopic recordings, and 2 
minutes of flicker recordings (Figure 4-1). The values of dark and light adaptation were 
chosen based on data obtained in cynomologus monkeys [27]. The animals were sedated with 
an intramuscular injection of a mixture of ketamine (10 mg/kg; Troy Laboratories, 
Glendenning, New South Wales, Australia) and xylazine (1 mg/kg; Lloyd Laboratories, 
Shenandoah, IA). In this condition, the pupils were fully dilated to approximately 9 mm in 
diameter and the accommodation reflex was paralyzed with topical application of 1% 
tropicamide (Mydriacyl) and 2.5% phenylephrine hydrochloride (Mydfrin) (Alcon 
Laboratories, Fort Worth, TX). Intraocular pressures (IOP) were also monitored before and 
after the recording session by applanation tonometry (TonoPen XL; Mentor, Norwell, MA, 
USA). There were no significant IOP and pupil size differences noted between the beginning 
and the end of the ERG procedure. The eyes were treated with 0.5% proparacaine 
hydrochloride (Alcaine; Alcon Laboratories, Fort Worth, TX, USA) to anesthetize the cornea 
and then protected by application of 2.5% methylcellulose (Gonak; Akorn, Inc., Buffalo 
Grove, IL, USA) to prevent corneal drying. Body temperature was maintained between 36.5°C 
and 38°C with a heating pad. Recording sessions lasted approximately two hours for each 
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animal, after which they were allowed to recover and returned to their prior naturalistic 
setting. 
Visual Stimulation 
Full-field stimulation was produced with an UTAS BigShot Ganzfeld light source (UTAS E-
3000 electrophysiology equipment; LKC Technologies, Inc., Gaithersburg, MD, USA) that 
was placed in front of the animal’s face. Both eyes were simultaneously recorded and 
averaged as detailed below. The ERGs were evoked by white flashes of light of intensities 
ranging from 0.00025 cd.sec.m-2 to 1000 cd.sec.m-2 delivered in full-field conditions. During 
the course of dark adaptation, ERGs were recorded at 3 minutes intervals over 30 minutes of 
dark adaptation with a constant stimulus of approximately 0.025 cd.s.m-2. LED flash 
luminance of 0.00025 to 6 cd.sec.m-2 (-50 dB to 4 dB in LKC units) was used for scotopic 
stimulation. Responses were averaged for each of the 14 time-integrated flash luminance 
levels presented (ranging from -3.6 to 2.9 log cd.s.m-2 in approximately 0.3 log-unit steps; 
flash duration, 20 µs; inter-stimulus interval, 5 sec for -3.6 to 0.4 log cd.s.m-2 and 15 sec for 
0.6 to 2.9 log cd.s.m-2) and xenon flash luminance of 2.5 to 800 cd.sec.m-2 (0 dB to 25 dB in 
LKC units) for photopic stimulation (ranging from -2.2 to 2.9 log cd.s.m-2 in approximately 
0.3 log-unit steps; flash duration, 20 µs; inter-stimulus interval, 2 sec for all intensities). For 
light-adapted ERGs a steady white background-adapting field (30 cd/m2) was presented inside 
the Ganzfeld to saturate the rod system. Flash intensities and background luminance were 
calibrated using a research radiometer (IL1700 Photometer; International Light Inc., 
Newburyport, MA, USA) with a SED033 detector placed at 36 cm from the source. 
 
 
	  	   159 
ERG recording and analysis 
All experimental protocols followed the guidelines of the ISCEV [4], specifying the 5 standard 
responses: (1) a dark-adapted response (rod response), (2) a dark-adapted maximal response 
(combined rod–cone response), (3) a dark-adapted oscillatory potentials response, (4) a light-
adapted response (cone response), and (5) a light-adapted response to a rapidly repeated 
stimulus (30 Hz flicker). ERG recordings and signal processing were recorded with contact 
lens electrodes lying across the center of the cornea of each eye moistened with 1% 
carboxymethylcellulose sodium (Refresh Celluvisc, Allergan Inc., Markham, ON, Canada). 
The corneal contact lens electrode (Jet electrodes; Diagnosys LLC, Lowell, MA, USA) was 
equipped with four small posts on the convex surface in order to keep the eyelids open. 
Reference and ground gold disc electrodes (model F-E5GH; Grass Technologies, Astro-Med, 
Inc., West Warwick, RI, USA) were kept in place with adhesive paste (Ten20 conductive EEG 
paste; Kappa Medical, Prescott, AZ, USA) at the external canthi and forehead, respectively. 
Responses were amplified 10,000 times and filtered with a band pass from 1 to 500 Hz except 
for the oscillatory potentials, which were extracted with the LKC software with a band pass 
from 75 to 500 Hz. Each tracing included a 20 ms pre-stimulus baseline. Depending on the 
measured stimulus, up to 10 waveforms were averaged to reduce variability and background 
noise. Based on literature focusing on the origins of ERG waves in a primate model (macaque 
monkey) whose retina is very similar to that of humans [2], the origins of the waveforms are 
described. For the waveform analysis, the amplitude of the a-wave, which mainly reflects the 
function of photoreceptors, was measured from the baseline to the peak of the a-wave for the 
combined rod-cone response and the single-flash cone response. The amplitude of the b-wave, 
which reflects the activity of the inner nuclear layer, was measured from the peak of the a-
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wave to the peak of the b-wave for all responses. The peak latency was defined from the onset 
of the flash to the peak. In the case of the oscillatory potentials, the latency to the second peak 
was usually determined, where the amplitude was defined as peak to trough amplitude from 
the peak of the second wave to the following trough. The amplitude of the i-wave was 
measured from the trough of the b-wave to the peak of the i-wave and its respective peak time 
was also measured from flash onset. The exact origin of the i-wave is still controversial. Some 
have suggested that this component is generated at the inner retinal level [28], and others that 
it origins at a more distal location [29]. The latter point is highlighted in ocular pathology 
studies. For example, the i-wave in glaucoma patients [30] and in glaucoma animal models 
[29] is increased, suggesting that it does indeed originate in the distal retina. In the 30 Hz 
flicker ERG, the second peak was evaluated in relation to the preceding trough. Retinal 
response diagrams were drawn using Adobe Illustrator and processed in Adobe InDesign 
(Adobe Systems, software version CS5; San Jose, CA, USA). The ERG procedure is 
summarized schematically in Figure 4-1. 
 
 
Figure 4-1 Summarized schematic procedure describing a typical electroretinography recording session in a Green 
Monkey (Chlorocebus sabaeus). Int, intensity; Fla, flashes; ISI, inter stimulus interval. 
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Results 
 
Figure 4-2 Standard responses for full-field electroretinography in a representative Green Monkey (Chlorocebus 
sabaeus), including the 5 standard responses: a rod response, a combined rod–cone response, oscillatory potentials, a 
cone response, and a flicker response. (A) Rod response elicited at -2.2 log cd.s.m-2 (0.0064 cd.s.m-2) after 30 minutes of 
dark adaptation. (B) Maximal response elicited at 0.4 log cd.s.m-2 (2.57 cd.s.m-2, standard flash) in the dark-adapted 
eye. (C1) Broadband scotopic ERG waveform and (C2) the corresponding software-filtered oscillatory potentials 
elicited at 0.6 log cd.s.m-2 (4.4 cd.s.m-2) in the dark-adapted eye. (D) The recommended additional stronger flash ERG 
elicited at 10.0 cd.s.m-2 in the dark-adapted eye. (E) White flash cone response elicited at 0.4 log cd.s.m-2 in the light 
adapted eye with a background illumination of 30 cd.m-2. (F) Flicker response (30 Hz) elicited at 0.4 log cd.s.m-2 after 
five minutes of light adaptation with a background illumination of 30 cd.m-2. Tracings (A, B, C1, D, E) included a 
20 ms pre-stimulus baseline. Horizontal calibration, 40 ms; vertical calibration, 50 µV. 
 
The five standard responses 
All 15 Green Monkeys displayed very well detectable and easily reproducible ERG 
recordings, using the protocol described in the Experimental Procedure section (Figure 4-1). 
As indicated by the ISCEV, the five standard responses and the recommended additional 
stronger scotopic flash ERG are illustrated in Figure 4-2 for a representative Green Monkey. 
The typical scotopic ERG signal is formed, as expected, by an initial negative wave (the a-
wave) and followed by a larger positive wave (the b-wave). Faster components of lower 
amplitude, known as the oscillatory potentials (OPs), are seen in the ascending limb of the 
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scotopic b-wave. These OPs were as prominent as those obtained in humans. Given 
uncertainty of how best to quantify OPs, we chose to measure the amplitude from the peak of 
the second wave to the following trough, as described in the Experimental Procedure section. 
Thus, the chronological sequence of electrical events in a typical photopic ERG response 
observed in the Green Monkey, as in humans, is the a-wave, b-wave, and i-wave. During 
30 Hz flicker stimulation, double peaks were often detectable in the b-waves. In these cases, 
both the amplitudes and implicit times were measured at the first peak. The signal-to-noise 
ratio was high for all categories, and no extra filter such as a notch filter had to be used, even 
in single sweep curves. Our mean results obtained in 15 Green Monkeys are summarized in 
Table 4-2; the mean amplitudes and latencies of the five standard ISCEV responses are 
specific to a flash intensity and light adaptation status. 
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Table 4-2 Responses to standardized electroretinography in Green Monkeys, Data are reported as mean ± SEM 
(Standard error of the mean). 
Standard 
response 
(ISCEV) 
a-wave 
amplitude 
(µV) 
a-wave 
peak 
latency 
(ms) 
b-wave 
amplitude 
(µV) 
b-wave 
peak 
latency 
(ms) 
Flash 
intensity 
(cd.s.m-2) 
Adaptatio
n status 
Rod response - - 88.9 ± 26.6 79.9 ± 6.1 0.0064 Dark 
Maximal 
response 
115.1 ± 40.2 14.8 ± 0.7 203.7 ± 52.6 36.7 ± 3.8 2.5 Dark 
Oscillatory 
potential 
- - 60.2 ± 15.5 20.3 ± 0.9 4.4 Dark 
Strong flash 
response 
174.9 ± 27.2 9.8 ± 0.4 230.7 ± 40.6 30.8 ± 3.6 10.0 Dark 
White flash 
cone response 
22.1 ± 4.5 12.3 ± 1.2 81.5 ± 19.4 27.7 ± 1.5 2.5 Light 
30 Hz flicker - - 88.9 ± 20.2 24.3 ± 1.0 2.5 Light 
 
ERG responses throughout dark-adaptation 
ERGs were recorded during the course of dark-adaptation at 3 min intervals over 
30 min with a constant stimulus intensity of approximately 0.006 cd.s.m-2 (Figure 4-3). We 
have not pursued the recordings over 30 minutes based on the human [4] and monkey 
literature [27]. For example, Bee (2001) reported that in cynomologus monkeys (Macaca 
fascicularis), plateau was reached around 20 minutes. 
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Figure 4-3 Response versus time functions of b-wave amplitude (A) and latency (B) throughout dark-adaptation 
elicited at -2.2 log cd.s.m-2 (0.0064 cd.s.m-2). Each data point indicates average (± SEM) of all 15 monkeys. 
 
Intensity–response function of scotopic and photopic ERG 
Beyond the ordinary requirements of the ISCEV, ERG responses to stimuli of increasing flash 
intensity in dark-adapted (Figure 4-4A) and light-adapted conditions (Figure 4-4B) were also 
recorded. Both intensity response series were obtained from the same monkey, and in the same 
recording session. It can be seen in the figure that the two recording conditions yield ERG 
responses of different amplitude, timing and morphology. The distribution of full-field ERG 
amplitudes and implicit times are often asymmetrical, even in large groups of normal 
monkeys, such that use of statistics based on a normal distribution can be misrepresentative 
[27]. We used a log transformation of the data to reduce variance. Figure 4-5 shows the results 
of the scotopic a-wave and b-wave amplitudes and latency versus log flash intensity (cd.s.m-2) 
functions. It is worthwhile to note a sigmoid curve characterizes the amplitudes as well as the 
latencies functions in the Green Monkey. Moreover, the b-wave amplitude decreased at the 
highest intensity of 2.9 log cd.s.m-2 with an inter-stimulus interval of 15 seconds (Figure 4-5A 
and 4-5C). The photopic functions are shown in Figure 6. The values given at 0.4 log cd.s.m-2 
(standard flash) represent the white flash cone response as recommended by the ISCEV. These 
results are also known from studies on non-human and human primate retinal functions [27], 
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[31]. 
 
Figure 4-4 ERG responses to stimuli of increasing flash intensity, from top to bottom, in the dark-adapted eye (A) and 
in the light-adapted eye (B) of a representative Green Monkey (Chlorocebus sabaeus). Vertical arrow indicates flash 
onset. Horizontal calibration, 20 ms; vertical calibration, 75 µV. 
 
 
The photopic hill effect 
In the recordings of light-adapted eyes, the amplitude of the a-wave augments 
regularly with the gradual increase in intensity of the stimulus, while amplitude of the b-wave 
first increases to a maximum (Vmax), and finally decreases with presentation of progressively 
brighter stimuli. This effect has been well demonstrated in humans [32]. The photopic flash 
ERG of the Green Monkey includes a post b-wave component identified as the i-wave that is 
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best seen using the standard flash (0.0 log cd.s.m-2) after light adaptation (Figure 4-4). 
 
Figure 4-5 Response versus intensity function for the a-wave amplitude (A), a-wave latency (B), b-wave amplitude (C), 
and b-wave latency (D) of the scotopic ERG. Each data point indicates average (± SEM) of all 15 monkeys. 
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Figure 4-6 Response versus intensity function for the a-wave amplitude (A), a-wave latency (B), b-wave amplitude (C), 
and b-wave latency (D) of the photopic ERG under rod-suppressing background illumination (30 cd.m-2). Each data 
point indicates average (± SEM) of all 15 monkeys. 
 
 
Discussion 
These results provide normative values for the standard ERG protocol in Green 
Monkeys, with the general finding that full field flash ERG responses in these monkeys are 
similar to those in humans. We report the 5 responses in Green Monkeys as recommended by 
ISCEV, which are the standard protocols for ERG in humans [4] and cynomolgus monkeys 
[27]. The ISCEV consensus standard provides the basis for stable comparison between 
research laboratories and clinical ERG recordings. However, information about additional 
stimuli is often necessary for specific applications, such as in considering the higher retinal 
illuminances for rod responses in human neonates [33], and dark-adapted flicker in retinitis 
pigmentosa [34]. Throughout the present study, particular attention was paid to IOP and pupil 
	  	   168 
dilatation, with an aim to reduce variability (Table 1). Human and non-human primates are 
mammals that share similar vascular anatomy of the eyes, and have a macular/foveal region 
and multiple cone types that offer them high visual acuity and color vision. It is notable that 
our values of amplitude and latency in Green Monkeys are closer to those in humans [4], 
relative to corresponding results in cynomolgus monkeys [27], [35], and it may be that the 
differences are as much attributable to laboratories they are to species differences. 
 
The ERG responses to the standard tests in Green Monkeys were similar to the 
responses in humans even though the axial length of Green Monkey eyes is a bit lower than 
humans, i.e. 18 mm in the Green Monkey and 24 mm in humans [36]. In particular, the shape 
and latency of the curves are highly comparable. We can safely assume that the higher 
amplitudes found in man [31] are due to the large diameter and larger retinal surface area of 
the human eye, which have a direct relation with the net electric field and thus on the 
measured responses. Accordingly, differences in amplitude but not latency have been 
observed in human subjects with high myopia or small refractive error, as expected due to 
differences in axial length [37]. In the present study, slight differences in amplitude were 
occasionally noticed in the other eye, but were in every case within the 10% inter-ocular 
amplitude differences in normal human subjects [38]. Furthermore, the standard amplitude of 
OPs was a bit larger than the range in cynomolgus monkeys [27], but lower than those of 
humans [39]. The implicit times of OPs were within the same range for monkeys and humans. 
 
Full-field stimulation, as employed presently, is the most effective way of eliciting an 
ERG representative of the entire population of cones and rods in the primate retina [40]. 
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Replicable peak amplitudes and implicit times can therefore be obtained with full-field ERG 
recordings. Recordings of photopic ERGs are used to assess the functioning of the cone 
system in humans and animals. As defined above, in response to progressively brighter 
stimuli, the b-wave of the photopic ERG gradually increases in amplitude, attains a plateau 
(the maximal b-wave amplitude which is reached for a narrow range of intensities, Vmax), and 
then rapidly decreases with further increments in the luminance of the flash. This unique 
luminance–response function was originally termed "the photopic hill" [41]. The photopic hill 
in the primate ERG results mainly from two factors: the reduction of the ON-component 
amplitude at higher intensities and the delay in the positive peak of the OFF-component at 
higher intensities [42]. Scotopic ERGs, on the other hand, are used to evaluate the integrity of 
the rod system in humans and animals [2], [43]. 
 
At about 20 ms after a typical human photopic b-wave, a second positive signal is 
seen, the i-wave [44]. This feature is common to the photopic ERG of many species except 
mice and rats [28]. The i-wave amplitudes and latencies in Green Monkeys were similar to 
those reported previously for most mammals [28]. It is interesting to note that in humans, the 
amplitude of the i-wave saturates at a dimmer flash intensity than that needed to evoke a b-
wave of maximal amplitude [45]. 
 
In general, it is important to consider how best to interpret a finding of altered 
electroretinogram in the clinic and in animal models. Normal scotopic and photopic a-waves 
indicate normal functioning of rod and cone outer segments. In particular, it has been proposed 
that the scotopic ERG b-wave is the result of depolarization of ON-bipolar cells [46], [47]. 
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Consequently, a pathological or pharmacological decrease in amplitude of the b-wave of the 
rod ERG and of the scotopic standard combined ERG might both result from a postsynaptic 
abnormality in the rod ON-pathway, plausibly due to a postsynaptic abnormality in the cone 
ON-pathway because it generates this response [46], [48]. The ON-pathway is often 
considered to influence contrast sensitivity [49], [50]. For instance, impairments of contrast 
sensitivity are reported clinically in disorders with ON-pathway dysfunction [51], such as 
melanoma-associated retinopathy [52], congenital stationary night blindness [53]. 
 
Specific values for amplitude and b-wave implicit time will necessarily differ between 
laboratories due to minor variations in recording electrodes, equipment, and protocol, not to 
mention species differences. Among the various technical factors potentially impacting the 
ERG amplitudes include contact lens placement, the structural integrity of the corneal surface, 
pupil size, and even IOP. It is important to consider these factors when interpreting the results. 
Nevertheless, in order to control for these technical and biological influences, we collected the 
physiological relevant data before and after the ERG recordings for each monkey, so as to 
provide a stable basis for comparison in future studies of pharmacology and disease models in 
the Green Monkey. The present results entailing recordings performed in accordance with the 
ISCEV, and with the ERG encompassing 30 minutes of dark adaptation correspond very well 
with similar results obtained in humans. Thus, the Green Monkey promises to serve as an 
excellent animal model for retinal function testing, for example in toxicity evaluation. 
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Abstract 
The expression patterns of the endocannabinoid (eCB) receptors and related metabolic 
components are well documented in rodents and primates. While the cannabinoid receptor 1 
(CB1R) is mainly expressed throughout the central retina, the cannabinoid receptor 2 (CB2R) 
is exclusively found in the retinal glia (Müller cells) of vervet monkeys. However, in primates, 
the role of these receptors in retinal function remains elusive. To study the retinal neural 
correlates that accompany the disruption of eCB signaling, we recorded the neural activity of 
the retina in adult vervet monkeys. We evaluated scotopic and photopic electroretinogram 
(ERG) response changes before and after blockade of the main cannabinoid receptors CB1R 
and CB2R by intravitreal administration of their specific antagonist (AM251 and AM630, 
respectively). Our results showed different effects of CB1R and CB2R on the ERG in 
photopic conditions: at low flash intensities, only the blockade of CB1R decreased the 
amplitude of the a -and b-waves, while at high flash intensities, blockade of CB2R increased 
the amplitude of both a- and b-waves. Moreover, blocking CB1R and CB2R resulted in an 
increase in the latency of the a- and b-waves of the ERG. In scotopic conditions, following 
dark-adaptation, blockade of CB1R and CB2R reduced the amplitude of the a-wave at high 
intensities only and decreased the b-wave at low intensities. Significant increases in latency 
were also observed by blocking cannabinoid receptors. Our results suggest an interaction 
between these retinal eCB receptors in the genesis and modulation of the ERG in normal 
vervet monkeys.  
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Introduction 
The eCB system is mainly composed of cannabinoid receptor 1 (CB1R), cannabinoid 
receptor 2 (CB2R), their endogenous ligands (anandamide, 2-arachidonoylglycerol), and 
metabolizing enzymes. The physiological and psychological effects of cannabinoids can be 
detected almost everywhere in the body due to the abundance of their specific receptors. 
Expression patterns of CB1R and CB2R are well documented in the retina of numerous 
species such as rodents and primates (Straiker et al., 1999; Yazulla et al., 1999; Lopez et al., 
2011; Cécyre et al., 2013), including vervet monkeys (Bouskila et al., 2012; Bouskila et al., 
2013a). In rodents, CB1R and CB2R are expressed in many retinal cell types, particularly 
cone and rod photoreceptors, horizontal cells, amacrine cells, bipolar and ganglion cells 
(Zabouri et al., 2011; Cécyre et al., 2013).  In vervet monkeys, CB1R is mainly found in cones 
of the central retina, in rod spherules with very low expression, horizontal cells, bipolar cells, 
amacrine and ganglion cells. CB2R, on the other hand, is strictly expressed in glial Müller 
cells (Bouskila et al., 2012; Bouskila et al., 2013a, b). Beyond the retina, the expression 
pattern of CB1R is also well documented in the dorsal lateral geniculate nucleus (Javadi et al., 
2015) and primary visual cortex (Eggan and Lewis, 2007) of primates. 
Most of our knowledge on the role of cannabinoids in human vision comes from 
reports, anecdotes and studies on cannabis consumers (for review see Schwitzer et al., 2014). 
Besides the well-known “red eye” effect (vasodilation) of marijuana and reduction of 
intraocular pressure (Flom et al., 1975; Green, 1979; Porcella et al., 1998), the functional 
effects of eCBs on the visual system are still not completely defined. Nevertheless, the 
administration of cannabinoids produces some alterations in the human visual system. Indeed, 
case studies suggested the existence of cannabis-mediated visual effects in humans, 
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particularly an increase in glare recovery at low contrast (Adams et al., 1978), a reduction in 
Vernier and Snellen acuities (Kiplinger et al., 1971; Adams et al., 1975), an increase dim light 
vision (Dawson et al., 1977; Merzouki and Mesa, 2002; Russo et al., 2004), a blurred vision 
(Noyes et al., 1975), changes in color discrimination, and an increase in photosensitivity 
(Dawson et al., 1977). Most of the latter effects have a retinal component. These various 
behavioral effects might be due to neurochemical changes induced by retinal eCB system. 
Indeed, a variety of physiological effects of cannabinoids have been reported for every retinal 
cell type in bovines, guinea pigs, rodents, and fishes (for review see Yazulla, 2008; Schwitzer 
et al., 2014). In the bovine retina, the activation of CB1R increases monoamine oxidase 
(Gawienowski et al., 1982). In the guinea pig retina, stimulation of CB1R results in the 
inhibition of dopamine release (Schlicker et al., 1996). In the rat retina, activation of 
cannabinoid receptors modulates [35S]GTPγ S-binding and voltage-dependent membrane 
currents in photoreceptors, bipolar cells and ganglion cells (Fan and Yazulla, 1999; Straiker et 
al., 1999; Yazulla et al., 2000; Fan and Yazulla, 2003; Straiker and Sullivan, 2003). 
Cannabinoid agonists increase the cone response to light offset in the goldfish retina (Struik et 
al., 2006). 
The electroretinogram (ERG) is a useful tool for assessing retinal function by 
measuring the electrical responses of all populations of retinal cells principally photoreceptors 
(cones and rods), bipolar cells, and Müller cells (Steinberg et al., 1985). The ERG waves 
include two main components: the negative amplitude (a-wave) and the positive one (b-wave). 
The a-wave mainly reflects the response of the outer photoreceptor layer (rods and cones) to 
light (Armington et al., 1952). The generation of the b-wave, the major component of the 
ERG, is attributed to the inner retina, mainly the depolarization of bipolar and Müller cells 
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(Miller and Dowling, 1970; Stockton and Slaughter, 1989; Wen and Oakley, 1990). Specific 
stimuli and recording environments are selected to separate the component of the ERG and 
target particular populations of retinal cells; for instance, the function of the rods assessed in 
dark-adapted eyes under scotopic conditions (Robson et al., 2003). Inversely, the optimal 
setting to gauge the cone responses is the use of high-intensity flashes with a more elevated 
frequency in photopic conditions (Robson et al., 2003). However, it is worth stressing that it is 
impossible to register a pure response from either photoreceptor and the resulting response to 
light comes from both cones and rods (Rosolen et al., 2008). 
The abundance of the CB1R and CB2R in the visual system, especially in the retina, 
indicates that they should play a role in vision. To the best of our knowledge, there is only one 
recent study that focused on the detailed function and morphology of the retina by using 
CB1R (cnr1-/-) and CB2R (cnr2-/-) knockout mice (Cécyre et al., 2013). Using ERG to 
measure the global evoked potential of various cells of the retina, the authors showed that no 
significant effect was observed in cnr1-/- mice under photopic and scotopic conditions. 
However, in cnr2-/- mice, the b-wave amplitude required more light adaptation time to reach 
stable values under photopic conditions and the a-wave amplitude increased in scotopic 
conditions (Cécyre et al., 2013). Based on the expression pattern of CB2R, mainly in Müller 
cells of the monkey retina, we have recently proposed that CB2R must play a role in the 
generation of the b-wave (Bouskila et al 2013a).  
Given the paucity of studies on the putative role of the retinal eCB system in vision, 
we investigated the changes in retinal function as measured by ERG in adult vervet monkeys 
after acute blockade of CB1R and CB2R by their antagonists AM251 and AM630, 
respectively. 
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Material and Methods 
Choice of species. Vervet monkeys are progressively employed in biomedical research with a 
second citation record among the non-human primates after the rhesus macaque (Jasinska et 
al., 2013). Vervets are very similar in physiology and behavior to macaque, and they are more 
accessible, disease-free with less health and safety risks. Vervet monkeys have a foveal 
binocular vision with a high cone density that decreases with eccentricity, trichromatic color 
vision and a six-layered dorsal lateral geniculate nucleus (Herbin et al., 1997; Boire et al., 
2001). Recently, we have standardized a non-invasive, painless ERG method for vervet 
monkeys (Bouskila et al., 2014) that showed recordings highly comparable to macaques (Bee, 
2001) and humans (McCulloch et al., 2014). 
 
Subjects. Seventeen vervet monkeys (Chlorocebus sabaeus) were tested before and after the 
intravitreal administration of the cannabinoid receptor antagonists. Six of those monkeys were 
injected with AM251, and another 6 were injected with AM630. An additional 5 monkeys 
were injected with the vehicle (DMSO) in order to provide post-injection control values 
(Table 1). The animals were fed with primate chow (Harlan Teklad High Protein Monkey 
Diet; Harlan Teklad, Madison, WI) and fresh local fruits, with water available ad libitum. 
Infant Green Monkeys are born into an outdoor social group comprising several females, one 
male and other offspring of the same general age. Infants live with their parents until about 8 
months of age, at which time they move to a playpen with 5 other age-mates. The natal cage is 
equipped with swings, perches, hiding places and jungle gyms. We do put in toys, but the 
animals are so busy playing with one another that they ignore the toys. In the smaller 
playpens, there are also swings, perches and climbing spots, as well as puzzle feeders and 
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foraging boards. At about 18 months of age, youngsters graduate to a large, outdoor peer 
group of about 16 animals (like-ages, both sexes) where there are tunnels, swings, ladders, 
jungle-gyms and a variety of manipulanda (more complex puzzle feeders; natural forage 
opportunities, such as brush and vines; foraging boards). Plastic chain and baited balls are 
popular toys, but vervets of this age are uninterested in most other commercially available 
toys. All experiments were performed according to the guidelines of the Canadian Council on 
Animal Care (CCAC) and the Association for Research in Vision and Ophthalmology 
(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. The 
experimental protocol was also reviewed and approved by the local Animal Care and Use 
Committee (University of Montreal, protocol # 14-007) and the Institutional Review Board of 
the Behavioral Science Foundation that is recognized by the CCAC. None of the animals were 
sacrificed for this study.  
 
Table 5- 2 Profile of the animals used in this study 
 Animal ID Sex Weight (Kg) Injection Concentration 
1 08275 Female 2.92 DMSO 100%/100 µl 
2 07862 Female 2.87 DMSO 100%/100 µl 
3 08376 Female 2.85 DMSO 100%/100 µl 
4 08456 Male 3.55 DMSO 100%/100 µl 
5 08560 Female 3.32 DMSO 100%/100 µl 
6 08297 Female 2.75 AM251 1 mg/100 µl 
7 07866 Female 2.95 AM251 1 mg/100 µl 
8 01336-7-1-3 Female 2.95 AM251 1 mg/100 µl 
9,10 08336 Female 2.92 AM251 0.3 mg/100 µl 
11,12 08377 Female 2.85 AM630-AM251 0.3 -1 mg/100 µl 
13 05010-6 Male 3.72 AM630-AM251 0.3 -1 mg/100 µl 
14 09093-1-3-1 Female 3.05 AM630 0.3 mg/100 µl 
15 05322-6 Female 3.25 AM630 0.3 mg/100 µl 
16 08498 Female 2.86 AM630 0.3 mg/100 µl 
17 08590 Female           2.94 AM630 0.3 mg/100 µl 
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Animal preparation for ERG recordings. All procedures were in accordance with the 
standard protocol of electroretinography in vervet monkeys (Bouskila et al., 2014). Briefly, all 
animals were sedated with ketamine (10 mg/kg; Troy Laboratories, Glendenning, New South 
Wales, Australia) and xylazine (1 mg/kg; Lloyd Laboratories, Shenandoah, IA, USA) 
intramuscular injection to maintain an adequate level that prevents the animals from moving 
and blinking. The sedation mixture shows no effect on ERG results (Nair et al., 2011). With 
1% tropicamide (Mydriacyl®) and 2.5% phenylephrine hydrochloride (Mydfrin®) (Alcon 
Laboratories, Fort Worth, TX, USA), the pupils were fully dilated (approximately 9 mm in 
diameter), and the accommodation paralyzed. The cornea was anesthetized with 0.5% 
proparacaine hydrochloride (Alcaine®; Alcon Laboratories, Fort Worth, TX, USA) treatment. 
To prevent corneal drying, the eyes were moisturized frequently with 2.5% methylcellulose 
(Gonak; Akorn, Inc., Buffalo Grove, IL, USA). Body temperature was maintained between 
36.5°C and 38°C with a heating pad. After a recording session of about two hours, animals 
were sent back to their prior natural settings after a period of isolated recovery. 
 
Intravitreal Injection. The selective CB1R antagonist AM251 was purchased from Cayman 
Chemicals (Ann Arbor, MI, USA). The selective CB2R antagonist AM630 was purchased 
from Tocris (Tocris Bioscience, Ellisville, USA). Both antagonists were diluted in DMSO 
under sterile condition. Assuming no leakage, the final concentration was 0.01 mg/µl for 
AM251 and 0.003 mg/µl for AM630. After inspection and examination of the eyes, the cornea 
was cleaned with 5% povidone-iodine solution for 45 seconds. A topical anesthetic was also 
applied over the injection site using pilocarpine proparacaine. The conjunctival and corneal 
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surfaces were then moistened with methylcellulose (Gonak;	   Akorn,	   Inc.,	   Buffalo	   Grove,	   IL,	  USA). The eye was covered with sterile coatings and a Barraquer eye speculum (1.75 inches, 
10 mm wide small blades) was placed. In a 1 mL syringe with a 25G needle, 100 µL drug 
solution was injected 2 mm posterior to the corneal limbus into the vitreous cavity. The 
injection site was compressed for a minute using a sterile cotton swab to avoid reflux on 
removal of the needle. The back of the eyes was inspected using an ophthalmoscope before 
and after the intravitreal injection to determine the integrity of the retina. No substantial 
difference in intraocular pressure was observed before and ten minutes after the intravitreal 
administration. As a follow up, the animal eyes were checked every day for seven days and the 
topical antibiotic ointment was administered. 
 
Visual Stimulation. Full-field stimulation was produced with a Ganzfeld light source (UTAS 
E-3000 electrophysiology equipment; LKC Technologies, Inc., Gaithersburg, MD, USA) that 
was placed in front of the animal’s face.  The ERG was acquired from both injected and non-
injected eyes simultaneously. The ERGs were evoked by flashes of light of intensity ranging 
from 0.00025 cd.sec.m-2 to 1000 cd.sec.m-2 (duration <5 ms) delivered in full-field conditions. 
During the 30-minute dark adaptation period, every 3 minutes, ERGs were recorded using a 
constant stimulus of approximately 0.025 cd.s.m-2. Xenon flash luminance of 2.5 to 
800 cd.sec.m-2 (0 dB to 20 dB in LKC units) was used for photopic ERGs and LED flash 
luminance of 2.5x10-5 to 6 cd.sec.m-2 (-40 dB to 4 dB in LKC units) for scotopic ERGs. For 
light-adapted ERGs, a steady background-adapting field (30 cd.m-2) was presented inside the 
Ganzfeld to saturate the rod system. Flash intensities and background luminance were 
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calibrated using a research radiometer (IL1700 Photometer, International Light Inc., 
Newburyport, MA, USA) with a SED033 detector placed at 36 cm from the source. Stimulus-
intervals of at least 20 seconds were used at high intensities in the dark-adapted eyes.  
 
ERG recording. All ERG procedures followed the ISCEV guidelines and recently published 
standardized ERG in vervet monkeys (Bouskila et al., 2014). Briefly, ERGs were recorded 
using corneal contact lens electrodes (Jet electrodes, Diagnosys LLC, Lowell, Massachusetts, 
USA) lying across the center of the cornea of each eye, moistened with 1% 
carboxymethylcellulose sodium (Refresh Celluvisc, Allergan Inc., Markham, ON, Canada). 
The jet electrodes were equipped with four small posts on the convex surface in order to keep 
the eyelids open. Reference and ground gold disc electrodes (model F-E5GH; Grass 
Technologies, Astro-Med, Inc., West Warwick, RI, USA) were respectively stick to the 
external canthi and forehead with adhesive paste (Ten20 conductive EEG paste; Kappa 
Medical, Prescott, AZ, USA). For the analysis of the waveforms, the a-wave amplitude, that 
mainly reflects the function of photoreceptors, was measured from the baseline to the peak of 
the a-wave for the combined rod-cone response and the single-flash cone response. As a 
measure of activity in the inner nuclear layer, the amplitude of the b-wave was measured from 
the trough of the a-wave to the peak of the b-wave for all responses. The peak latency was 
defined from the onset of the flash to the peak. Retinal response diagrams were drawn using 
Adobe Illustrator and processed in Adobe InDesign (Adobe Systems, software version CS5; 
San Jose, CA, USA). The recording procedure is summarized in Figure 5-1. 
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Figure 5- 1 Illustration of a typical ERG recording session after an intravitreal injection (modified from Bouskila et 
al., 2014). 
 
Statistical analysis. The absolute trough (a-wave) and peak (b-wave) of the ERG curves were 
detected for each intensity. When no wave was detected, an amplitude and latency of 0 were 
recorded for that specific stimulus intensity. Outliers (±2 IQR) and blank values were 
replaced with a within-subject average obtained from stimuli with an intensity similar to the 
one being replaced. Additionally, when the ERG curve for weak stimulus intensities (<-2 log 
cd.sec/m2) did not return to baseline 350 ms after the stimulus, the amplitude of the a- and b-
waves were corrected to account for the shift. To determine the effect of injecting AM251 and 
AM630 in the eye, the standardized amplitude and latency post-injection values were 
calculated and then subtracted from the standardized baseline values (pre-injection, calculated 
individually for each monkey) and from the post-injection values obtained from the control 
group (DMSO-injected).  
	   189	  
Results 
Retinal Function in Photopic Conditions 
To assess the effect of the blockade of CB1R and CB2R on the light-adapted retina, ERGs 
responses were registered before and 40 minutes after administration of DMSO, AM251 or 
AM630 in photopic conditions. The representative responses for stimuli of increasing intensity 
in different treatments (AM251 and AM630) are compared with the control vehicle (DMSO) 
(Figure 5-2). Latencies and amplitudes of a-waves and b-waves obtained during full-light 
conditions were submitted to a 12 (intensities levels) for 2 antagonists (AM251, AM630) 
mixed model ANOVA to demonstrate that the effect of the antagonist is modulated by the 
intensity of the flash (p≤0.009). A tendency of augmentation in amplitude of both a- and b-
waves in higher intensities can be observed in both treatment groups AM251 and AM630 
(Figure 5-2).  
	  
Figure 5- 2 Representative photopic ERGs recorded in animals that received the vehicle only (DMSO) as the baseline 
compared with the responses after injection of the CB1R antagonist AM251 (middle column) and the CB2R antagonist 
AM630 (right column). ERG recordings of each treated animal were established by presenting progressively brighter 
flashes indicated to the left of the traces as the log luminance (cd.s/m2). Horizontal calibration, 10 ms; vertical 
calibration, 100 µV. 
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The Effect of Blockade of Cannabinoid Receptor in Photopic Conditions 
To verify if the observed tendencies in Figure 5-2 are significant, the latencies and 
amplitudes of a- and b-waves obtained in a photopic condition with 12 intensity levels were 
calculated in different treatments using t-test for each stimulus intensity. At low flash 
intensities (0 log cd.sec/m2 ≥), AM251 significantly decreases the amplitude of the a-wave 
and b-wave compare with DMSO (Figure 3, left column). Inversely, blockade of CB2R by 
AM630 increases the amplitude of both a- and b-waves in high flash intensities (Figure 5-3, 
left column). Moreover, blockade of CB1R, only increases the latency of a-wave in lower 
flash intensity. Both antagonists significantly delayed the time to peak time for b-wave in 
higher intensities (Figure 5-3, right column). 
	  
Figure 5- 3 The Effect of Blockade of Cannabinoid Receptor in Photopic Conditions. Amplitude (left) and latency 
(right) of a-wave (upper) and b-wave (lower) are plotted as a function of flash intensities presented in photopic 
conditions. Intensities at which the proportional differences are significantly different from DMSO control are 
identified with a * (indicating p<0.05 on a two-directional, one-sample t-test); Grey stars indicate that the CB1R is 
different from DMSO, and black stars indicate CB2R is different from DMSO. Values above zero indicate larger 
amplitudes or latencies following injection (relative to DMSO). Error bars represent standard error of the mean 
(SEM). 
	  	  (log cd.sec/m2) (log cd.sec/m2) 
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Retinal Function in Scotopic Condition 
To assess the effect of the cannabinoid receptor antagonists on dark-adapted retina, 
ERGs responses were registered before and about 80 minutes after administration of DMSO, 
AM251 or AM630 in scotopic conditions. The representative responses for stimuli of 
increasing intensity in different treatments (AM251 and AM630) are compared with control 
(DMSO) (Figure 5-4). Latency and amplitude of the a-wave and b-wave obtained following 
dark adaptation were submitted to a 13 (intensities levels) for 2 antagonists (AM251, AM630) 
mixed model ANOVA to demonstrate that the effect of the drugs is modulated by the 
intensity of the flash (p ≤ 0.05). A tendency of augmentation in amplitude of both a- and b-
waves at higher intensities (0 log cd.sec/m2 ≤) can be observed in both treatment groups 
(Figure 5-4). 
 
	  
Figure 5- 4 Representative scotopic ERGs recorded in monkeys that received the vehicle only (DMSO) as the baseline 
compared with the responses after injection of AM251 (middle column) and AM630 (right column). The amplitude of 
the ERG responses seems to increase. Horizontal calibration, 10 ms; vertical calibration, 100 µV. The left column is the 
control injected with DMSO. 
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The Effect of Blockade of Cannabinoid Receptors in Scotopic Conditions 
To verify if the observed tendencies in Figure 4 are meaningful, the amplitudes and 
latencies of a- and b-waves obtained in a scotopic condition with 13 intensity levels were 
calculated in different treatments using t-test for each stimulus intensity.  At low flash 
intensities, AM251 and AM630 decrease significantly the amplitude of the b-wave (Figure 5-
5, left column). Blockade of CB2R increases the amplitude of both a- and b-waves in high 
flash intensities (Figure 5-5, left column). At higher intensities, both treatments significantly 
reduce the amplitude of the a-wave. Both antagonists significantly delayed the time to peak 
for a- and b-wave in higher intensities (Figure 5-5, right column). 
	  
Figure 5- 5 The Effect of Blockade of Cannabinoid Receptors in Scotopic Conditions. Amplitude (left) and latency 
(right) of a-wave (upper) and b-wave (lower) are plotted as a function of flash intensities presented after dark 
adaptation in scotopic viewing conditions. Intensities at which the proportional differences are significantly different 
from DMSO are identified with a * (indicating p<0.05 on a two-directional, one-sample t-test); Grey stars indicate 
CB1R is different from DMSO, and black stars indicate CB2R is different from DMSO. Values above zero indicate 
larger amplitudes or latencies following injection (relative to baseline/control). Error bars represent SEM. 
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Discussion 
The purpose of this study was to explore the role of eCB receptor CB1 and CB2 in 
visual processing in the monkey retina. To do so, we compare photopic and scotopic ERG 
responses before and after blocking these receptors with specific antagonists. Here, for the 
first time, we demonstrate that, in photopic conditions, blockade of retinal CB1R decreases 
the amplitude of the a-and b-waves at low flash intensities; blocking CB2R increases the 
amplitude of a-and b-waves in response to high flash intensities. In scotopic conditions, 
blockade of CB1R or CB2R decreases the a-wave amplitude at higher flash intensities and 
decreases the b-wave at lower intensities. Some significant increases in latency were observed 
in both cases following blockade of these eCB receptors. The summary of the ERG responses 
can be found in Table 5-3. 
 
Table 5- 3 Summary of the ERG components after blockade of the CB1R and CB2R. 
 
  Photopic Scotopic 
  CB1R CB2R CB1R CB2R 
  Amplitude Latency Amplitude Latency Amplitude Latency Amplitud
e 
Latenc
y 
a-
wave 
Low 
intensity 
ê	   é	   NS	   NS	   NS	   NS	   NS	   NS	  
High 
Intensity 
NS NS	   é	   NS ê	   é	   ê	   é	  
b-
wave 
Low 
intensity 
ê	   NS	   NS	   NS	   ê	   NS	   ê	   NS	  
High 
Intensity 
NS	   é	   é	   é	   NS	   NS	   NS	   é	  
NS = non-significant, arrows p<0.05 
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Photopic Condition 
CB1R decreases the amplitude of both a- and b-wave at low flash intensities 
The amplitude of the a-wave in the photopic ERG originates from the activity of the 
photoreceptor layer mainly the cones (Hood and Birch, 1993, 1996). The activation of CB1R 
with WIN 55212-2 increases calcium current in rods and decreases it in large single cones. 
This agonist also suppresses the potassium current in both rods and cones (Straiker and 
Sullivan, 2003). Light-mediated hyperpolarization of the photoreceptors decreases the 
calcium current and reduces neurotransmitter release. The CB1R activation differentially 
modulates the calcium and potassium currents in rods and cones of the goldfish and 
salamander (Fan and Yazulla, 2003; Straiker and Sullivan, 2003; Fan and Yazulla, 2007). 
However, this effect was not observed in cnr1-/- mice, probably because the modulation of the 
ion currents was too weak to be detected by ERG (Cécyre et al., 2013).  CB1R is mainly 
concentrated in the cone pedicles but is also slightly expressed in rod spherules (Bouskila et 
al., 2012) that may change the balance of differential modulation of CB1R in rods and cones. 
One of the visual side effects of cannabis consumption is an increase in photosensitivity 
(Dawson et al., 1977; Yazulla, 2008). Reduction of the a-wave amplitude after blockade of 
CB1R at lower intensities supports the idea that CB1R plays a role in the retinal 
photoreceptor responses and photosensitivity. Since there is little CB1R in rods (Bouskila et 
al., 2012), the effect might also be due to the presynaptic modulation of CB1R in cone 
photoreceptors. Indeed, higher photosensitivity might be the result of a decrease in 
neurotransmitter release and inhibition of the calcium current following CB1R activation 
(Straiker and Sullivan, 2003).  
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CB2R increases the amplitude of both a- and b-wave in higher intensities  
The amplitude of the other main component of the ERG, the b-wave, is attributed to 
the interaction between the ON-bipolar cells and the Müller glial cells (Stockton and 
Slaughter, 1989; Wen and Oakley, 1990). In the vervet monkey, CB1R is expressed in the 
neuroretina cells and CB2R exclusively in the Müller cells leading to a complementary 
relationship between neurons and glia regarding eCB action (Bouskila et al., 2013a).  Our 
results revealed an increase in the photopic b-wave amplitude following blockade of CB2R. 
The light-induced potassium increase in outer and inner plexiform cells that are depolarized 
by light (Dick et al., 1985), changes the Müller cell membrane potential and generates 
electrical responses.  Müller cells, through siphoning of the excess potassium ions into the 
vitreous (Newman et al., 1984) controls the light-mediated potassium increase in retinal 
extracellular space (Newman and Reichenbach, 1996). The potassium channel responsible for 
the buffering of the Müller cells is reflected in the b-wave of the ERG (Miller and Dowling, 
1970) so that the blockade of these potassium channels results in the decrease of the ERG b-
wave (Wen and Oakley, 1990).  Bouskila et al., (2013) recently proposed a model whereby 
CB2R in Müller cells uses potassium channel, KIR4.1 to modulate the ERG. In summary, 
given that CB2R coupling via Gi/o decreases cAMP and PKA levels (Howlett et al., 2002) and 
that PKA increases the activity of KIR4.1 channels in the Müller cells, it is reasonable to 
propose that the blockade of the CB2R will therefore activate the potassium channels and 
increase the amplitude of the b-wave (Bouskila et al., 2013a). Our results support this model 
and explain the significant increase in the photopic amplitude of b-wave at high intensities. 
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Scotopic Condition 
CB1R or CB2R blockade decreases the a-wave at higher intensities and the b-wave at lower 
intensities 
In the dark-adapted retina, blockade of the CB1R significantly decreases the 
amplitude of the a-wave at high intensity values where the cones (mainly expressing CB1R) 
are responsive. A reduction in the amplitude of the b-wave was also observed following 
blockade of CB1R or CB2R at lower intensities where the rods are mostly responsive. The 
expression pattern of these receptors in the vervet retina may explain this reduction. The b-
wave originates from bipolar and Müller cells. CB1Rs are mainly expressed in bipolar cells 
and suggest that this decrease can be due to their blockade. The fact that CB2R is mainly 
found in Müller cells, the potassium-buffering role of Müller cells (explained before) can 
proposed the reason for this reduction. At intensities from -3.6 to -0.6, the b-wave response 
represents the activation of the rod photoreceptors. Here we show that the blockade of the 
cannabinoid receptors in lower flash intensities decreases the amplitude of the b-wave. Our 
result is in line with the claim that activation of the cannabinoid receptors may cause an 
increase in rod responses through bipolar cells and/or Müller cells (Straiker and Sullivan, 
2003) that can also explain the reports on the role of cannabis in improving the night vision 
(West, 1991, Merzouki and Mesa, 2002, Russo et al., 2004). 
 
Cannabinoid receptors blockade increases the time to peak of a- and b-waves 
In scotopic conditions, blockade of CB2R increases the latency of both a- and b- 
waves in higher intensity flashes. Blockade of CB1R only delays the a-wave amplitude with 
high intensity stimuli. However, in photopic conditions, high intensity stimuli only increase 
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the latency of the b- wave after blockade of either CB2R or CB1R. CB1R antagonist also 
increases the latency of a-wave in response to low intensity flashes. All other latencies do not 
show significant changes. The temporal component of the ERG waves is the implicit time that 
is the time required for each wave to get into their peak. The implicit time, similar to 
amplitude, is affected by light intensity, but there is little information in the literature on the 
meaning of this latency. It has been reported that the a-wave latency represents the optic 
nerve activity (Adrian and Matthews, 1927, Crampton and Boggs, 1959). Since CB1R was 
detected in the vervet monkey optic nerve (Javadi et al., 2013), the decrease in the a-wave 
latency can be due to the blockade of the CB1R modulators in the ganglion cells whose axons 
form the optic nerve. We also know that the time course of light adaptation after intense light 
exposure is significantly delayed by marijuana at low contrasts (Adams et al., 1978). The 
increase in the latency of the b-wave in the photopic condition, and both a- and b-wave in the 
scotopic condition suggests that cannabinoid receptors play a modulatory role in glare 
recovery. 
 
Diseases and functions 
Non-human primates and especially the vervet monkey have an ocular structure, 
retinal anatomy and ERG pattern very similar to humans (Bouskila et al., 2014) that make this 
species an ideal model for visual neuroscience research. The role of the eCB antagonists in 
the modification of the ERG waves may open new doors as a target for treatment of retinal 
intoxications (Hennekes, 1982; Duncker and Bredehorn, 1996) and diseases (Nilsson, 1971) 
where a general decrease in ERG amplitude is observed.  
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CHAPTER 6: The endocannabinoid system within the dorsal 
lateral geniculate nucleus of the vervet monkey 
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Abstract 
The endocannabinoid system mainly consists of cannabinoid receptors type 1 (CB1R) 
and type 2 (CB2R), their endogenous ligands termed endocannabinoids (eCBs), and the 
enzymes responsible for the synthesis and degradation of eCBs. These cannabinoid receptors 
have been well characterized in rodent and monkey retinae. Here, we investigated the 
expression and localization of the eCB system beyond the retina, namely the first thalamic 
relay, the dorsal lateral geniculate nucleus (dLGN), of vervet monkeys using 
immunohistochemistry methods. Our results show that CB1R is expressed throughout the 
dLGN with more prominent labeling in the magnocellular layers. The same pattern is observed 
for the degradation enzyme, fatty acid amide hydrolase (FAAH). However, the synthesizing 
enzyme N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) is expressed 
homogenously throughout the dLGN with no preference for any of the layers. These proteins 
are weakly expressed in the koniocellular layers. These results suggest that the presence of the 
eCB system throughout the layers of the dLGN may represent a novel site of neuromodulatory 
action in normal vision. The larger amount of CB1R in the dLGN magnocellular layers may 
explain some of the behavioral effects of cannabinoids associated with the integrity of the 
dorsal visual pathway that plays a role in visual-spatial localization and motion perception. 
 
Keywords: CB1R, FAAH, NAPE-PLD, dLGN, Monkey, Cannabinoid receptors. 
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Introduction 
The physiological and psychological effects of phytocannabinoids, the active 
components of the cannabis plant, can be detected almost everywhere in the body due to their 
actions on specific receptors: mainly the cannabinoid receptors type 1 (CB1R) and type 2 
(CB2R). Cannabinoid receptors are membrane receptors principally coupled to inhibitory G-
proteins that modulate the release of neurotransmitters (Piomelli 2003; Gómez-Ruiz et al, 
2007). They mediate biological functions not only via the exogenous cannabinoids, but also 
via endocannabinoids (eCBs) such as N-arachidonoylethanolamide (anandamide or AEA) and 
2-arachidonoylglycerol (2-AG). Unlike the classical neurotransmitters, eCBs are synthesized 
“on demand” by catalyzing the release of N-acylethanolamines (NAEs) from N-acyl-
phosphatidylethanolamine (NAPE) by specific enzyme, like N-acyl-phosphatidylethanolamine 
phospholipase D (NAPE-PLD) or from arachidonic acid via diacylglycerol lipase enzyme 
(DAGL). The eCBs are not accumulated into synaptic vesicles and are rather degraded rapidly 
by specific enzymes like fatty acid amid hydrolase (FAAH) and monoglycerol lipase (MAGL) 
(for review, see Deutsch and Chin 1993). 
 
The localization and function of the molecular components of the eCB system in the 
central nervous system have been the subject of recent research. In fact, the role of the eCB 
system in learning, memory, neuroprotection and visual processing is essentially due to the 
modulation of neurotransmitter release by the presynaptic location of CB1R (Di Marzo et al., 
1998; Straiker et al., 1999a). CB1R expression is found in the hippocampus, prefrontal cortex, 
cerebellum and basal ganglia of rodents (Herkenham et al., 1991) and primates (Eggan and 
Lewis 2007). It is expressed in glutamatergic and GABAergic neurons throughout the central 
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and peripheral nervous systems (Egertová and Elphick 2000). In the visual system, CB1R and 
FAAH have been localized in cone photoreceptors, horizontal, amacrine, bipolar, and retinal 
ganglion cells in the central and peripheral retina of vervet monkeys (Bouskila et al., 2012). 
CB1R is also found in the human retina (Straiker et al., 1999b). 
 
Earlier studies reported that cannabis could affect several visual functions, such as 
photosensitivity (Adams et al., 1978), visual acuity (Moskowitz et al., 1972; Adams and 
Brown 1975), color vision (Dawson et al., 1977), ocular tracking (Flom et al., 1976), binocular 
depth inversion, and stereoscopic vision (Emrich et al., 1991; Leweke et al., 1999; Semple et 
al., 2003). Some case studies later claimed other visual effects of cannabis such as visual 
distortions, altered perception of distance, illusions of movement in stationary and moving 
objects, color intensification of objects, dimensional distortion and blending of patterns and 
objects (Levi and Miller 1990; Lerner et al., 2011). Given the localization of CB1R in the 
central retina, from cones to ganglion cells, it is reasonable to assume its implication in these 
visual manifestations. 
 
In homogenates of rodent thalamus, high levels of AEA (Felder et al., 1996) and 
FAAH (Egertová et al., 2003), as well as an elevated cannabinoid receptor/G-protein 
amplification ratio (Breivogel et al., 1997) have been found. Also, using 
immunohistochemistry, moderate to low levels of CB1R expressions have been found both in 
thalamus of rats (Egertová et al., 1998; Tsou et al., 1998; Moldrich and Wenger 2000), non-
human primates (Ong and Mackie 1999) and humans (Glass et al., 1997) without focusing on 
dLGN. However, there is no study, to our knowledge, that has thoroughly studied the 
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expression of the eCB system in this retino-recipient primary thalamic relay of the primate. 
Similar to apes and humans, the dLGN of vervet monkeys consists of six layers. The first two 
ventral layers, the magnocellular layers, receive input from large ganglion cells (rod signals) 
and are necessary for the perception of movement, depth and small difference in brightness. 
The four dorsal layers, parvocellular layers, receive input from small ganglion cells of the 
retina (cone signals) and play a role in color and form perception. These layers are well 
separated by an inter-laminar zone called koniocellular layers that contribute to short-
wavelength "blue" cones (Xu et al., 2001). Given the expression and localization of CB1R in 
the retinal mosaic, we expect to find this receptor in the optic nerve and the dLGN layers. 
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Experimental procedures 
Animals.	  Monkey tissues were obtained from 4 adult vervet monkeys (Chlorocebus	  sabaeus). 
The monkeys were part of Dr Ptito’s and Dr Palmour’s research project that was approved by 
McGill University Animal Care and Use Committee. The animals were born and raised under 
an enriched natural environment in the laboratories of the Behavioral Sciences Foundation (St-
Kitts, West Indies), a facility recognized by the Canadian Council on Animal Care (CCAC). 
The experimental protocol was reviewed and approved by the local Animal Care and Use 
Committee (University of Montreal) and the Institutional Review Board of the Behavioral 
Science Foundation.	  
 
Tissue preparation. Each animal was sedated with ketamine hydrochloride (10  mg/kg, i.m.) 
and euthanized by an overdose of intravenously administered sodium pentobarbital 
(25  mg/kg), followed by transcardial perfusion of 0.1  M PBS (pH 7.4). The brains were then 
removed, blocked and flash-frozen in an isopentane bath cooled in a dry ice chamber and 
maintained at −80˚C. The blocks were cut along the coronal plane in 20 µm sections at −18˚C 
on a Leica CM3050S cryostat and mounted onto gelatinized subbed glass slides. The slide-
mounted tissue sections were stored at −80˚C until further histological processing. 
 
Immunohistochemistry (DAB). At least one slide-mounted 20 µm fresh-frozen tissue section 
per animal was selected from A6 to A9, at a level where the lamination of the dLGN is the 
clearest and thawed at room temperature. A hydrophobic barrier was created surrounding the 
slides, using PAP pen (Vector, Burlingame, CA, USA) to keep staining reagents localized on 
the tissue section. Sections were fixed with 70% ethanol solution for 15 minutes, followed by 
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two 5-min rinses with 0.1 M Tris buffer, pH 7.4/0.03% Triton X-100. To block the 
endogenous peroxidase activity, sections were washed with 0.3% hydrogen peroxide in PBS 
for 15 minutes. Following three times 5-min PBS-triton rinse, sections were blocked for 60 
minutes with a solution of 10% normal donkey serum (NDS) and 0.1 M Tris buffer/0.5% 
Triton. Each section was incubated overnight at room temperature with primary antibodies 
(Table 1) diluted in the blocking solution. The next day, sections underwent three 10-min 
PBS-triton washes, followed by incubation in a secondary antibody solution (biotinylated 
donkey anti-rabbit antibody diluted 1:200 in blocking solution) for 2 hours. After three 
consecutive 10-min washes with PBS-triton, the sections were incubated for 1 hour in an 
avidin-biotin-conjugated horseradish peroxidase (Vectastain ABC kit, Burlingame, CA, USA) 
solution (1:500). Following three subsequent 10-min washes in PBS-triton, the sections were 
treated with a 3,3-diaminobenzidine (DAB) substrate. After rinsing in PBS-triton three times 
for 5 minutes each, sections underwent dehydration in graded ethanol steps, cleared in xylene, 
and cover-slipped with Permount mounting media (Fisher Scientific; Pittsburgh, PA, USA). 
Sections were examined on a Leica DMRB under bright field illumination. 
 
Immunofluorescence. Double and triple labeling of the brain tissues were performed 
according to previously published methods on the vervet monkey retina (Bouskila et al., 2012; 
Bouskila et al., 2013a, b). Briefly, sections were post-fixed for 15 minutes in 70% ethanol, 
rinsed two times 5-min in 0.1 M Tris buffer, pH 7.4/0.03% Triton and blocked for 90 minutes 
in 10% NDS and 0.1 M Tris buffer/0.5% Triton. Sections were incubated overnight at room 
temperature with primary antibodies in blocking solution. The antibodies directed against 
molecular eCB components all raised in rabbit were used conjointly with a known cell marker: 
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glial fibrillary acidic protein (GFAP) (astrocytes marker), VGLUT1 (glutamatergic cell 
marker) and GABA (GABAergic cell marker) (Table 6-1). The next day, sections were 
washed for 10-min and two times 5-min in 0.1 M Tris /0.03% Triton and incubated with 
biotinylated donkey anti-rabbit diluted 1:200 in blocking solution for 2 hours for the eCB 
targets to amplify the signals. Sections were then incubated for another 2 hours with 
streptavidin 647 in order to amplify the signal and alexa 555 or 488 secondary antibodies 
when necessary. Sections were cover-slipped with Fluoromount-GTM Mounting Medium 
(SouthernBiotech, Birmingham, AL) after 3x 10 min washes with 0.1 M Tris buffer. In the 
case of the GABA antibody, the sections had to fixed in PFA 4% and gluteraldehyde 1%. The 
GABA signals were amplified with biotinylated donkey anti-mouse and the cannabinoid 
signals with donkey anti rabbit HRP and alexa fluor tyramide (Invitrogen, Eugene, Oregon). 
 
Antibody characterization. The source and working dilution of all primary antibodies used 
in this study are summarized in Table 6-1. The antibodies with the exception of NAPE-PLD 
were successfully used in previous studies and were well characterized in the vervet monkey 
(Bouskila et al., 2012).  
 
CB1R. The rabbit anti-CB1R (Calbiochem, Gibbstown, NJ, USA) was developed using a 
highly purified fusion protein with the first 77 amino acid residues of rat CB1R. According to 
the manufacturer's data sheet, it recognizes a major band of 60 kDa with also less intense 
bands of 23, 72, and 180 kDa. This antibody was shown to be specific using CB1R knockout 
mouse retinal tissue (Zabouri et al., 2011). It recognizes the CB1R (60 kDa) from many 
species, including the vervet monkey tissues (Bouskila et al., 2012). 
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GFAP. The mouse anti-glial fibrillary acidic protein (GFAP, Clone G-A-5, Sigma-Aldrich, St. 
Louis, MO, USA) was produced using purified GFAP isolated from the pig spinal cord. This 
antibody recognizes the GFAP protein of 50 kDa in Western blots (manufacturer’s data sheet). 
GFAP stains cells with the morphology and distribution expected for astrocytes in monkey 
dLGN (Takahata et al., 2010). 
 
FAAH. The rabbit anti-fatty acid amide hydrolase (FAAH, Cayman Chemical, Ann Arbor, 
MI, USA) was developed using a synthetic peptide from rat FAAH amino acids 561-579 
(CLRFMREVEQLMTPQKQPS) conjugated to KLH. As expected, it recognizes a dense band 
at about 66 kDa and a very light one below 37 kDa. The specificity of this antibody has been 
demonstrated in rat (Suárez et al., 2008; Zabouri et al., 2011) and vervet monkey (Bouskila et 
al., 2012) tissues. 
 
NAPE-PLD. The rabbit anti-N-acyl phosphatidylethanolamine-specific phospholipase D 
(NAPE-PLD, Cayman Chemical, Ann Arbor, MI, USA) was developed using a synthetic 
peptide from human NAPE-PLD amino acids 159-172 (YMGPKRFRRSPCTI). Its cross 
reactivity has been tested in many species, and it recognizes an intense band at 46 kD on 
Western blot of the human cerebellum (manufacturer's data sheet). 
 
NAPE-PLD blocking peptide. The NAPE-PLD blocking peptide containing the human 
NAPE-PLD amino acid sequence 159-172 (YMGPKRFRRSPCTI; Cayman Chemical, Ann 
Arbor, MI, USA) was used in the present study for Western blot analysis. The specificity of 
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the NAPE-PLD antibody was tested by pre-incubation with the corresponding blocking 
peptide. For pre-adsorption, the primary antibody was diluted in PBS and incubated with a 
ratio 1:5 for 2 hours at room temperature, with occasional inversion. Thereafter, the antibody-
blocking peptide solution was added to the blot and subsequent Western blotting followed the 
protocol as described further. 
 
VGLUT1. The mouse anti-vesicular glutamate transporter 1 (VGLUT1, Synaptic System, 
Goettingen 
Germany) was raised against the aa 456-560 of the rat VGLUT1 protein. It is used as a 
glutamatergic neuron marker and its specificity has been verified in vglut1 KO mouse tissue 
(Wojcik et al., 2004) as well as using the corresponding blocking peptide (Zhou et al., 2007).  
 
GABA. The mouse anti-gamma aminobutyric acid antibody (GABA, Millipore, MA, USA) 
was synthesized coupling to BSA with gluteraldehyde. It is used as a marker of GABAergic 
neurons. Thus, for the GABA antibody, sections were fixed for 20 min in 1% gluteraldehyde, 
4% PFA in PBS. The antibody has been frequently used in different animals, and its 
specificity has been verified in monkey (Jongen-Relo et al., 1999). 
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Table 6-1 Primary antibodies used in this study 
 
 
Microscopy. To detect the fluorescence signals, a Leica TCS SP2 confocal laser-scanning 
microscope (Leica Microsystems, Exton, PA) with 40x (n.a. 1.25–0.75) and 100x (n.a. 1.40–
0.7) objectives was used. Subsequently, images were acquired from the green and far-red 
channels on optical slices of less than 0.9 µm. Adobe Photoshop (CS5; Adobe Systems, San 
Jose, CA) was used for all photomicrographic adjustments on size, color and shape before 
exporting them to Adobe InDesign (CS5; Adobe Systems), where the final figure layout was 
completed. For DAB staining, all photomicrographs were captured with a Leica DMR 
photomicroscope equipped with a Retiga 1300 video camera system (Q Imaging) using the 
QCapture software with a Leica 2.5x (0.07) objective. 
 
Quantification. In order to enhance the visualization of CB1R spatial distribution throughout 
the dLGN layers, photomicrographs demonstrating the entire structure were generated in an 8-
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bit gray scale. Using a MatLab code, the minimum and maximum thresholds of the gray 
values in the image were measured. The gray spectrum values were then eventually distributed 
within the RGB spectral subdivision in which the maximum threshold gray values were 
presented in red and the minimum in blue. Moreover, the average contrast intensity of each 
layers were calculated using the FIJI program (v. 1.48t, Wayn Rasband, NIH, USA). The 
program was calibrated using a calibration grid slide. The RGB images inverted to 8-bit with a 
linearly gray scaling from a minimum to a maximum pixel intensity (arbitrary value 0-255). 
The mean intensity of 4 sections (per condition) in their whole magno-, parvo- and 
koniocellular layers (±SEM) was reported after subtracting the average background intensity. 
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Results 
Spatial expression of the endocannabinoid system in dLGN 
To examine the laminar expression of the endocannabinoid system profile in dLGN, 
tissues were labeled with specific antibodies against CB1R, FAAH, and NAPE-PLD. Their 
expression pattern in the brain was quantified using heatmap analysis. Immunolabeled sections 
for CB1R were found throughout the magnocellular and parvocellular layers of the dLGN 
with a higher intensity in the magnocellular layers (Figure 6-1 a, d, g). The koniocellular 
layers had the lowest expression of CB1R (Figure 6-1 a, d, g). Similar patterns of expression 
were observed for FAAH (Figure 6-1 b, e, g). NAPE-PLD was expressed homogenously with 
no preferences for the magnocellular or parvocellular layers. The koniocellular layers still 
showed very low expression of the synthesizing enzyme (Figure 6-1 c, f, g). A consistent 
staining pattern across all 4 monkeys dLGN was found. Interestingly, all these three proteins 
were also highly expressed in the optic nerve (data not shown). 
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Figure 6-1 Spatial distribution of CB1R, FAAH, and NAPE-PLD throughout the dLGN (a-c) of vervet monkeys. The 
RGB heat map was used to enhance the display of the abundance of the CB1R (d), FAAH (e) and NAPE-PLD (f) in the 
dLGN. The gray spectrum was distributed within the RGB spectral subdivision in which the maximum threshold gray 
values were expressed as red and the minimum as blue. CB1R is more expressed within the first two layers of dLGN. 
FAAH expression pattern is similar to CB1R. The NAPE-PLD expression is similarly distributed throughout the 
magno and parvo cellular layers. Scale bars = 500 µm. (g) Quantification of the mean contrast intensity of CB1R, 
FAAH and NAPE-PLD-IR in magno-, parvo- and koniocellular layer. The bars indicate the standard error. 
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CB1R, FAAH and NAPE-PLD are not present in LGN astrocytes 
The double immunostaining was carried out with molecular markers to examine the 
eCB system expression at the cellular level. Cytosolic spread expression of CB1R is not co-
localized with GFAP positive glial cells (Figure 6-2 a-f). There is an apparent higher 
expression of CB1R in the magnocellular layers (Figure 6-2 a-c) compare to the parvocellular 
layers (Figure 6-2 d-f). The very weak expression of this receptor in the koniocellular layers is 
also evident (Figure 6-1 g-h). Similarly, FAAH-IR is not detected in astrocytes of 
magnocellular layer (Figure 6-2 j-l). 
 
In contrast to the difference in the pattern of expression of NAPE-PLD, the cellular 
expression of this synthesizing enzyme is similar to that of CB1R and FAAH. NAPE-PLD is 
also absent in astrocytes; however, it is abundant in the cytosol of both magnocellular (Figure 
6-2 m-o) and parvocellular (data not shown) dLGN neurons. 
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Figure 6-2 Triple-label immunofluorescence of the CB1R (magenta) and GFAP (green) expression with nucleic acid 
stain Sytox (blue), respectively in magnocellular (a-c), parvocellular (d-f) and koniocellular layers (g-i). The absence of 
GFAP with FAAH (j-l) and NAPE-PLD (m-o) co-localizations in the magnocellular layers of the monkey dLGN are 
shown. Each immunostaining is presented alone in gray scale in the first two columns (1st column: GFAP and 2nd 
column: CB) following their merged image in the third column. Arrows point at GFAP cell bodies with no expression 
of CB. Scale bars = 75 µm. 
 
CB1R, FAAH and NAPE-PLD are expressed in glutamatergic and GABAergic neurons 
As previously reported in rat brain, CB1R is expressed in both GABAergic and 
glutamatergic cells (Egertová and Elphick 2000). Our results validate the expression of CB1R 
within the GABAergic (Figure 6-3 a-c) and glutamatergic cells in the magnocellular layers 
(Figure 6-3 d-f). Furthermore, we report the same pattern of expression for FAAH and NAPE-
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PLD in both GABAergic (Figure 6-3 g-i and m-o) and glutamatergic neurons (Figure 6-3 j-l 
and p-r) without any preferences for any of them. 
 
 
 
 
Figure 6-3 Immunofluorescence labeling illustrating the co-localization of CB1R (a-f), FAAH (g-l) and NAPE-PLD (m-
r) with GABAergic (three left columns) and glutamatergic (three right columns) neurons in the magnocellular layer 1 
of the dLGN. Each immunostaining is presented alone in gray scale in the first two columns following their merged 
image in the third column. Arrows point to the co-localization of eCB components with GABA and VGLUT1. Scale 
bar = 75 µm. 
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Discussion 
To our knowledge, this is the first study reporting the spatial distribution of CB1R and 
the enzymes regulating the levels of its ligands, namely FAAH and NAPE-PLD in the dLGN 
of primates. Given that CB1R, FAAH and NAPE-PLD are expressed in an overlapping pattern 
in the dLGN (Figure 6-1), it might play a role in the auto-feedback control of neurotransmitter 
release, as proposed for the retina of the same species (Bouskila et al., 2012). This means that 
the same neurons that produce endocannabinoids may also respond to its ligands in order to 
control the release of neurotransmitters. 
 
CB1R: from the retina to the dLGN 
There are studies that assessed CB1R expression in the whole brain and reported its 
expression in the thalamus. The dorsal thalamus was found to slightly express CB1Rs in rats 
(Tsou et al., 1998), not at all (Eggan and Lewis 2007) or moderately (Ong and Mackie 1999) 
in primates and humans (Glass et al., 1997), without any focus on the dLGN. To date, we have 
found only one study looking specifically at the rodent dLGN and reporting CB1R expression 
(Argaw et al., 2011). These results are however difficult to generalize to the monkey and 
human dLGN given the major anatomical differences in its organization as well as its cortical 
projections. Moreover, while the vast majority of retinal inputs projects to the dLGN in 
primates, only a limited number of retinal ganglion cells axons converge to the basic dLGN of 
rodents (Dacey et al., 2003; Huberman and Niell 2011). 
 
Retinal ganglion cells receive their input from rods and cones and transfer the visual 
information via parasol and midget cells to the magnocellular layers and the parvocellular 
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layers of dLGN, respectively. Magnocellular and parvocellular layers target layer 4 of area V1 
(4Cα and 4Cβ respectively). Both the M and P pathways also project to layer 6 of the primary 
visual cortex and receive a robust corticogeniculate feedback from the same layer that is 
mainly excitatory and glutamatergic (McCormick and von Krosigk 1992; Fitzpatrick et al., 
1994). The LGN is not just a passive relay; about 90% of its inputs are coming from sites 
other than retina, and about 30% of them are feedback inputs from V1 (Van Horn et al., 2000). 
Recent studies revealed that a close relationship in feedforward and feedback parallel streams 
instigates the functional influence of the LGN in visual processing. The magnocellular 
pathway is more sensitive to low spatial frequencies, low luminance contrasts, and responsible 
for the perception of motion and luminance, but it is chromatically non-opponent. On the other 
hand, parvocellular neurons (8 times more numerous than magno cells) convey chromatic and 
form information and are less sensitive to luminance contrasts (Briggs and Usrey 2011). 
Additionally, the middle temporal visual area (MT) and medial superior temporal area (MST), 
motion detection centers, mainly receive the magnocellular layers primary inputs (Maunsell et 
al., 1990; Merigan et al., 1991). In human and non-human primates, low to moderate density 
of CB1R has been reported in several cortical areas like the primary visual cortex (V1), 
specially layer 5 and 6, in higher-order visual areas (V2, V3, V4) with more density in MT and 
MST (Eggan and Lewis 2007). In V1, layers 5 and 6 contained the highest expression of 
CB1R (Eggan and Lewis 2007). Interestingly, the higher density of CB1R in magnocellular 
layers of LGN in our study concurs with well-defined thalamo-recipient cortical areas. Thus, 
expression of eCB components in the visual cortex of rodent and primate brains (Eggan and 
Lewis 2007; Jiang et al., 2010) indicates that the whole visual pathway, from retina to cortex, 
can be influenced by cannabinoids. 
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CB1R and FAAH are highly co-expressed throughout the retinal layers of the same 
species (Bouskila et al., 2012). Here, we show that both CB1R and FAAH are present in the 
dLGN mainly in the magnocellular layers. Previous studies showed a similar overlapping 
distribution of FAAH and CB1R in pyramidal cells of the mouse hippocampus, amygdala and 
entorhinal cortex (Marsicano and Lutz 1999) and the rat cortex (Hill et al., 2007). 
 
NAPE-PLD: a dissimilar pattern of expression 
NAPE-PLD is widely expressed in the mouse thalamus (Egertová et al., 2008). 
Furthermore, the presence of NAPE-PLD in the rat brain has been reported, with an increased 
expression in the thalamus (Morishita et al., 2005). Unlike CB1R and FAAH, the synthesizing 
enzyme, NAPE-PLD, is expressed homogenously throughout the magnocellular and 
parvocellular layers of the dLGN without any laminar preference (Figure 6-1c, f, g). Besides 
synthesizing the endocannabinoid anandamide, NAPE-PLD also generates NAEs that are 
major substrates for mediating various motivational functions (Viveros et al., 2008). 
Interestingly, the degrading enzyme FAAH can metabolize NAEs into cellular membrane 
components (Cravatt et al., 1996; Cravatt et al., 2001). Even though both FAAH and NAPE-
PLD are expressed in rodent thalamic nuclei neuronal cells, FAAH is only present in neuronal 
somata (Egertová et al., 2003). Given that these proteins are targeted to the axons, axon 
terminals and cytosol of neurons suggest a putative role of the eCB system as a mediator of 
anterograde signaling at thalamic synapses. Our results show that FAAH and NAPE-PLD are 
also co-expressed in the monkey dLGN (Figure 6-1b, c). They support previously reported 
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results that NAE could serve as an autocrine synaptic signaling molecules regulating the 
release of neurotransmitters (Egertová et al., 2008). 
 
CB1R, FAAH and NAPE-PLD are not present in LGN astrocytes 
The presence of CB1R in astrocytes is controversial. While some studies have failed to 
show any expression of CB1R in astrocytes (reviewed in Stella 2004), others have detected it 
in the caudate, putamen (Rodriguez et al., 2001) and hippocampal astrocytes (Navarrete and 
Araque 2008). In the hippocampus, astrocyte activation of CB1R leads to phospholipase C-
dependent Ca2+ mobilization from the store and mediation of the eCBs communication with 
the neurons. This intermediation might play a role in the physiology of CB addiction 
(Navarrete and Araque 2008). Our results show no co-expression between CB1R, FAAH and 
NAPE-PLD with GFAP in the LGN. 
 
Functional significance 
The geniculo-cortical distribution of CB1R (Figure 6-1) sheds light into the putative 
functions of the eCB system in vision. Indeed, cannabis at the retinal level could affect the 
upstream visual pathways namely the ventral and dorsal visual streams. The higher expression 
of CB1R and FAAH in the magnocellular layers could have a functional value for the dorsal 
visual system involved in motion processing and object location (“how/where” pathway) 
(Goodale and Milner 1992; Kupers and Ptito 2014). The abundance of the CB1R in the 
magnocellular layers of dLGN, areas MT and MST supports a role of eCB system in motion 
perception. In agreement with our findings, case studies on high-potency heavy cannabis 
smokers reported visual disturbances and impairment in motion perception (Levi and Miller 
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1990). Likewise, cannabis causes impaired performance in tests that require fine psychomotor 
control such as tracking a moving point of light on a screen (Adams et al., 1975; Adams et al., 
1978). Magnocellular neurons are also more sensitive to low luminance contrasts (Tootell et 
al., 1988) and relatively unresponsive to chromatic contrasts (Croner and Kaplan 1995). 
Higher expression of CB1R in the magnocellular pathway prompts a role of the 
endocannabinoid system in the night vision. In agreement with this speculation, numerous 
reports claim that smoking marijuana improves dim light vision and photosensitivity (Dawson 
et al., 1977; Merzouki and Mesa 2002; Russo et al., 2004). Besides, the neurons in the 
magnocellular pathway are also sensitive to flickering stimuli (Lee et al., 1989) and lesions to 
the magnocellular layers of the dLGN can cause deficits in critical flicker fusion (Merigan and 
Maunsell 1990) and flicker detection (Schiller et al., 1990). 
 
Even though the expression of the CB1R and FAAH is more abundant in 
magnocellular layers, they are nonetheless present in the parvocellular layers of the dLGN. If 
the eCB system plays any role in color perception, it should be through chromatic properties 
of parvo cells and retinal cones. Both of these components of the visual system express CB1R. 
Conjointly, one of the most frequently reported effects of cannabis is more intense and 
brighter colours (Green et al., 2003; Lerner et al., 2011). Although the eCB system is 
considered as a good candidate for modulation of the dynamics of the cortical networks 
(Robbe et al., 2006), there are few electrophysiological studies on the role of cannabinoids in 
the visual system. Recently, in primary and secondary visual cortices, it has been reported that 
the CB1R and CB2R full agonist, CP55940, decreases electroencephalogram and local field 
potential power in V1 and V2 in macaque monkeys. Moreover, it delayed the individual 
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neuronal response by almost 10 ms, although they referred to the low level of CB1R in the 
thalamus (Ong and Mackie, 1999) and linked this activity at the retinal level (Ohiorhenuan et 
al., 2014). To the best of our knowledge, there is only one study that has characterized the 
physiological effects of CB1R-mediated activity in the rat visual thalamus (Dasilva et al., 
2012). Using single-unit extracellular recordings, the authors showed that, at the level of 
thalamus, CB1R activation revealed two cellular populations, one exhibiting excitatory effects 
(28%) and the other inhibitory ones (72%). These actions were blocked using AM251, a 
specific inverse agonist of CB1R. This suggests that CB1R in the rat thalamus acts as a 
dynamic modulator of visual information funneled to the cortex. The modulatory role of 
CB1R in the thalamus of monkeys and especially the dLGN could have a higher impact on 
visual processing due to its complex laminar structure and increased retinal inputs. Our results 
are in accordance with these electrophysiological findings and revealed that this 
neuromodulation of CB1R receptors may be due to their expression in the dLGN. 
 
The expression pattern of these eCB components has been also well characterized in 
the primate retinal cells (Bouskila et al., 2012; Bouskila et al., 2013a, b) that project to the 
dLGN through the optic nerve. The importance of CB1R has been highlighted in a recent 
electroretinographic study (ERG) that showed the implication of this cannabinoid receptor in 
the generation of the ERG responses (Ptito et al., 2014). Indeed, blocking CB1R induces an 
increase in the b-wave component of the ERG. This increase is possibly reflecting the gating 
of calcium (Ca2+) and potassium (K+) ionic channels (Bouskila et al., 2013a). The change in 
neuronal membrane permeability to Ca2+ ions and activity of adenylyl cyclase may affect 
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neurotransmitter release and action (Di Marzo et al., 1998) not only at the retinal level, but 
also probably at the dLGN level. 
 
The data presented here provide the first insight into the neuroanatomy of CB1R, 
FAAH, and NAPE-PLD expression in the primate dLGN and a new perspective of the neural 
function of this system. In other words, the presence of the endocannabinoid system in the 
dLGN and especially in the magnocellular pathway suggests a putative neuromodulatory 
action that affects the functions of the dorsal visual pathway involved in motion perception, 
object localization and action-oriented behaviors that depend on the perception of space. 
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The importance of cannabinoid research has become more apparent with time. 
Cannabinoid researchers have diverged from studying the adverse events of recreational 
cannabis in the sixties to investigating the utility of the endogenous system as a therapeutic 
target. It has since become clear that the complex eCB system is present throughout the animal 
kingdom and in almost every organ and cell type. It worth mentioning that there are several 
research projects that focus mainly on the roles of endocannabinoid system in attention, 
memory, appetite, stress response, inflammation, immune functions, analgesia, sleep and etc., 
and reveal many interesting aspects of this polyhedron system.  The work presented in this 
thesis seeks to elaborate on the relationship between the eCB system and vision. Thus, we 
report here for the first time that: 
1. CB2R is present in the retinal layers of the vervet monkey but with striking 
dissimilar laminar pattern of expression. We show that CB2R is restricted to Müller cell 
processes with very low staining in the internal limiting membrane and heavy labeling in the 
external limiting membrane. We conclude that CB2R is indeed present in the retina but 
exclusively in the retinal glia, whereas CB1R is expressed only in the neuroretina (Bouskila et 
al., 2013a). 
2. The expression of the eCB system components in the tree shrew retina and the 
distribution of NAPE-PLD, MAGL and DAGLα in the monkey retina (vervet and macaque) 
were compared. We also verified the expression pattern of eCB system and found that CB1R 
and FAAH distributions are well preserved among mouse, tree shrews, and vervet and 
macaque monkeys. By contrast to mice and tree shrews, NAPE-PLD expression in monkeys is 
circumscribed to the photoreceptor layer. CB2R expression is variable across these species; in 
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mice, CB2R is found in retinal neurons, in tree shrews, it is expressed in Müller cell processes 
of the outer retina and in retinal neurons of the inner retina, and in monkeys, CB2R is 
restricted to Müller cells that span the entire retinal thickness. Expression patterns of MAGL 
and DAGLα are complementary in the inner retinal layers. Overall, these results provide 
evidence that the eCB system is differentially expressed in the retina of these mammals and 
suggest a distinctive role of eCBs in visual processing (Javadi et al., Submitted to Frontiers in 
Neuroanatomy). 
3. The development of a standardized protocol for photopic and scotopic ERG in 
vervet monkeys to assess the retinal function of the CB1R and CB2R. When testing the 
protocol, we found that the recordings obtained in healthy Green Monkeys matched very well 
with those in humans (Marmor et al., 2009) and other non-human primate species (Macaca 
mulatta and Macaca fascicularis, reported by (Bee, 2001). Furthermore, the results from the 
standardized protocol validate the Green Monkey as an excellent non-human primate model, 
with the potential to serve for testing retinal function after manipulations such as visual 
deprivation or drug evaluation (Bouskila et al., 2014). 
 
4. Blockade of CB2R increases the amplitude of the photopic ERG a-wave and b-wave 
at certain higher flash intensities, while at some lower flash intensities, blockade of CB1R 
reduces the amplitude of both a- and b-waves. In dark-adapted eyes, blockade of the CB1R 
and CB2R reduces the a-wave amplitudes in the higher intensities and decrease the b-wave in 
lower intensities. Also the cannabinoid receptors antagonists AM251 and AM630 delayed the 
time to peak in both a- and b-waves.  
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5. The expression pattern of the CB1R, FAAH, and NAPE-PLD in the dLGN of the 
vervet monkey beyond the retina. Our results show that CB1R and FAAH are expressed 
throughout the dLGN with more prominent labeling in the magnocellular layers. However, the 
synthesizing enzyme NAPE-PLD is diffused homogenously throughout the magnocellular and 
parvocellular layers of dLGN. These proteins are weakly expressed in the koniocellular layers. 
The higher expression of CB1R in the magnocellular layer suggests some of the behavioral 
effects of cannabinoids associated with the integrity of the dorsal visual pathway that plays a 
role in visual-spatial localization and motion perception (Javadi et al., In press, Neuroscience). 
 
The activation of the CBRs via exogenous agonists such as THC seldom produces 
mutual and critical visual symptoms other than IOP reduction and vasodilation; however, the 
abundance of these receptors throughout the visual system, from retina to visual cortex, 
suggests that eCBs play a role in normal visual function. Otherwise, spending this quantity of 
protein and consuming energy to produce such copious receptors without any crucial role, will 
not be economic for the cell. In case studies and anecdotal reports, chronic marijuana users 
reported various visual symptoms including visual distortions, distorted perception of distance, 
illusions of movement, color intensification, dimmed color, dimensional distortion, blending 
of patterns and objects (Levi and Miller, 1990; Lerner et al., 2011;), impaired performance in 
tracking a moving point of light (Adams et al., 1975; Adams et al., 1978), increased glare 
recovery time, blurred vision (Noyes et al., 1975), double vision and vision dimness (Consroe 
et al., 1997), improved dim light vision (Dawson et al., 1977; Merzouki and Mesa, 2002; 
Russo et al., 2004), reduced Vernier and Snellen acuity, altered color discrimination, increased 
photosensitivity, decreased dark adaptation (Kiplinger et al., 1971; Dawson et al., 1977; Russo 
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et al., 2004), reduction in acuity of moving targets when coordinated eye movements were 
required (Leweke et al., 1999), and reduction of binocular depth inversion (Semple et al., 
2003). 
 
Most of our knowledge about the eCB system and mammalian vision is based on the 
research that has been performed in rodents (Yazulla, 2008; Casanova et al., 2010; Cécyre et 
al., 2011; Zabouri et al., 2011a; Zabouri et al., 2011b; Dasilva et al., 2012; Cécyre et al., 2013; 
Cécyre et al., 2014). Mice exhibit very low resolution of about 20/2000 (Prusky and Douglas, 
2004) with eyes and visual pathways of about one to two magnitudes of order smaller than 
primates.  Thus, it is difficult to compare the refraction, chromatic aberration, and retinal 
illumination of rodents to that of primates (Remtulla and Hallett, 1985). By contrast, the 
vervet monkey possesses large eyes with high visual acuity and foveal vision. Similar to 
humans, the vervet visual pathway displays well-segregated parallel pathways in the visual 
thalamus, six layers dLGN, ocular dominance, and orientation columns in the visual cortex. In 
addition, vervets and macaques have RGB trichromatic vision (Jacobs, 2008), making them a 
great animal model for visual research that can be easily translated to humans.  
 
Here, with anatomical and electrophysiological approaches, we tried to speculate on 
certain roles of the eCB systems in the primate vision.    
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Expression of CB2R in Müller Cells of the Monkey Retina   	  
First, we assessed the localization of two cannabinoid receptors (CB1R, CB2R), two 
eCB synthesizing enzymes (NAPE-PLD and DAGLα), and two eCB degrading enzymes 
(FAAH and MAGL) in the retina and compared expression in three phylogenetically related 
mammals; mice, tree shrews, and monkeys.  
 The primary CBR, CB1R, is expressed throughout the retinal layers in all of our 
animal models, with the exception of the rods and Müller cells in monkey.  We show here that 
in the retina of the vervet monkey, CB2R is specifically present in the Müller cells. This 
agrees with its glial expression in the CNS and suggests a specific role for each of these 
receptors. Among the three glial cells of the primate retina (Müller cells, astrocytes, and 
microglia), Müller cells are the main glial cells with processes that extend from the outer 
limiting membrane to the inner limiting membrane throughout the retina. The similar 
expression pattern of CB2R, with higher polarization towards the outer retina and 
colocalization with GS, supports our finding that CB2R is exclusively expressed in Müller 
cells. It has been reported that activation of CB2R triggers a series of protective activities 
(Pacher and Mechoulam, 2011) such as augmentation of microglial cell proliferation (Carrier 
et al., 2004) and reduction of the release of harmful factors such as tumor necrosis factor and 
free radicals (Stella, 2009). In human, exposing activated Müller cells to eCBs reduces the 
production of pro-inflammatory cytokines (Krishnan and Chatterjee, 2012). CB2R activation 
in Müller cells may protect neurons from exposure to excess neurotransmitters (Placzek et al., 
2008), which can play important roles in mediating neurotoxicity, inflammation, and 
neuroprotection. CB2R expressed in distal Müller cell fibers adjacent to photoreceptor layers 
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that express CB1R may also mediate light transduction. The junction between the Müller cells 
and photoreceptors, at outer limiting membrane, represents the outer border of CB2R 
expression. The neuronal expression of CB1R and glial presence of CB2R suggests a 
complementary relationship between these two receptors in the monkey’s retina. We speculate 
that the eCBRs are important for light transduction where CB1R plays a role in neurons and 
CB2R in glia. Based on these anatomical data, we proposed the following model for eCB 
function in the retina: light increases the K+ concentration in the extracellular space of the 
retina. Müller cells release the excess amount of the K+ ions into vitreous to maintain the 
electrolytic balance (Newman and Reichenbach, 1996). The b-wave of the ERG is attributed 
to ON-bipolar and Müller cell interactions and reflects the K+ level of the Müller cells in such 
a way that blocking the K+ channels reduces the ERG b-wave. Based on the role of CB2R 
activation in the reduction of cAMP and PKA, which indirectly increases the activity of Kir4.1 
channels in Müller cells (MacGregor et al., 1998), we proposed that the deactivation of CB2R, 
as a negative modulator of K+ channel, increases the amplitude of the b-wave. The functional 
data we report here supports this model. 
 
 
Comparison of the Retinal Expression Pattern of the eCB Components 
 
CB1R and CB2R are unique to chordates but the enzymes involved in the synthesis 
and degradation of eCBs have been discovered throughout the vertebrate and many species in 
the whole animal kingdom (Elphick, 2012). Thus, it is likely that proteins have evolved as pre- 
or postsynaptic receptors for eCBs. Although the expression pattern of some components such 
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as CB1R and FAAH seem to be similar in different species, such is not the case for other eCB 
components such as CB2R and NAPE-PLD. Considering the differential expression of CB2R 
in the retina of mice (Cecyre et al., 2013) and vervets (Bouskila et al., 2012), we compared the 
expression of other components of the eCB system in these two species as well as in a 
phylogenetically intermediary animal, the tree shrew. Moreover, we verified the similarity in 
the retinal expression of eCBs in vervets and macaques to demonstrate the utility of these 
animal models for eCB research in the visual system. The overlapping distribution of CB1R 
and FAAH suggested that the degrading enzyme might remotely influence CB1R (Egertová et 
al., 2003). In the monocular, rod dominant visual system of the mouse, CB2R is expressed in 
the photoreceptor layer, mainly in cones and some rods (Cecyre et al., 2013). The tree shrew, 
with cone-dominant binocular vision, is an appropriate phylogenetic midpoint, exhibiting 
expression in all layers (similar to rodents) as well as in Müller cells (as seen in primates). 
This interspecies pattern is repeated in other eCB components such as NAPE-PLD. Both 
anandamide and NAEs are biosynthesized from the phospholipids of the cell membrane with 
NAPE-PLD hydrolysis. Despite the well-preserved sequence of NAPE-PLD among rodents 
and humans, it exhibits different retinal expression between species. Unlike the mouse but 
similar to primates, the tree shrew has a higher expression of NAPE-PLD in the photoreceptor 
layer.  This variation may be due to non-eCB related functions of NAPE-PLD; these include 
diverse physiological roles such as anti-inflammatory effects (Lambert et al., 2002), anorexic 
effects (Rodriguez de Fonseca et al., 2001), and pro-apoptotic effects (Maccarrone et al., 
2002). Moreover, NAE products in axons suggest a role in the regulation of postsynaptic 
neuron activity as anterograde synaptic signaling molecules (Egertová et al., 2008). This 
pattern of expression also indicates another direct role of NAEs in primate photo-transduction. 
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For the first time, we report the expression pattern of DAGLα and MAGL in the retina 
of the monkey and the tree shrew. Logically, eCB ligands should synthesize and degrade in 
the vicinity of their receptors; thus DAGLα and MAGL should be expressed near CB2R. 
Their expression pattern in mouse retina follows this logic as they are in the vicinity of both 
CB1R and CB2R, meaning that the CBs such as 2-AG are faithfully expressed adjacent to 
cannabinoid receptors and could be involved in their retinal function. Through evolution, tree 
shrews and primates have chosen a complementary distribution pattern. It seems that the eCB 
system has become more highly specialized in species with complex visual systems to adopt a 
more specific strategy for modulation of their visual activity.  
 
Standard protocol for vervet monkeys 
To assess our hypothesis and verify the role of eCB in normal retinal function we utilized the 
full field ERG as a non-invasive method. The ERG measures the electrical responses of 
various retinal cells such as photoreceptors (rods and cones) and inner retinal cells (bipolar 
and amacrine cells) in response to diverse stimuli. The ERG represents a useful tool in 
toxicology and eye research. The progressive use of vervets as a model in visual research led 
us to publish our methodology as a standard protocol. Our standard values for vervets were 
very similar to humans by standard ERG. ISCEV standards provide a consensus for stable 
comparison between research laboratories and clinical ERG recordings (Marmor et al., 2009). 
The shape and latency of the primate waves were similar to human; however, their waves 
tended to show lower amplitude. This decrease in amplitude is due to the smaller diameter of 
the eye and retinal surface of the monkey. 
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Blockade of the CB1R, reduces photopic a-waves amplitude; role in 
photosensitivity 
The photopic a-wave amplitude originates from the activity of the cone photoreceptors 
(Hood and Birch, 1993, 1996).  CB1R agonists raise calcium current in rods and decrease it in 
large single cones. These agonists can also reduce the potassium current in both rods and 
cones (Straiker and Sullivan, 2003). Light-mediated hyperpolarization of the photoreceptors 
decreases the calcium current and reduces neurotransmitter release. The CB1R activation 
differentially modulates the calcium and potassium currents in rods and cones of the goldfish 
and salamander (Fan and Yazulla, 2003; Straiker and Sullivan, 2003; Fan and Yazulla, 2007). 
We show that the blockade of the CB1R reduce the photoreceptor responses in lower 
intensities. This result can be an explanation for the increase of the photosensitivity after the 
consumption of cannabis (Dawson et al., 1977; Yazulla, 2008). 
CB2R antagonist increases the amplitude of  b-wave through Müller cells  
 In chapter 2 of this thesis, we demonstrate the anatomical expression of the CB2R and 
speculated a function for CB2R. Briefly, we proposed that CB2R in Müller cells uses 
potassium channel, KIR4.1 to modulate the ERG. Given that CB2R coupling via Gi/o decreases 
cAMP and PKA levels (Howlett et al., 2002) and that PKA increases the activity of KIR4.1 
channels in the Müller cells, we therefore suggest that the blockade of the CB2R will therefore 
activate the potassium channels and increase the amplitude of the b-wave (Bouskila et al., 
2013a). Here, we confirm the proposed model via ERG, that blockade of this receptor increase 
the b-wave amplitude. 
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Blockade of CBR decreases scotopic b-wave amplitude in lower intensity; 
role in dim light vision 
Our results demonstrate that both cannabinoid receptors antagonists decrease the 
amplitude of scotopic b-wave in lower flash intensities. This is in line with the claim that 
activation of the cannabinoid receptors may cause an increase in rod responses through 
bipolar cells and/or Müller cells (Straiker and Sullivan, 2003). This reduction can be due to 
the blockade of the CB1Rs that are mainly expressed in bipolar cells. The fact that CB2R is 
mainly found in Müller cells, the potassium-buffering role of Müller cells (explained before) 
could be the reason for this reduction. This can also elucidate the reports on the role of 
cannabis in improving the night vision (West, 1991, Merzouki and Mesa, 2002, Russo et al., 
2004). 
Monkeys vs mice results  
In their recent ERG study, Cécyre et al revealed that in transgenic mice, while CB1R 
removal does not affect the ERG responses in scotopic condition, CB2R elimination increased 
significantly the amplitude of the a-wave in higher intensity (Cécyre et al., 2013). They 
suggested that the reported alteration of rod sensitivity by cannabinoid agonist in tiger 
salamander (Straiker and Sullivan, 2003) is mediated by CB2R.  Here we show a decrease of 
a-wave response in higher intensities for mainly CB1R and also CB2R.  This controversy can 
be due to the difference in the visual system of these species and animal models. Firstly, the 
expression pattern of CB2R in the vervet monkey is dissimilar to rodents. In rodents, CB1R 
and CB2R have a very similar expression pattern (Zabouri et al., 2011, Cécyre et al., 2013) 
but in the vervet monkey while CB1R is expressed throughout the retina (Bouskila et al., 
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2012), CB2R is mainly detected in Müller cells (Bouskila et al., 2013a).  Secondly, transgenic 
animal without CB1R or CB2R went through an adaptations procedure through their 
development. This adaptation may result in different physiological responses from the normal 
animals that their receptors were blocked temporarily with an antagonist.    
Limitations on Functional Study of the Cannabinoid Systems  
One of the main limitations of cannabinoid research is the dose effect (Yazulla, 2008). 
Agonists in some dosage can cause complete opposite effects on the cannabinoid receptors 
activity (Henstridge et al., 2010). A CB1R agonist can be a stimulant at low dose and an 
inhibitor at high concentrations (Sulcova et al., 1998). In low concentrations, CB1R agonists 
like anandamide or WIN 55212-2 enhance the current via coupling to Gi/o but in higher 
concentrations, they do inhibit the current by pairing to Gs  (Chabre et al., 1994). Although 
these controversial effects were mainly reported in cannabinoid agonists and not antagonists, 
that same issue can also be raised for the blockers. In our study, due to lack of any 
information regarding eCB intravitreal injection dosage in primates, we opted for the lowest 
possible concentration that would produce an effect on the ERG since no effect was observed 
at lower doses. 
Moreover, since some studies have claimed that AM251, at some concentrations, is an 
agonist for the orphan G-protein coupled receptor, GPR55, a putative third cannabinoid 
receptor, one may attribute the effect of AM251 on the ERG responses to GPR55 activation. 
However, from an anatomical point of view, CB1R and CB2R were slightly detected in the 
rod photoreceptors of the vervet monkey whereas GPR55 was exclusively expressed in rods 
(Bouskila et al., 2013b).
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Expression of eCB components beyond the retina 
Rods and cones transfer visual information to retinal ganglion cells. The presence of 
CB1R and FAAH in GCL has been previously reported (Zabouri et al., 2011a; Zabouri et al., 
2011b; Bouskila et al., 2012). The ganglion cell axons leave the orbit as the optic nerve 
towards the optic chiasm, including the ganglion cells that output visual information. We 
assessed the expression of the CB1R, FAAH and NAPE-PLD beyond the retina of the vervet 
monkey.  We found that the track of the CB1R, FAAH and NAPE-PLD in the optic nerve of 
the vervet is diffused throughout the coronal section.  
 
Two magnocellular layers and the four parvocellular layers of the dLGN receive the 
input from the parasol and midget ganglion cells, respectively. Both magno- and parvocellular 
layers target layer 4 of area V1 (4Cα and 4Cβ respectively). Layer 4 of the visual cortex 
expressed the lowest intensity of the CB1R (Eggan and Lewis 2007). Beside layer 4, the M 
and P pathways also project to layer 6 of V1 and receive robust corticogeniculate feedback 
from the same layer, primarily excitatory and glutamatergic signaling (McCormick and von 
Krosigk 1992; Fitzpatrick et al., 1994). Layer 6 of the V1 shows the highest expression of 
CB1R (Eggan and Lewis 2007). Here, for the first time, we report that CB1R and FAAH are 
expressed more abundantly in magnocellular layers and NAPE-PLD is homogeneously 
expressed in both magno- and parvocellular layers. None of these components are expressed 
richly in the koniocellular layer. Previous reports have shown slight expression of CB1Rs in 
the dorsal thalamus of rats (Tsou et al., 1998) but no (Eggan and Lewis 2007) or only 
moderate (Ong and Mackie 1999) expression in primates and humans (Glass et al., 1997). 
However, none of these studies focused on the visual pathway and the dLGN per se.  Argaw et 
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al. reported the presence of CB1R in the dLGN of the rodent; however, due to the fundamental 
structural difference of the dLGN in rodents and primates, it is impossible to make any 
conclusions for the human visual pathway based on the rodent results.  Moreover, the number 
of the retinal inputs to the primitive dLGN of the rodents is considerably lower than that of the 
ganglion cells converging to the dLGN of the primates. About 90% of the dLGN inputs are 
coming from sites other than retina, and about 30% of them are feedback inputs from V1 (Van 
Horn et al., 2000).  
 
Since the magnocellular pathway is more sensitive to low spatial frequencies and low 
luminance contrasts but is chromatically non-opponent, the eCB system may play a role in 
related functions. In addition, since the MT and MST are motion detection centers that also 
express the highest level of CB1R in the visual cortex and mainly receive their primary inputs 
from magnocellular layers, it appears likely that the eCB system plays a role in motion 
detection.   
 
Compared to CB1R and FAAH, the unusual diffused expression of the NAPE-PLD 
throughout the vervet dLGN is not unexpected. NAPE-PLD is widely present in the mouse 
thalamus (Egertová et al., 2008). Rat brain also exhibits high expression of NAPE-PLD in the 
thalamus (Morishita et al., 2005). NAPE-PLD is not only responsible for anandamide 
production; it also generates NAEs as the major substrate for mediating various motivational 
functions (Viveros et al., 2008) besides synthesizing eCB agonist. 
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From the functional point of view, CB1R and FAAH in the magnocellular layers could 
regulate the dorsal visual system involved in motion processing and object location 
(“how/where” pathway) (Goodale and Milner 1992; Kupers and Ptito 2014). The high 
expression of CB1R in MT and MST areas supports this theorized role of eCB system in 
motion perception. Case studies and interviews with high-potency, heavy cannabis smokers 
reported some motion related visual impairments (Levi and Miller 1990) and a reduced ability 
to track a moving point of light on a screen that requires fine psychomotor control (Adams et 
al., 1975; Adams et al., 1978). 
 
The magnocellular pathway may also play a role in nystagmus, the rhythmic 
involuntary movement of the eyes. It has been suggested that alterations of the magnocellular 
motion-processing pathway and the superior colliculus (SC) may be involved in the 
production of nystagmus (Hepp et al., 1993; Leigh et al., 2002). Interestingly, several studies 
reported that cannabis could be effective in suppressing acquired pendular nystagmus (Schon 
et al., 1999; Dell'Osso 2000; Pradeep et al., 2008). Since the main input signals to the SC rely 
on activity in the magnocellular geniculostriate pathway (Schiller et al., 1979), in which 
moderate CB1R expression has been shown in rats (Tsou et al., 1998), we suggest that 
cannabis may partially modulate nystagmus suppression through magnocellular pathways in 
the monkey dLGN. Based on the modulatory role of presynaptic eCB receptors and their 
expression in both excitatory glutamatergic and inhibitory GABAergic neurons, the precise 
mechanism of action still needs to be verified. 
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One of the other characteristics of magnocellular neurons is their sensitivity to low 
luminance contrasts (Tootell et al., 1988). Frequent reports and anecdotes claim that smoking 
marijuana improves scotopic vision and increases photosensitivity (Dawson et al., 1977; 
Merzouki and Mesa 2002; Russo et al., 2004). The high expression of CB1R in magnocellular 
layers suggests a putative role for the eCB system in dim light vision.  
The lower expression of the CB1R in parvocellular layers does not mean that the eCB 
system is absent in this pathway. It is worthy to note that in parvocellular layers, the CB1Rs 
are spread out over a larger area (four layers) compare to magnocellular layers (two layers). In 
addition, the scarcity of these receptors in parvocellular layers makes them more sensitive to 
agonists and antagonists. In other words, a low dosage of ligand can saturate these receptors 
and trigger related symptoms. However, the abundance of CB1R in the magnocellular layer 
increases the likelihood that some receptors will not be affected by low concentration of 
ligands. Hence, if the eCB system plays any role in color perception, it should be through the 
chromatic properties of parvo cells and retinal cones. One of the most frequently reported 
symptoms of cannabis consumption is intensification of the perception of colors and their 
brightness (Green et al., 2003; Lerner et al., 2011), where parvocellular pathway may play a 
role beside the cones.   
  
Our results also show that there is weak expression of CB1R, FAAH or NAPE-PLD in 
the koniocellular layers of the dLGN. There are three populations of relay neurons that 
represent three different visual pathways in primates. Koniocellular neurons make up a third 
channel in the primate dLGN and are located between and within the principal dLGN layers 
(Casagrande 1994; Hendry and Yoshioka 1994; Casagrande 1999; Hendry and Reid 2000). 
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The retinal input of K neurons suggests that they are involved in blue/yellow chromatic 
processing (Martin et al., 1997). Even though CB1R is present in the retinal ganglion cell 
layers of vervets, there is a minority of ganglion cells that are not CB1R positive (Bouskila et 
al., 2012). This could represent the blue/yellow neurons that project to the koniocellular layers 
of the dLGN. 
 
 
Conclusion 
The physiological systems of a living body tend to follow an elegant economical logic. 
Evolutionarily, it is highly unlikely that the body would spend a considerable amount of 
energy and material to produce numerous eCB components in the visual system for no other 
reason than getting activated after a “joint”. Accordingly, the abundance of the eCB system 
components through the visual system suggests that they play an important role in normal 
vision.  The variation in the pattern of expression of these components such as exclusive 
expression of CB2R in retinal glia and CB1R in neuroglia demonstrate that CBRs do not play 
the same role in all species. The eCB expression pattern in the mouse (rod-dominated retina 
with monocular vision), tree shrew (cone-dominated retina with binocular vision), and 
monkey (duplex retina with binocular vision) strongly supports the hypothesis that the retinal 
eCB system plays a fundamental role in mammalian visual processing.  
Moreover, alteration of the retinal responses after blockade of these receptors with 
antagonists supports that eCB system is an important role player in the normal function of the 
visual system. Based on our ERG results we also endorse some of the eCB system roles in dim 
light vision and photosensitivity.    
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Beyond the retina, the neuroanatomy of CB1R, FAAH, and NAPE-PLD in the primate 
dLGN provides a new standpoint for the visual function of this system. This specific presence 
in the magnocellular pathway suggests a putative neuromodulatory action that affects the 
functions of the dorsal visual pathway involved in motion perception, object localization and 
action-oriented behaviors that depend on the perception of space, dim light vision, and 
nystagmus. 
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Chapter 8: Future Direction 
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Anatomy  
The expression pattern of other eCB system components beyond the retina, such as 
CB2R, MAGL and DAGLα throughout the dLGN, and expression of eCB system components 
in the visual cortex (V1, V2, V4, MT, MST) needs to be verified. Another important pathway 
required to assess eCBs presence is saccadic and eye movement structures of vision. CB1R 
has been detected in human SC (Glass et al., 1997); however, its pattern of expression 
throughout the SC layers still needs to be clarified to reveal its role. Additionally, the 
expression pattern of other eCB components in the SC and the pretectal area may suggest new 
visual functions for eCB system while also explaining some of the symptoms present after 
marijuana consumption, including impaired performance in tests that require fine psychomotor 
control such as tracking a moving point of light on a screen (Adams et al., 1975; Adams et al., 
1978). 
Other than our previous work (for the article see index) (Bouskila et al., 2013b) on the retinal 
expression of the potential CBR, GPR55, to our knowledge there is no other study that 
reported its expression in the visual system of monkeys. The orphan GPR55 is thought to be 
responsible for some of the observed properties of the cannabinoids such as blood pressure 
lowering (Johns et al., 2007), gastrointestinal functions (Schicho and Storr, 2012), and anti-
cancer effects (Farsandaj et al., 2012). These effects have attracted the attention of 
investigators and have increasingly become the focus of research in the field. The expression 
pattern of GPR55 in other sections of the visual system will complete our anatomic model in 
non-human primate and consequently in human.  
It has been reported that a 2 day monocular deprivation upregulated the expression level of 
CB1R in the mouse visual cortex (Yoneda et al., 2013). An interesting future direction would 
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be to examine eCB expression patterns in blind or visually impaired monkeys compared to 
normally sighted ones. 
Functional  
ERG 
In our ERG study, we utilized only receptor antagonists; examining receptor agonists 
and antagonists concurrently would yield a more complete picture of the roles of eCB 
signaling in normal retinal function. Similarly, recording ERG waves after using an inhibitor 
(e.g. tetrahydrolipstatin) or enhancer of the NAPE-PLD may enable us to elucidate the 
function of this enzyme in the retina. Verification of the functional role of NAPE-PLD in 
retina will be another interesting project.  
In humans, comparing the ERG patterns of regular consumers of marijuana with standard 
ERG may show how consistent activation of the CBRs can affect the retina.    
Finally, it is worthy of note that ligand concentration is very important in the cannabinoid 
system and can have paradoxical effects. In this study, we used only one concentration for 
blockers. The efficacy and optimal concentration still needs to be defined and examination 
may yield even more insights to the roles of cannabinoid signaling. 
 
Visual Evoked Potential (VEP)  
To assess the function of eCB beyond the retina, a VEP test can be performed with the 
same equipment and a similar procedure as ERG. We began registering primary VEP results 
during our data collection in St-Kitts to verify the electrode positions. The electrodes are 
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placed topically using stereotaxic coordinates close to the Oz point in the occipital lobe to 
register electrical responses from the visual cortex and dLGN. Classic checkerboards can 
isolate the activity of dLGN layers to compare their VEP wave patterns before and after 
blockade of the CBRs. Additionally; VEP can be used as a measure of visual acuity (Hamilton 
et al., 2010).  
 
Behavioral  
For our behavioural studies, we designed a series of easy-to-implement routines to tap 
the perceptual and cognitive functions of normally developing and adult nonhuman primates 
based on spontaneously generated behaviour; gaze preference. We developed a protocol to 
measure preferential looking time at a given stimulus as its position was shifted from the left 
to the right side of the screen (or vice versa). The amount of looking time was expressed as a 
proportion of total looking time at the entire display containing both the stimulus and the 
control (Zangenehpour et al., 2014). These tests can measure visual acuity, chromatic contrast 
sensitivity, and spatial-temporal contrast sensitivity function. Our experience in implementing 
this procedure showed that training the monkeys to be attentive to our stimuli was a challenge 
that required lengthier training periods.  However, the same procedure would be useful to 
compare regular cannabis consumers versus a control group when demonstrating the role of 
chronic marijuana consumption in visual function.  
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Brain Imaging 
Chronic consumption of cannabis might cause structural changes in brain. Lately, brain 
imaging studies solidly show alteration or neuroadaptation in activation of higher cognitive 
part of the brain networks. A lower global cerebellar glucose metabolism in resting brain 
function of marijuana users has been reported (Volkow et al., 1996). Intravascular THC 
administration increased cerebellar metabolism as well as cerebellar blood flow (CBF) in 
frontal cortices, basal ganglia, insula, cingulate cortex and some subcortical regions with 
higher increase in right hemisphere (Volkow et al., 1996; Mathew et al., 1998). This 
augmentation is lower in regular users (Volkow et al., 1996, Lindsey et al., 2005). Auditory 
attention network shows a reduction in activation following smoking marijuana (Chang and 
Chronicle, 2007). Chronic administration of THC down-regulate and desensitize CB1R in 
animal (Sim-Selley, 2003).  The BOLD contrast of marijuana users in simple tasks showed 
reduced activation in the supplemental motor area and the cingulate region (Chang and 
Chronicle, 2007). In complex tasks, brain activation is altered or increased in cannabinoid 
users (Ganis et al., 2004). Brain activation in attention network (prefrontal, medial, dorsal 
parietal cortices, medial vermis of cerebellum) is reduced in marijuana users (Dasilva et al., 
2012). Higher activation has been found in inferior and middle frontal gyri and right superior 
temporal gyrus of smokers in visuospatial working memory tasks (Smith et al., 2010). These 
alterations in regular users are possibly related to down-regulation of CB1R and its mRNA 
expression in chronic exposure to THC that is reversible (Villares, 2007).   
Over the past decade, considerable effort has been devoted to develop a PET ligand to study 
the CB1R, in vivo. Endogenous ligands of CB1R are highly lipophilic. This lipophilicity is a 
great challenge to design the PET ligands. Most of the attempts result in high non-specific 
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binding and low brain penetration. [123I] AM251 brain uptake was low and  [123I] AM281was 
more promising with a higher brain uptake but lower specificity (Li et al., 2005; Lindsey et al., 
2005). The CB1R distribution in human and rhesus brain has been identified using specific, 
high affinity [18F] MK-9470 antagonist (Burns et al., 2007). Some attempt to visualize CB2R 
has been reported in primates using radioligand [11C] NE40 (Evens et al., 2012). 
Comparison of CB1R distribution in sighted and congenital blinds using PET 
The successful PET studies that are tracing the CB1R in brain were not attentive to 
visual pathways and focused more on prefrontal lobe, cerebellum and hippocampus (Burns et 
al., 2007). Moreover studies on cross-modal plasticity in the congenitally blinds demonstrated 
the anatomic and functional viability of their primary and associative visual cortices (Ptito et 
al., 2008). PET studies show a supranormal metabolism at rest state of the occipital lobe in 
congenitally blind subjects (De Volder et al., 1997; Ptito et al., 2008; Kupers et al., 2011;). 
The visual lobes are still active in blind subject and respond to somatosensory and auditory 
inputs (Kupers and Ptito, 2011). Investigating the distribution of this receptor in visual areas of 
normal sighted subjects compared to that of the congenitally blind brain will shed a light to the 
role of CB1R in vision. Development of the highly specific [18F] MK-9470 ligand produced 
remarkable outcomes in the human central nervous system (Burns et al., 2007) and makes it 
possible to track the CB1R in human and non-human primate visual system.  
Comparison of CB1R distribution in control and regular marijuana users using PET 
Chronic administration of THC down-regulate and desensitize the CB1R in animal 
(Villares, 2007). However no association has been found between alteration of the volume of 
gray matter, white matter, Cerebrospinal fluid, hippocampi and chronic use (Jager et al., 
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2006), but voxel-based morphometry reveal reduction of gray matter density in right 
parahippocampal gyrus and augmentation in right pre-central gyrus and thalamus as well as 
white matter density (Chang and Chronicle, 2007). In situ hybridization demonstrated a 
significant decrease of CB1R in postmortem human brain in regular cannabis users (Sim-
Selley, 2003). Verification of the expression of the CB1R in the visual pathway of the chronic 
marijuana users using highly specific [18F] MK-9470 ligand can shed a light on the putitative 
roles of eCB system in vision.  
Comparing the visual processing and brain activation before and after administration of 
CB1R antagonist, rimonabant, in normal subjects under fMRI 
Most of our knowledge on the effects of cannabinoids on vision has been studied 
through the use of marijuana. Rimonabant is an antagonist for CB1R that had been used as an 
anorectic anti-obesity drug to reduce appetite (Duarte et al., 2004). It had been also used as an 
anti-addiction drug for smoking cessation therapy and reducing cocaine-seeking habits (Le 
Foll and Goldberg, 2005; Cahill and Ussher, 2011). The threshold of the visual acuity, 
chromatic contrast sensitivity, and motion perception subjects before and after blocking the 
receptors can be compared. Moreover, the effects of the blockers on activations of the visual 
pathways can be verified with fMRI.  
 
eCB research is a complex but highly promising field. Characterization of  eCB 
components and discovering their role will pave the road to new therapeutics for vision. 
Finally, in light of the seemingly inevitable wave of cannabis legalization, I concur that 
accurately quantifying adverse effects and interactions will help us avoid the irrevocable 
mistakes that had been made with tobacco and cigarettes in the 1960s. 
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